[go: up one dir, main page]

US20030072794A1 - Encapsulation of plasmid DNA (lipogenes™) and therapeutic agents with nuclear localization signal/fusogenic peptide conjugates into targeted liposome complexes - Google Patents

Encapsulation of plasmid DNA (lipogenes™) and therapeutic agents with nuclear localization signal/fusogenic peptide conjugates into targeted liposome complexes Download PDF

Info

Publication number
US20030072794A1
US20030072794A1 US09/876,904 US87690401A US2003072794A1 US 20030072794 A1 US20030072794 A1 US 20030072794A1 US 87690401 A US87690401 A US 87690401A US 2003072794 A1 US2003072794 A1 US 2003072794A1
Authority
US
United States
Prior art keywords
seq
peptide
dna
nls
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US09/876,904
Inventor
Teni Boulikas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regulon Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US09/876,904 priority Critical patent/US20030072794A1/en
Publication of US20030072794A1 publication Critical patent/US20030072794A1/en
Assigned to REGULON, INC. reassignment REGULON, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BOULIKAS, TENI
Priority to US12/830,118 priority patent/US20120183596A1/en
Priority to US13/900,433 priority patent/US9278067B2/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277—Preparation processes; Proliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277—Preparation processes; Proliposomes
    • A61K9/1278—Post-loading, e.g. by ion or pH gradient

Definitions

  • the present invention relates to the field of gene therapy and is specifically directed toward methods for producing peptide-lipid-polynucleotide complexes suitable for delivery of polynucleotides to a subject.
  • the peptide-lipid-polynucleotide complexes so produced are useful in a subject for inhibiting the progression of neoplastic disease.
  • Gene therapy is a newly emerging field of biomedical research that holds great promise for the treatment of both acute and chronic diseases and has the potential to bring a revolutionary era to molecular medicine.
  • routine use of gene therapy for the treatment of human disease has not yet been perfected. It remains an important unmet need of gene therapy to create gene delivery systems that effectively target specific cells of interest in a subject while controlling harmful side effects.
  • Gene therapy is aimed at introducing therapeutically important genes into somatic cells of patients.
  • Diseases already shown to be amenable to therapy with gene transfer in clinical trials include, cancer (melanoma, breast, lymphoma, head and neck, ovarian, colon, prostate, brain, chronic myelogenous leukemia, non-small cell lung, lung adenocarcinoma, colorectal, neuroblastoma, glioma, glioblastoma, astrocytoma, and others), AIDS, cystic fibrosis, adenosine deaminase deficiency, cardiovascular diseases (restenosis, familial hypercholesterolemia, peripheral artery disease), Gaucher disease, ⁇ 1-antitrypsin deficiency, rheumatoid arthritis and others.
  • Human diseases expected to be the object of clinical trials include hemophilia A and B, Parkinson's disease, ocular diseases, xeroderma pigmentosum, high blood pressure, obesity.
  • ADA deficiency was the disease successfully treated by the first human “gene transfer” experiment conducted by Kenneth Culver in 1990. See, Culver, K. W. (1996) in: Gene Therapy: A Primer for Physicians, Second Ed., Mary Ann Liebert, Inc. Publ, New York, pp. 1-198.
  • Human cancer presents a particular disease condition for which effective gene therapy methods would provide a particularly useful clinical benefit.
  • Gene therapy concepts for treatment of such diseases include stimulation of immune responses as well as manipulation of a variety of alternative cellular functions that affect the malignant phenotype.
  • the immune system can be reinforced and instructed to eliminate cancer cells after transduction of a patient's cells ex vivo with the cytokine genes GM-CSF, IL-12, IL-2, IL-4, IL-7, IFN- ⁇ , and TNF- ⁇ , followed by cell vaccination of the patient (e.g. intradermally) to potentiate T-lymphocyte-mediated antitumor effects (cancer immunotherapy).
  • DNA vaccination with genes encoding tumor antigens and immunotherapy with synthetic tumor peptide vaccines are further developments that are currently being tested.
  • the genes used for cancer gene therapy in human clinical trials include a number of tumor suppressor genes (p53, RB, BRCA1, E1A), antisense oncogenes (antisense c-fos, c-myc, K-ras), and suicide genes (HSV-tk, in combination with ganciclovir, cytosine deaminase in combination with 5-fluorocytosine).
  • genes that have been proposed for cancer gene therapy include bcl-2, MDR-1, p21, p16, bax, bcl-xs, E2F, IGF-I, VEGF, angiostatin, CFTR, LDL-R, TGF- ⁇ , and leptin.
  • One major hurdle preventing successful implementation of these gene therapies is the difficulty of efficiently delivering an effective dose of polynucleotides to the site of the tumor.
  • gene delivery systems with enhanced transfection capabilities would be highly advantageous.
  • a number of different vector technologies and gene delivery methods have been proposed and tested for delivering genes in vivo, including viral vectors and various nucleic acid encapsulation techniques.
  • Alternative viral delivery vehicles for genes include murine retroviruses, recombinant adenoviral vectors, adeno-associated virus, HSV, EBV, HIV vectors, and baculovirus.
  • Nonviral gene delivery methods use cationic or neutral liposomes, direct injection of plasmid DNA, and polymers.
  • Various strategies to enhance efficiency of gene transfer have been tested such as fusogenic peptides in combination with liposomes or polymers to enhance the release of plasmid DNA from endosomes.
  • Adeno-associated virus AAV is not pathogenic and does not elicit immune responses but new production strategies are required to obtain high AAV titers for preclinical and clinical studies. Wild-type AAVs integrate into chromosome 19, whereas recombinant AAVs are deprived of site-specific integration and may also persist episomally.
  • HSV vectors can infect non-replicating cells, such as neuronal cells, and has a high payload capacity for foreign DNA but inflict cytotoxic effects. It seems that each delivery system will be developed independently of the others and that each will demonstrate strengths and weaknesses for certain applications. At present, retroviruses are most commonly used in human clinical trials, followed by adenoviruses, cationic liposomes and AAV.
  • cell-based gene delivery using polymer-encapsulated syngeneic or allogeneic cells implanted into a tissue of a patient can be used to secrete therapeutic proteins.
  • This method is being tested in trials for amyotrophic lateral sclerosis using the ciliary neurotrophic factor gene, and may be extended to Factor VIII and IX for hemophilia, interleukin genes, dopamine-secreting cells to treat Parkinson's disease, nerve growth factor for Alzheimer's disease and other diseases.
  • Additional methods that have been proposed for improving the efficacy of gene therapy technologies include designing p53 “gene bombs” that explode into tumor cells, exploiting the HIV-1 virus to engineer vectors for gene transfer, combining viruses with polymers or cationic lipids to improve gene transfer, the attachment of nuclear localization signal peptides to oligonucleotides to direct genes to nuclei, and the development of molecular switch systems allowing genes to be turned on or off at will. Nevertheless, because of the wide range of disease conditions for which gene therapies are required, and the complexities of developing treatments for such diseases, there remains a need for improved techniques for performing gene therapy. The present invention provides methods and compositions for addressing these issues.
  • the liposomes are able to reach primary tumors and their metastases after intravenous injection to animals and humans.
  • the method includes micelle formation between DNA with a mixture of cationic lipid and peptide molecules at molar ratios to nearly neutralization ratios in 10-90% ethanol; the cationic peptides specify nuclear localization and have a hydrophobic moiety endowed with membrane fusion to improve entrance across the cell membrane of the complex.
  • the DNA/lipid/peptide micelles are converted into liposomes by mixing with pre-made liposomes or lipids followed by dilution in aqueous solutions and dialysis to remove the ethanol and allow liposome formation and extrusion through membranes to a diameter below 160 nm entrapping and encapsulating DNA with a very high yield.
  • the encapsulated DNA has a high therapeutic efficacy in eradicating a variety of solid human tumors including, but not limited to, breast carcinoma and prostate carcinoma.
  • a plasmid is constructed with DNA carrying anticancer genes including, but not limited to p53, RB, BRCA1, E1A, bcl-2, MDR-1, p21, pl6, bax, bcl-xs, E2F, IGF-I VEGF, angiostatin, oncostatin, endostatin, GM-CSF, IL-12, IL-2, IL-4, IL-7, IFN- ⁇ , TNF- ⁇ , HSV-tk (in combination with ganciclovir), E. coli cytosine deaminase (in combination with 5-fluorocytosine) and is combined with encapsulated cisplatin or with other similarly systemically delivered antineoplastic drugs to suppress cancer.
  • anticancer genes including, but not limited to p53, RB, BRCA1, E1A, bcl-2, MDR-1, p21, pl6, bax, bcl-xs, E2F, IGF-I VEGF
  • FIG. 1 illustrates the structure of the cancer targeted liposome complex.
  • FIG. 2 illustrates the results of plasmid DNA condensation with various agents as well as various formulation of cationic liposomes in affecting the level of expression of the reporter beta-galactosidase gene after transfection of K562 human erythroleukemia cell cultures.
  • FIG. 3 illustrates tumor targeting in SCID mice.
  • FIG. 3A shows a SCID mouse with a large and small human breast tumor before and after staining with X-Gal to test the expression of the transferred gene. Both tumors turn dark blue. The intensity of the blue color is proportional to the expression of the beta-galactosidase gene.
  • FIG. 3B shows that in the initial staining of the small tumor, the skin and the intestines at the injection area are the first organs to turn blue.
  • FIG. 3C is a view of the back of the animal. The two tumors are clearly visible after removal of the skin (top). Dark staining of the small tumor and light blue staining of the large tumor is evident at an initial stage of staining (bottom).
  • FIG. 3D is a view of the front side of the animal. The two tumors are clearly visible after removal of the skin. On the figure to the bottom the dark staining of both tumors is evident at a later stage during staining.
  • FIG. 3E shows the front (top) and rear (bottom) higher magnification view of the dark staining of both tumors at a later stage during staining. Staining of the vascular system around the small tumor can also be seen (bottom).
  • Table 1 is a list of molecules able to form micelles.
  • Table 2 lists several fusogenic peptides and describes their properties, along with a reference.
  • Table 3 lists simple Nuclear Localization Signal (NLS) peptides.
  • Table 4 shows a list of “bipartite” or “split” NLS peptides.
  • Table 5 lists “nonpositive NLS” peptides lacking clusters of arginines/lysines.
  • NoLS nucleolar localization signals
  • Table 7 lists peptides having karyophilic clusters on non-membrane protein kinases.
  • Table 8 lists peptide nuclear localization signals on DNA repair proteins.
  • Table 9 lists NLS peptides in transcription factors.
  • a cell includes a plurality of cells, including mixtures thereof.
  • compositions and methods include the recited elements, but not excluding others.
  • Consisting essentially of when used to define compositions and methods, shall mean excluding other elements of any essential significance to the combination. Thus, a composition consisting essentially of the elements as defined herein would not exclude trace contaminants from the isolation and purification method and pharmaceutically acceptable carriers, such as phosphate buffered saline, preservatives, and the like.
  • Consisting of shall mean excluding more than trace elements of other ingredients and substantial method steps for administering the compositions of this invention. Embodiments defined by each of these transition terms are within the scope of this invention.
  • polynucleotide and “nucleic acid molecule” are used interchangeably to refer to polymeric forms of nucleotides of any length.
  • the polynucleotides may contain deoxyribonucleotides, ribonucleotides, and/or their analogs.
  • Nucleotides may have any three-dimensional structure, and may perform any function, known or unknown.
  • polynucleotide includes, for example, single-, double-stranded and triple helical molecules, a gene or gene fragment, exons, introns, mRNA, tRNA, rRNA, ribozymes, cDNA, recombinant polynucleotides, branched polynucleotides, plasmids, vectors, isolated DNA of any sequence, isolated RNA of any sequence, nucleic acid probes, and primers.
  • a nucleic acid molecule may also comprise modified nucleic acid molecules.
  • a “gene” refers to a polynucleotide containing at least one open reading frame that is capable of encoding a particular polypeptide or protein after being transcribed and translated.
  • a “gene product” refers to the amino acid (e.g., peptide or polypeptide) generated when a gene is transcribed and translated.
  • DDAB dimethyldioctadecyl ammonium bromide (same as N,N-distearyl-N,N-dimethylammonium bromide);
  • DODAC N,N-dioleyl-N,N-dimethylammonium chloride;
  • DODAP 1,2-dioleoyl-3-dimethylammonium propane;
  • DMRIE N-[1-(2,3-dimyristyloxy)propyl]-N,N-dimethyl-N-(2-hydroxyethyl) ammonium bromide;
  • DMTAP 1,2-dimyristoyl-3-trimethylammonium propane;
  • DOGS Dioctadecylamidoglycylspermine;
  • DOTAP (same as DOTMA): N-(1-(2,3-dioleoyloxy)propyl)-N,N,N-trimethylammonium
  • the term “pharmaceutically acceptable anion” refers to anions of organic and inorganic acids that provide non-toxic salts in pharmaceutical preparations.
  • examples of such anions include the halides anions, chloride, bromide, and iodide, inorganic anions such as sulfate, phosphate, and nitrate, and organic anions.
  • Organic anions may be derived from simple organic acids, such as acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, malic acid, malonic acid, succinic acid, maleic, acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methane sulfonic acid, ethane sulfonic acid, p-toluenesulfonic acid, and the like.
  • the preparation of pharmaceutically acceptable salts is described in Berge, et al., J. Pharm. Sci. 66:1-19 (1977), incorporated herein by reference.
  • Physiologically acceptable carriers, excipients or stabilizers are nontoxic to recipients at the dosages and concentrations employed, and include buffers such as phosphate, citrate, and other organic acids; antioxidants including ascorbic acid; low molecular weight (less than about 10 residues) polypeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, arginine or lysine; monosaccharides, disaccharides, and other carbohydrates including glucose, mannose, or dextrins; chelating agents such as EDTA: sugar alcohols such as mannitol or sorbitol; salt-forming counter ions such as sodium; and/or nonionic surfactants such as Tween, Pluronics or polyethylene glycol (PEG). PEG molecules also contain a fusogenic peptide with an attached Nuclear Localization Signal (NLS)
  • cationic lipid refers to any of a number of lipid species that carry a net positive charge at physiological pH. Such lipids include, but are not limited to, DDAB, DMRIE, DODAC, DOGS, DOTAP, DOSPA and DC-Chol. Additionally, a number of commercial preparations of cationic lipids are available that can be used in the present invention.
  • LIPOFECTIN commercially available cationic liposomes comprising DOTMA and DOPE, from GIBCO/BRL, Grand Island, N.Y., USA
  • LIPOFECTAMINE commercially available cationic liposomes comprising DOSPA and DOPE, from GIBCO/BRL
  • TRANSFECTAM commercially available cationic lipids comprising DOGS in ethanol from Promega Corp., Madison, Wis., USA.
  • This invention further provides a number of methods for producing micelles with entrapped therapeutic drugs.
  • the method is particularly useful to produce micelles of drugs or compositions having a net overall negative charge, e.g., DNA, RNA or negatively charged small molecules.
  • the DNA can be comprised within a plasmid vector and encode for a therapeutic protein, e.g., wild-type p53, HSV-tk, p21, Bax, Bad, IL-2, IL-12, GM-CSF, angiostatin, endostatin and oncostatin.
  • the method requires combining an effective amount of the therapeutic agent with an effective amount of cationic lipids.
  • Cationic lipids useful in the methods of this invention include, but are not limited to, DDAB, dimethyldioctadecyl ammonium bromide; DMRIE: N-[1-(2,3-dimyristyloxy)propyl]-N,N-dimethyl-N-(2-hydroxyethyl) ammonium bromide; DMTAP: 1,2-dimyristoyl-3-trimethylammonium propane; DOGS: Dioctadecylamidoglycylspermine; DOTAP (same as DOTMA): N-(1-(2,3-dioleoyloxy)propyl)-N,N,N-trimethylammonium chloride; DPTAP: 1,2-dipalmitoyl-3-trimethylammonium propane; DSTAP: 1 ,2-disteroyl-3-trimethylammonium propane.
  • DDAB dimethyldioctadecyl ammonium bromide
  • a ratio of from about 30 to about 90% of phosphates contained within the negatively charged therapeutic agent are neutralized by positive charges on lipid molecules (negative charges are in excess) to form an electrostatic micelle complex in an effective concentration of ethanol.
  • the ethanol solution is from about 20% to about 80% ethanol.
  • the ethanol concentration is about 30%.
  • the ethanol/cationic lipid/therapeutic agent complex is then combined with an effective amount of a fusogenic-karyophilic peptide conjugate.
  • an effective amount of the conjugate is a ratio range from about 0.0 to about 0.3 (positive charges on peptide to negative charges on phosphate groups) to neutralize the majority of the remaining negative charges on the phosphate groups of the therapeutic agents thereby leading to an almost complete neutralization of the complex.
  • the optimal conditions give to the complex a slightly negative charge.
  • the excess of positive charges are neutralized by DPPG (dipalmitoyl phosphatidyl glycerol) and its derivatives, or by other anionic lipid molecules in the final micelle complex.
  • the above methods can be modified by addition of DNA condensing agents selected from spermine, spermidine, and magnesium or other divalent metal ions neutralizing a certain percentage (1-20%) of phosphate groups.
  • the cationic lipids are combined with an effective amount of fusogenic lipid DOPE at various molar ratios for example, in a molar ratio of from about 1:1 cationic lipid:DOPE.
  • the cationic lipids are combined with an effective amount of a fusogenic/NLS peptide conjugate.
  • fusogenic/NLS peptide conjugates include, but are not limited to (KAWLKAF) 3 (SEQ ID NO:1), GLFKAAAKLLKSLWKLLLKA (SEQ ID NO:2), LLLKAFAKLLKSLWKLLLKA (SEQ ID NO:3), as well as all derivatives of the prototype (Hydrophobic3-Karyophilic1-Hydrophobic2-Karyophilic1) 2-3 where Hydrophobic is any of the A, I, L, V, P, G, W, F and Karyophilic is any of the K, R, or H, containing a positively-charged residue every 3rd or 4th amino acid, which form alpha helices and direct a net positive charge to the same direction of the helix.
  • KAWLKAF KAWLKAF 3
  • GLFKAAAKLLKSLWKLLLKA SEQ ID NO:2
  • LLLKAFAKLLKSLWKLLLKA SEQ ID NO:3
  • Hydrophobic is any
  • Additional examples include but are not limited to GLFKAIAGFIKNGWKGMIDGGGYC (SEQ ID NO:4) from influenza virus hemagglutinin HA-2; YGRKKRRQRRR (SEQ ID NO:5) from TAT of HIV; MSGTFGGILAGLIGLL(K/R/H) 1-6 (SEQ ID NO:6), derived from the N-terminal region of the S protein of duck hepatitis B virus, but with the addition of one to six positively-charged lysine, arginine or histidine residues, and combinations of these, able to interact directly with the phosphate groups of plasmid or oligonucleotide DNA, compensating for part of the positive charges provided by the cationic lipids.
  • GAAIGLAWIPYFGPAA (SEQ ID NO:7) is derived from the fusogenic peptide of the Ebola virus transmembrane protein; residues 53-70 (C-terminal helix) of apolipoprotein (apo) AII peptide; the 23-residue fusogenic N-terminal peptide of HIV-1 transmembrane glycoprotein gp41; the 29-42-residue fragment from Alzheimer's ⁇ -amyloid peptide; the fusion peptide and N-terminal heptad repeat of Sendai virus; the 56-68 helical segment of lecithin cholesterol acyltransferase.
  • shorter versions of these peptides that are known to induce fusion of unilamellar lipid vesicles or all that are similarly derivatized with the addition of one to six positively-charged lysine, arginine or histidine residues (K/R/H) 1-6 able to interact directly with the phosphate groups of plasmid or oligonucleotide DNA, compensating for part of the positive charges provided by the cationic lipids.
  • the fusogenic peptides in the fusogenic/NLS conjugates represent hydrophobic amino acid stretches, and smaller fragments of these peptide sequences, that include all signal peptide sequences used in membrane or secreted proteins that insert into the endoplasmic reticulum.
  • the conjugates represent transmembrane domains and smaller fragments of these peptide sequences.
  • the NLS peptide component in fusogenic/NLS peptide conjugates is derived from the fusogenic hydrophobic peptides.
  • NLS Nuclear Localization Signals
  • NLS peptides are shown in Tables 1-8.
  • the NLS peptide component in fusogenic/NLS peptide conjugates are synthetic peptides containing the above said NLS, but further modified by additional K, R, H residues at the central part of the peptide or with P or G at the N- or C-terminus.
  • the fusogenic/NLS peptide conjugates are derived from the said fusogenic hydrophobic peptides but with the addition of a stretch of H 4-6 (four to six histidine residues) in the place of NLS. Micelle formation takes place at pH 5-6 where histidyl residues are positively charged but lose their charge at the nearly neutral pH of the biological fluids, thus releasing the plasmid or oligonucleotide DNA from their electrostatic interaction.
  • the fusogenic peptide/NLS peptide conjugates are linked to each other with a short amino acid stretch representing an endogenous protease cleavage site.
  • the structure of the preferred prototype fusogenic/NLS peptide conjugate used in this invention is: PKKRRGPSP(L/A/I) 12-20 (SEQ ID NO:8), where (L/A/I) 12-20 is a stretch of 12-20 hydrophobic amino acids containing A, L, I, Y, W, F and other hydrophobic amino acids.
  • the micelles made by the above methods are further provided by this invention by conversion into liposomes.
  • An effective amount of liposomes (diameter from about 80 to about 160 nm), or of a lipid solution composed of cholesterol (from about 10% to about 50%), neutral phospholipid such as hydrogenated soy phosphatidylcholine (HSPC) (from about 40% to about 90%), and the derivatized vesicle-forming lipid PEG-DSPE (distearoylphosphatidyl ethanolamine) from about 1-to about 7 mole percent, is added to the micelle solution.
  • HSPC hydrogenated soy phosphatidylcholine
  • PEG-DSPE disivatized vesicle-forming lipid PEG-DSPE
  • the liposomes are composed of vesicle-forming lipids and between from about 1 to about 7 mole percent of distearoylphosphatidyl ethanolamine (DSPE) derivatized with a polyethyleneglycol.
  • DSPE distearoylphosphatidyl ethanolamine
  • Micelles are converted into liposomes with a concomitant decrease of the ethanol concentration which can be accomplished by removal of the ethanol by dialysis of the liposome complexes through permeable membranes or reduced to a diameter of 80-160 nm by extrusion through membranes.
  • Liposome encapsulated therapeutic agents produced by the above methods are further provided by this invention.
  • Also provided herein is a method for delivering a therapeutic agent such as plasmid DNA or oligonucleotides to a tissue cell in vivo by intravenous, or other type of injection of the micelles or liposomes.
  • This method specifically targets a primary tumor and the metastases by the long circulating time of the micelle or liposome complex because of the exposure of PEG chains on its surface, its small size (80-160 nm) and the decrease in hydrostatic pressure in the solid tumor from the center to its periphery supporting a preferential extravasation through the tumor vasculature to the extracellular space in tumors.
  • a method for delivering plasmid or oligonucleotide DNA across the cell membrane barrier of the tumors using the micelle or liposome complexes described herein is capable because of the presence of the fusogenic peptides in the complex.
  • a method for delivering plasmid or oligonucleotide DNA to the liver, spleen and bone marrow after intravenous injection of the complexes is provided.
  • a method for delivering therapeutic genes to the liver, spleen and bone marrow of cancer and noncancer patients including but not limited to, factor VIII or IX for the therapy of hemophilias, multidrug resistance, cytokine genes for cancer immunotherapy, genes for the alleviation of pain, genes for the alleviation of diabetes and genes that can be introduced to liver, spleen and bone marrow tissue, to produce a secreted form of a therapeutic protein.
  • the disclosed therapies also provide methods for reducing tumor size by combining the encapsulated plasmid DNA carrying one or more anticancer genes selected from the group consisting of p53, RB, BRCA1, E1A, bc1-2, MDR-1, p21, p16, bax, bc1-xs, E2F, IGF-I VEGF, angiostatin, oncostatin, endostatin, GM-CSF, IL-12, IL-2, IL-4, IL-7, IFN- ⁇ , TNF- ⁇ , HSV-tk (in combination with ganciclovir), E.
  • anticancer genes selected from the group consisting of p53, RB, BRCA1, E1A, bc1-2, MDR-1, p21, p16, bax, bc1-xs, E2F, IGF-I VEGF, angiostatin, oncostatin, endostatin, GM-CSF, IL-12, IL-2,
  • coli cytosine deaminase in combination with 5-fluorocytosine
  • encapsulated antisense oligonucleotides antisense c-fos, c-myc, K-ras
  • ribozymes or triplex-forming oligonucleotides directed against genes that control the cell cycle or signaling pathways.
  • encapsulated plasmid DNA carrying one or more anticancer genes of can be modified by combining the encapsulated plasmid DNA carrying one or more anticancer genes of with encapsulated or free antineoplastic drugs, consisting of the group of adriamycin, angiostatin, azathioprine, bleomycin, busulfane, camptothecin, carboplatin, carmustine, chlorambucile, chlormethamine, chloroquinoxaline sulfonamide, cisplatin, cyclophosphamide, cycloplatam, cytarabine, dacarbazine, dactinomycin, daunorubicin, didox, doxorubicin, endostatin, enloplatin, estramustine, etoposide, extramustinephosphat, flucytosine, fluorodeoxyuridine, fluorouracil, gallium nitrate, hydroxyurea, idoxuridine,
  • Liposomes are microscopic vesicles consisting of concentric lipid bilayers. Structurally, liposomes range in size and shape from long tubes to spheres, with dimensions from a few hundred Angstroms to fractions of a millimeter. Vesicle-forming lipids are selected to achieve a specified degree of fluidity or rigidity of the final complex providing the lipid composition of the outer layer.
  • phospholipids such as phosphatidylcholine (PC), phosphatidylethanolamine (PE), phosphatidylinositol (PI), and sphingomyelin (SM) and other type of bipolar lipids including but not limited to dioleoylphosphatidylethanolamine (DOPE), with a hydrocarbon chain length in the range of 14-22, and saturated or with one or more double C ⁇ C bonds.
  • PC phosphatidylcholine
  • PE phosphatidylethanolamine
  • PI phosphatidylinositol
  • SM sphingomyelin
  • DOPE dioleoylphosphatidylethanolamine
  • lipids capable of producing a stable liposome are phospholipids, such as hydrogenated soy phosphatidylcholine (HSPC), lecithin, phosphatidylethanolamine, lysolecithin, lysophosphatidylethanolamine, phosphatidylserine, phosphatidylinositol, sphingomyelin, cephalin, cardiolipin, phosphatidic acid, cerebrosides, distearoylphosphatidylethanolamine (DSPE), dioleoylphosphatidylcholine (DOPC), dipalmitoylphosphatidylcholine (DPPC), palmitoyloleoylphosphatidylcholine (POPC), palmitoyloleoylphosphatidylethanolamine (POPE) and dioleoylphosphatidylethanolamine 4-(N-maleimido-methyl)cyclohexane
  • HSPC hydrogenated soy phosphati
  • Additional non-phosphorous containing lipids that can become incorporated into liposomes include stearylamine, dodecylamine, hexadecylamine, isopropyl myristate, triethanolamine-lauryl sulfate, alkyl-aryl sulfate, acetyl palmitate, glycerol ricinoleate, hexadecyl stereate, amphoteric acrylic polymers, polyethyloxylated fatty acid amides, and the cationic lipids mentioned above (DDAB, DODAC, DMRIE, DMTAP, DOGS, DOTAP (DOTMA), DOSPA, DPTAP, DSTAP, DC-Chol).
  • DDAB DODAC
  • DMRIE DMTAP
  • DOGS DOGS
  • DOTAP DOTMA
  • DOSPA DPTAP
  • DSTAP DC-Chol
  • Negatively charged lipids include phosphatidic acid (PA), dipalmitoylphosphatidylglycerol (DPPG), dioleoylphosphatidylglycerol and (DOPG), dicetylphosphate that are able to form vesicles.
  • Preferred lipids for use in the present invention are cholesterol, hydrogenated soy phosphatidylcholine (HSPC) and, the derivatized vesicle-forming lipid PEG-DSPE.
  • liposomes can be divided into three categories based on their overall size and the nature of the lamellar structure.
  • the three classifications as developed by the New York Academy Sciences Meeting, “Liposomes and Their Use in Biology and Medicine,” December 1977, are multi-lamellar vesicles (MLVs), small uni-lamellar vesicles (SUVs) and large uni-lamellar vesicles (LUVs).
  • SUVs range in diameter from approximately 20 to 50 nm and consist of a single lipid bilayer surrounding an aqueous compartment.
  • Unilamellar vesicles can also be prepared in sizes from about 50 nm to 600 nm in diameter. While unilamellar are single compartmental vesicles of fairly uniform size, MLVs vary greatly in size up to 10,000 nm, or thereabouts, are multi-compartmental in their structure and contain more than one bilayer.
  • LUV liposomes are so named because of their large diameter that ranges from about 600 nm to 30,000 nm; they can contain more than one bilayer.
  • Liposomes may be prepared by a number of methods not all of which produce the three different types of liposomes. For example, ultrasonic dispersion by means of immersing a metal probe directly into a suspension of MLVs is a common way for preparing SUVs.
  • Preparing liposomes of the MLV class usually involves dissolving the lipids in an appropriate organic solvent and then removing the solvent under a gas or air stream. This leaves behind a thin film of dry lipid on the surface of the container. An aqueous solution is then introduced into the container with shaking, in order to free lipid material from the sides of the container. This process disperses the lipid, causing it to form into lipid aggregates or liposomes.
  • Liposomes of the LUV variety may be made by slow hydration of a thin layer of lipid with distilled water or an aqueous solution of some sort. Alternatively, liposomes may be prepared by lyophilization.
  • This process comprises drying a solution of lipids to a film under a stream of nitrogen. This film is then dissolved in a volatile solvent, frozen, and placed on a lyophilization apparatus to remove the solvent. To prepare a pharmaceutical formulation containing a drug, a solution of the drug is added to the lyophilized lipids, whereupon liposomes are formed.
  • Cationic lipids with the exception of sphingosine and some lipids in primitive life forms, do not occur in nature.
  • the present invention uses single-chain amphiphiles which are chloride and bromide salts of the alkyltrimethylammonium surfactants including but not limited to C12 and C16 chains abbreviated DDAB (same as DODAB) or CTAB.
  • DDAB chloride and bromide salts of the alkyltrimethylammonium surfactants
  • CTAB CTAB
  • the molecular geometry of these molecules determines the critical micelle concentration (ratio between free monomers in solution and molecules in micelles).
  • Lipid exchange between the two states is a highly dynamic process; phospholipids have critical micelle concentration values below 10 ⁇ 8 M and are more stable in liposomes; however, single chain detergents, such as stearylamine, may emerge from the liposome membrane upon dilution or intravenous injection in milliseconds (Lasic, 1997).
  • Cationic lipids include, but are not limited to, DDAB: dimethyldioctadecyl ammonium bromide (same as N,N-distearyl-N,N-dimethylammonium bromide); DMRIE: N-[1-(2,3-dimyristyloxy)propyl]-N,N-dimethyl-N-(2-hydroxyethyl) ammonium bromide; DODAC: N,N-dioleyl-N,N-dimethylammonium chloride; DMTAP: 1,2-dimyristoyl-3-trimethylammonium propane; DODAP: 1,2-dioleoyl-3-dimethylammonium propane; DOGS: Dioctadecylamidoglycylspermine; DOTAP (same as DOTMA): N-(1-(2,3-dioleoyloxy)propyl)-N,N,N-trimethylammoni
  • Lipid-based vectors used in gene transfer have been formulated in one of two ways.
  • the nucleic acid is introduced into preformed liposomes made of mixtures of cationic lipids and neutral lipids.
  • the complexes thus formed have undefined and complicated structures and the transfection efficiency is severely reduced by the presence of serum.
  • Preformed liposomes are commercially available as LIPOFECTIN and LIPOFECTAMINE.
  • the second method involves the formation of DNA complexes with mono- or poly-cationic lipids without the presence of a neutral lipid. These complexes are prepared in the presence of ethanol and are not stable in water. Additionally, these complexes are adversely affected by serum (see, Behr, Acc. Chem. Res.
  • the nucleotide polymers can be single-stranded DNA or RNA, or double-stranded DNA or DNA—RNA hybrids.
  • double-stranded DNA include structural genes, genes including control and termination regions, and self-replicating systems such as plasmid DNA.
  • Particularly preferred nucleic acids are plasmids.
  • Single-stranded nucleic acids include antisense oligonucleotides (complementary to DNA and RNA), ribozymes and triplex-forming oligonucleotides.
  • nucleotide linkages substituted with stable, non-phosphodiester linkages, including, for example, phosphorothioate, phosphorodithioate, phosphoroselenate, methylphosphonate, or O-alkyl phosphotriester linkages.
  • Cationic lipids used with fusogenic peptide/NLS conjugates to provide the inner layer of the particle can be any of a number of substances selected from the group of DDAB, DODAC, DMRIE, DMTAP, DOGS, DOTAP (DOTMA), DOSPA, DPTAP, DSTAP, DC-Chol.
  • the cationic lipid is combined with DOPE.
  • the preferred cationic lipid is DDAB:DOPE 1: 1.
  • Neutral lipids used herein to provide the outer layer of the particles can be any of a number of lipid species that exist either in an uncharged or neutral zwitterionic form at physiological pH.
  • Such lipids are selected from a group consisting of diacylphosphatidylcholine, diacylphosphatidylethanolamine, ceramide, sphingomyelin, cephalin, and cerebrosides.
  • lipids containing saturated, mono-, or di-unsaturated fatty acids with carbon chain lengths in the range of C14 to C22 are preferred.
  • lipids having a variety of acyl chain groups of varying chain length and degree of saturation are available or may be isolated or synthesized by well-known techniques.
  • lipids with carbon chain lengths in the range of C14 to C22 are used.
  • the neutral lipids used in the present invention are hydrogenated soy phosphatidylcholine (HSPC), cholesterol, and PEG-distearoylphosphatidyl ethanolamine (DSPE) or PEG-ceramide.
  • Preparing liposomes of the MLV class usually involves dissolving the lipids in an appropriate organic solvent and then removing the solvent under a gas or air stream. This leaves behind a thin film of dry lipid on the surface of the container. An aqueous solution is then introduced into the container with shaking, in order to free lipid material from the sides of the container. This process disperses the lipid, causing it to form into lipid aggregates or liposomes.
  • Liposomes of the LUV variety may be made by slow hydration of a thin layer of lipid with distilled water or an aqueous solution of some sort. Alternatively, liposomes may be prepared by lyophilization.
  • This process comprises drying a solution of lipids to a film under a stream of nitrogen.
  • the film is then dissolved in a volatile solvent, frozen, and placed on a lyophilization apparatus to remove the solvent.
  • a solution of the drug is added to the lyophilized lipids, whereupon liposomes are formed.
  • the liposomes may be sized to achieve a desired size range and relatively narrow distribution of liposome sizes.
  • the preformed liposomes are sized to a mean diameter of about 80 to 160 nm (the upper size limit for filter sterilization before in vivo administration).
  • Several techniques are available for sizing liposomes to a desired size. Sonicating a liposome suspension either by bath or probe sonication produces a progressive size reduction down to small unilamellar vesicles less than about 0.05 microns (50 nm) in size. Extrusion of liposome through a small-pore polycarbonate is our preferred method for reducing liposome sizes to a relatively well-defined size distribution.
  • the liposomes may be extruded through successively smaller-pore membranes, to achieve a gradual reduction in liposome size.
  • compositions comprising the cationic liposome/nucleic acid complexes of the invention are prepared according to standard techniques and further comprise a pharmaceutically acceptable carrier. Generally, normal saline will be employed as the pharmaceutically acceptable carrier.
  • the pharmaceutical compositions are preferably administered parenterally, i.e., intravenously, intraperitoneally, subcutaneously, intrathecally, injection to the spinal cord, intramuscularly, intraarticularly, portal vein injection, or intratumorally. More preferably, the pharmaceutical compositions are administered intravenously or intratumorally by a bolus injection.
  • the pharmaceutical preparations may be contacted with the target tissue by direct application of the preparation to the tissue. The application may be made by topical “open” or “closed” procedures.
  • topical means the direct application of the pharmaceutical preparation to a tissue exposed to the environment, such as the skin, to any surface of the body, nasopharynx, external auditory canal, ocular administration and administration to the surface of any body cavities, inhalation to the lung, genital mucosa and the like.
  • Open procedures are those procedures that include incising the skin of a patient and directly visualizing the underlying tissue to which the pharmaceutical preparations are applied. This is generally accomplished by a surgical procedure, such as a thoracotomy to access the lungs, abdominal laparotomy to access abdominal viscera, or other direct surgical approach to the target tissue.
  • “Closed” procedures are invasive procedures in which the internal target tissues are not directly visualized, but accessed via insertion of instruments through small wounds in the skin.
  • the preparations may be administered to the peritoneum by needle lavage.
  • the pharmaceutical preparations may be administered to the meninges or spinal cord by infusion during a lumbar puncture followed by appropriate positioning of the patient as commonly practiced for spinal anesthesia or metrazamide imaging of the spinal cord.
  • the preparations may be administered through endoscopic devices.
  • DDAB dioleoylphosphatidylethanolamine
  • DOPE dioleoylphosphatidylethanolamine
  • PEG-DSPE was from Syngena.
  • the pGL3-C (Promega) was cut with XbaI and blunt-end ligated using the Klenow fragment of E. coli DNA polymerase. It was then cut with HindIII and the 1689-bp fragment, carrying the luciferase gene, was gel-purified.
  • the pGFP-N1 plasmid (Clontech) was cut with SmaI and HindIII and the 4.7 kb fragment, isolated from an agarose gel, was ligated with the luciferase fragment. JM109 E. Coli cells were transformed and 20 colonies were selected; about half of them showed the presence of inserts; 8 clones with inserts were cut with BamHI and XhoI to further confirm the presence of the luciferase gene; seven of them were positive.
  • Radiolabeled plasmid pLF was generated by culturing Escherichia coli in 3 H-thymidine-5′-triphosphate or 32 P inorganic phosphate (5 mCi) (Dupont/NEN, Boston, Mass.) and purified using standard techniques as described above.
  • a Coulter N4M light scattering instrument was used, at a 90° angle, set at a run time of 200 sec, using 4 to 25 microsec sample time.
  • the scan of the particle size distribution was obtained in 1 ml sample volume using plastic cuvettes, at 20° C. and at 0.01 poise viscosity.
  • this invention provides a method for entrapping DNA into lipids that enhances the content of plasmid per volume unit, and reduces the toxicity of the cationic lipids used to trap plasmid or oligonucleotide DNA.
  • the DNA becomes hidden in the inner membrane bilayer of the final complex.
  • the gene transfer complex is endowed with long circulation time in body fluids and extravasates preferentially into solid tumors and their metastatic foci and nodules. The extravasation occurs through their vasculature at most sites of the human or animal body after intravenous injection of the gene-carrying vehicles.
  • a suitable solvent for preparing a micelle from the desired lipid components is ethanol, methanol, or other aliphatic alcohols such as propanol, isopropanol, butanol, tert-butanol, iso-butanol, pentanol and hexanol. Mixtures of two or more solvents may be used in the practice of the invention. It is also to be understood that any solvent that is miscible with an ethanol solution, even in small amounts, can be used to improve micelle formation and its subsequent conversion into liposomes, including chloroform, dichloromethane, diethylether, cyclohexane, cyclopentane, benzene, and toluene.
  • the liposome encapsulated DNA described herein further comprises an effective amount of cationic lipids.
  • Cationic lipids have been widely used for gene transfer; a number of clinical trials (34 out of 220 total RAC-approved protocols as of December, 1997) use cationic lipids. Although many cell culture studies have been documented, systemic delivery of genes with cationic lipids in vivo has been very limited. All clinical protocols use subcutaneous, intradermal, intratumoral, and intracranial injection as well as intranasal, intrapleural, or aerosol administration but not I.V. delivery, because of the toxicity of the cationic lipids and DOPE (see, Martin and Boulikas, 1998).
  • Liposomes formulated from DOPE and cationic lipids based on diacyltrimethylammonium propane (dioleoyl-, dimyristoyl-, dipalmitoyl-, disteroyl-trimethylammonium propane or DOTAP, DMTAP, DPTAP, DSTAP, respectively) or DDAB were highly toxic when incubated in vitro with phagocytic cells (macrophages and U937 cells), but not towards non-phagocytic T lymphocytes.
  • the rank order of toxicity was DOPE/DDAB >DOPE/DOTAP >DOPE/DMTAP >DOPE/DPTAP >DOPE/DSTAP; and the toxicity was determined from the effect of the cationic liposomes on the synthesis of nitric oxide (NO) and TNF- ⁇ produced by activated macrophages (Filion and Phillips, 1997).
  • Condensing agents used for plasmid delivery including polylysine, transferrin-polylysine, a fifth-generation poly(amidoamine) (PAMAM) dendrimer, poly(ethyleneimine), and several cationic lipids (DOTAP, DC-Chol/DOPE, DOGS/DOPE, and DOTMA/DOPE), were found to activate the complement system to varying extents. Strong complement activation was seen with long-chain polylysines, the dendrimer, poly(ethyleneimine), and DOGS. Modifying the surface of preformed DNA complexes with polyethyleneglycol (Plank et al., 1996) considerably reduced complement activation.
  • Cationic lipids increase the transfection efficiency by destabilizing the biological membranes, including plasma, endosomal, and lysosomal membranes.
  • Incubation of isolated lysosomes with low concentrations of DOTAP caused a striking increase in free activity of ⁇ -galactosidase, and even a release of the enzyme into the medium.
  • the mechanism of destabilization was thought to involve an interaction between cationic liposomes and anionic lipids of the lysosomal membrane, thus allowing a fusion between the lipid bilayers. The process was less pronounced at pH 5 than at pH 7.4, and anionic amphipathic lipids were able to prevent partially this membrane destabilization (Wattiaux et al., 1997).
  • DC-CHOL In contrast to DOTAP and DMRIE that were 100% charged at pH 7.4, DC-CHOL was only about 50% charged as monitored by a pH-sensitive fluorophore. This difference decreases the charge on the external surfaces of the liposomes, and was proposed to promote an easier dissociation of bilayers containing DC-CHOL from the plasmid DNA, and an increase in release of the DNA-lipid complex into the cytosol from the endosomes (Zuidam and Barenholz, 1997).
  • cationic lipids have been used widely for the delivery of genes, very few studies have used systemic I.V. injection of cationic liposome-plasmid complexes. This is because of the toxicity of the lipid component in animal models, not humans.
  • a number of different organs in vivo can be targeted after liposomal delivery of genes or oligonucleotides.
  • Intravenous injection of cationic liposome-plasmid complexes by tail vein in mice targeted mainly the lung and to a smaller extent the liver, spleen, heart, kidney and other organs (Zhu et al., 1993).
  • Steps to improve liposome-mediated gene delivery to somatic cells include, persistence of the plasmid in blood circulation, port of entry and transport across the cell membrane, release from endosomal compartments into the cytoplasm, nuclear import by docking through the pore complexes of the nuclear envelope, expression driven by the appropriate promoter/enhancer control elements, and persistence of the plasmid in the nucleus for long periods (Boulikas, 1998a).
  • the liposome encapsulated DNA described herein is condensed with spermine and/or spermidine.
  • DNA can be presented to cells in culture as a complex with polycations such as polylysine, or basic proteins such as protamine, total histones or specific histone fractions, protamine (Boulikas and Martin, 1997).
  • polycations such as polylysine, or basic proteins such as protamine, total histones or specific histone fractions, protamine (Boulikas and Martin, 1997).
  • the interaction of plasmid DNA with protamine sulfate, followed by the addition of DOTAP cationic liposomes offered a better protection of plasmid DNA against enzymatic digestion.
  • the method gave consistently higher gene expression in mice via tail vein injection as compared with DOTAP/DNA complexes.
  • luciferase-plasmid 50 ⁇ g of luciferase-plasmid per mouse gave 20 ng luciferase protein per mg extracted tissue protein in the lung, that was detected as early as 1 h after injection, peaked at 6 h and declined thereafter.
  • Intraportal injection of protamine/DOTAP/DNA led to about a 100-fold decrease in gene expression in the lung as compared with I.V. injection.
  • Endothelial cells were the primary locus of lacZ transgene expression (Li and Huang, 1997).
  • Protamine sulfate enhanced plasmid delivery into several different types of cells in vitro, using the monovalent cationic liposomal formulations (DC-Chol and lipofectin). This effect was less pronounced with the multivalent cationic liposome formulation, lipofectamine (Sorgi et al., 1997).
  • the liposome encapsulates oligonucleotide DNA.
  • Encapsulation of oligonucleotides into liposomes increased their therapeutic index, prevented degradation in cultured cells, and in human serum and reduced toxicity to cells (Thierry and Dritschilo, 1992; Capaccioli et al., 1993; Lewis et al., 1996).
  • most studies have been performed in cell culture, and very few in animals in vivo. There are still an important number of improvements needed before these approaches can move into clinical studies.
  • oligonucleotide-DDAB/DOPE complexes with a net positive charge were released from vesicles into the cytoplasm. It was determined that DDAB/DOPE mediated nuclear import of the oligonucleotides.
  • DOPE-heme (ferric protoporphyrin IX) conjugates inserted in cationic lipid particles with DOTAP, protected oligoribonucleotides from degradation in human serum and increased oligoribonucleotide uptake into 2.2.15 human hepatoma cells. The enhancing effect of heme was evident only at a net negative charge in the particles (Takle et al., 1997). Uptake of liposomes labeled with 111 In and composed of DC-Chol and DOPE was primarily by liver, with some accumulation in spleen and skin and very little in the lung after I.V. tail injection.
  • oligonucleotide Preincubation of cationic liposomes with phosphorothioate oligonucleotide induced a dramatic, yet transient, accumulation of the lipid in lung that gradually redistributed to liver.
  • the mechanism of lung uptake involved entrapment of large aggregates of oligonucleotides within pulmonary capillaries at 15 min post-injection via embolism. Labeled oligonucleotide was localized primarily to phagocytic vacuoles of Kupffer cells at 24 h post-injection. Nuclear uptake of oligonucleotides in vivo was not observed (Litzinger et al., 1996).
  • the liposome encapsulated DNA described herein further comprise coating of the final complex in step 2 (FIG. 1) with PEG.
  • PEG polyethylene glycol
  • Derivatized lipids that are employed include PEG-modified DSPE or PEG-ceramide. Addition of PEG components prevents complex aggregation, increases circulation lifetime of particles (liposomes, proteins, other complexes, drugs) and increases the delivery of lipid-nucleic acid complexes to the target tissues. See, Maxfield et al., Polymer 16:505-509 (1975); Bailey, F. E.
  • Conjugation to PEG is reported to have reduced immunogenicity and toxicity. See, Abuchowski et al., J. Biol. Chem. 252:3578-3581 (1977).
  • the extent of enhancement of blood circulation time of liposomes, by coating with PEG is described in U.S. Pat. No. 5,013,556.
  • the concentration of the PEG-modified phospholipids, or PEG-ceramide in the complex will be about 1-7%.
  • the PEG-modified lipid is a PEG-DSPE.
  • the first breakthrough came in 1987 when a glycolipid (the brain tissue-derived ganglioside GM 1), was identified that, when incorporated within the lipid matrix, allowed liposomes to circulate for many hours in the blood stream (Allen and Chonn, 1987).
  • the PEG hydrophilic polymers form dense “conformational clouds” to prevent other macromolecules from interaction with the surface, even at low concentrations of the protecting polymer (Gabizon and Papahadjopoulos, 1988; Papahadjopoulos et al., 1991; reviewed by Torchilin, 1998).
  • the increased hydrophilicity of the liposomes after their coating with the amphipathic PEG5000 leads to a reduction in nonspecific uptake by the reticuloendothelial system.
  • the liposome encapsulated DNA described herein further comprise an initial step of micelle formation between cationic lipids and condensed plasmid or oligonucleotide DNA in ethanol solutions.
  • Micelles are small amphiphilic colloidal particles formed by certain kinds of lipid molecules, detergents or surfactants under defined conditions of concentration, solvent and temperature. They are composed of a single lipid layer. Micelles can have their hydrophilic head groups assembled exposing their hydrophobic tails to the solvent (for example in 30-60% aqueous ethanol solution) or can reverse their structures exposing their polar heads toward the solvent such as by lowering the concentration of the ethanol to below 10% (reverse micelles).
  • Micelle systems are in thermodynamic equilibrium with the solvent molecules and environment. This results in constant phase changes, especially upon contact with biological materials, such as upon introduction to cell culture, injection to animals, dilution, contact with proteins or other macromolecules. These changes result in rapid micelle disassembly or flocculation. This is in contrast to the much higher stability of liposome bilayers.
  • Single-chain surfactants are able to form micelles (see Table 1, below). These include the anionic (sodium dodecyl sulfate, cholate or oleate) or cationic (cetyl-trimethylammonium bromide, CTAB) surfactants.
  • CTAB, CTAC, and DOIC micelles yielded larger solubility gaps (lower concentration of colloidally suspended DNA) than corresponding SUV particles containing neutral lipid and CTAB (1:1) (Lasic, 1997).
  • a long circulating complex needs to be slightly anionic. Therefore the liposomes used for the conversion of the micelles into liposomes contain bipolar lipids (PC, PE) and 1-30% negatively charged lipids (DPPG).
  • PC, PE bipolar lipids
  • DPPG negatively charged lipids
  • the cationic lipids which are toxic, are hidden in the inner liposome membrane bilayer. Those reaching the solid tumor will exert their toxic effects causing apoptosis. Apoptosis will be caused by the delivery of the toxic drug or anti-neoplastic gene or oligonucleotide to the cancer cell but also by the nuclear localization of the cationic lipids (along with plasmid DNA) to the nucleus.
  • plasmid DNA is imported to nuclei; its translocation docks cationic lipid molecules electrostatically attached to the DNA. These cationic lipid molecules exert their toxicity by interfering with the nucleosome and domain structure of the chromatin causing local destabilization. This disturbance or aberrant chromatin reorganization could be exerted at the level of the nuclear matrix where plasmid DNA is attached for transcription, autonomous replication, or integration via recombination.
  • HLB hydrophile/lipophile balance
  • Nonionic surfactants find wide application in pharmaceutical and cosmetic products and are usable over a wide range of pH values. In general, their HLB values range from 2 to about 18, depending on their structure.
  • Nonionic surfactants include, nonionic esters such as ethylene glycol esters, propylene glycol esters, glyceryl esters, polyglyceryl esters, sorbitan esters, sucrose esters, and ethoxylated esters.
  • Nonionic alkanolamides and ethers such as fatty alcohol ethoxylates, propoxylated alcohols, and ethoxylated/propoxylated, block polymers are also included in this class.
  • the polyoxyethylene surfactants are the most popular members of the nonionic surfactant class.
  • Anionic surfactants include carboxylates such as soaps, acyl lactylates, acyl amides of amino acids, esters of sulfuric acid such as alkyl sulfates and ethoxylated alkyl sulfates, sulfonates such as alkyl benzene sulfonates, acyl isethionates, acyl taurates and sulfosuccinates, and phosphates.
  • the most important members of the anionic surfactant class are the alkyl sulfates and the soaps.
  • Cationic surfactants include quaternary ammonium salts and ethoxylated amines.
  • the quaternary ammonium salts are the most used members of this class. If the surfactant molecule has the ability to carry either a positive or negative charge, the surfactant is classified as amphoteric.
  • Amphoteric surfactants include acrylic acid derivatives, substituted alkylamides, N-alkylbetaines and phosphatides.
  • Classical micelles may not be effective as gene transfer vehicles, but important intermediates in the formation of liposome complexes encapsulating drugs or nucleic acids.
  • the stability of single chain surfactants-DNA-colloidal systems is lower than SUV particles containing neutral lipid and CTAB (1:1).
  • second generation micelles are able to target tumors in vivo.
  • Weissig and co-workers (1998) used the soybean trypsin inhibitor (STI) as a model protein to target tumors.
  • STI was modified with a hydrophobic residue of N-glutaryl-phosphatidyl-ethanolamine (NGPE) and incorporated into both polyethyleneglycol (MW 5000)-distearoyl phosphatidyl ethanolamine (PEG-DSPE) micelles ( ⁇ 20 nm) and PEG-DSPE-modified long-circulating liposomes (ca. 100 ⁇ m).
  • N-glutaryl-phosphatidyl-ethanolamine NGPE
  • PEG-DSPE polyethyleneglycol
  • PEG-DSPE polyethyleneglycol
  • PEG-DSPE polyethyleneglycol
  • PEG-DSPE polyethyleneglycol
  • DTPA protein-attached diethylene triamine pentaacetic acid
  • Loading a liposomal dispersion with an amphiphilic drug may cause a phase transformation into a micellar solution.
  • the transition from high ratios of phospholipid to drug (from 2:1 to 1:1 downwards) were accompanied by the conversion of liposomal dispersions of milky-white appearance (particle size 200 m) to nearly transparent micelles (particle size below 25 nm). See, Schutze and Muller-Goymann (1998).
  • the liposome encapsulated DNA described herein further comprises an effective amount of a fusogenic peptide.
  • Fusogenic peptides belong to a class of helical amphipathic peptides characterized by a hydrophobicity gradient along the long helical axis. This hydrophobicity gradient causes the tilted insertion of the peptides in membranes, thus destabilizing the lipid core and, thereby, enhancing membrane fusion (Decout et al., 1999).
  • Hemagglutinin is a homotrimeric surface glycoprotein of the influenza virus. In infection, it induces membrane fusion between viral and endosomal membranes at low pH. Each monomer consists of the receptor-binding HA1 domain and the membrane-interacting HA2 domain. The NH2-terminal region of the HA2 domain (amino acids 1 to 127), the so-called “fusion peptide,” inserts into the target membrane and plays a crucial role in triggering fusion between the viral and endosomal membranes.
  • This peptide has the sequence: GLFEAIAGFI ENGWEGMIDG GGYC (SEQ ID NO:9) and is able to induce the release of the fluorescent dye calcein from liposomes prepared with egg yolk phosphatidylcholine, which was higher at acidic pH.
  • This peptide was also able to increase up to 10-fold the anti-HIV potency of antisense oligonucleotides, at a concentration of 0.1-1 mM, using CEM-SS lymphocytes in culture. This peptide changes conformation at the slightly more acidic environment of the endosome, destabilizing and breaking the endosomal membrane (reviewed by Boulikas, 1998a).
  • HA-chimeras were designed in which the cytoplasmic tail and/or transmembrane domain of HA was replaced with the corresponding domains of the fusogenic glycoprotein F of Sendai virus.
  • Constructs of HA were made in which the cytoplasmic tail was replaced by peptides of human neurofibromin type 1 (NF1) (residues 1441 to 1518) or c-Raf-1, (residues 51 to 131) and were expressed in CV-1 cells by using the vaccinia virus-T7 polymerase transient-expression system.
  • NF1 human neurofibromin type 1
  • c-Raf-1 c-Raf-1
  • Membrane fusion between CV-1 cells and bound human erythrocytes (RBCS) mediated by parental or chimeric HA proteins showed that, after the pH was lowered, a flow of the aqueous fluorophore calcein from preloaded RBCs into the cytoplasm of the protein-expressing CV-1 cells took place. This indicated that membrane fusion involves both leaflets of the lipid bilayers and leads to formation of an aqueous fusion pore (Schroth-Diaz et al., 1998).
  • TAT protein of HIV is able to cross cell membranes (Green and Loewenstein, 1998) and that a 36-amino acid domain of TAT, when chemically cross-linked to heterologous proteins, conferred the ability to transduce into cells.
  • the 11-amino acid fusogenic peptide of TAT (YGRKKRRQRRR (SEQ ID NO:10)) is a nucleolar localization signal (see Boulikas, 1998b).
  • Another protein of HIV contains fusogenic peptides.
  • Linear peptides derived from the membrane proximal region of the gp41 ectodomain have potential applications as anti-HIV agents and inhibit infectivity by adopting a helical conformation (Judice et al., 1997).
  • the 23 amino acid residue, N-terminal peptide of HIV-1 gp41 has the capacity to destabilize negatively charged large unilamellar vesicles. In the absence of cations, the main structure was a pore-forming alpha-helix, whereas in the presence of Ca 2+ the conformation switched to a fusogenic, predominantly extended beta-type structure.
  • PrP The prion protein
  • PrP is a glycoprotein of unknown function normally found at the surface of neurons and of glial cells. It is involved in diseases such as bovine spongiform encephalopathy, and Creutzfeldt-Jakob disease in humans, where PrP is converted into an altered form (termed PrPSc).
  • PrPSc The prion protein
  • the 120 to 133 and 118 to 135 domains of PrP are tilted lipid-associating peptides inserting in a oblique way into a lipid bilayer and able to interact with liposomes to induce leakage of encapsulated calcein (Pillot et al., 1997b).
  • the C-terminal fragments of the Alzheimer amyloid peptide have properties related to those of the fusion peptides of viral proteins inducing fusion of liposomes in vitro. These properties could mediate a direct interaction of the amyloid peptide with cell membranes and account for part of the cytotoxicity of the amyloid peptide.
  • Fusion peptides have been formulated with DNA plasmids to create peptide-based gene delivery systems.
  • MSGTFGGILAGLIGLL N-terminal region was inserted into the Rodriguez-Crespo et (SEQ ID NO:6) of the S protein of hydrophobic core of the al., 1999 duck hepatitis B lipid bilayer and induced Virus (DHBV) leakage of internal aqueous contents from both neutral and negatively charged liposomes
  • MSPSSLLGLLAGLQVV S protein of Was inserted into the Rodriguez-Crespo et (SEQ ID NO:14) woodchuck hydrophobic core of the al., 1999 hepatitis B virus lipid bilayer and induced (WHV) leakage of internal aqueous contents from both neutral and negatively charged liposomes N-terminus of Nef Nef protein of Membrane-perturbing and Macreadie et al., human fusogenic activities in 1997 inimuno- artificial membranes; causes deficiency cell killing in E.
  • DOPE is a fusogenic lipid; elastase cleavage of N-methoxy-succinyl-Ala-Ala-Pro-Val-DOPE (SEQ ID NO:19) converted this derivative to DOPE (overall positive charge) to deliver an encapsulated fluorescent probe, calcein, into the cell cytoplasm (Pak et al., 1999).
  • oligodeoxynucleic sequence of 30 bases complementary to a region of beta-endorphin mRNA elicited a concentration-dependent inhibition of beta-endorphin production in cell culture after it was encapsulated within small unilamellar vesicles (50 nm) containing dipalmitoyl-DL-alpha-phosphatidyl-L-serine endowed with fusogenic properties (Fresta et al., 1998).
  • the liposome encapsulated plasmid or oligonucleotide DNA described herein further comprise an effective amount of nuclear localization signal (NLS) peptides.
  • NLS nuclear localization signal
  • Protein translocation from the cytoplasm to the nucleoplasm involves: (i) the formation of a complex of karyopherin ⁇ with NLS-protein; (ii) subsequent binding of karyopherin ⁇ ; (iii) binding of the complex to FXFG peptide repeats on nucleoporins; (iv) docking of Ran-GDP to nucleoporin and to karyopherin heterodimer by p10; (v) a number of association-dissociation reactions on nucleoporins that dock the import substrate toward the nucleoplasmic side with a concomitant GDP-GTP exchange reaction transforming Ran-GDP into Ran-GTP and catalyzed by karyopherin ⁇ ; and (vi) dissociation from karyopherin ⁇ and release of the karyopherin ⁇ /NLS-protein by Ran-GTP to the nucleoplasm.
  • An NLS is defined as four arginines (R) plus lysines (K) within an hexapeptide; the presence of one or more histidines (H) in the tetrad of the karyophilic hexapeptide, often found in protein kinases that have a cytoplasmic and a nuclear function, may specify a weak NLS whose function might be regulated by phosphorylation or may specify proteins that function in both the cytoplasm and the nucleus (Boulikas, 1996);
  • NLS signals may not be flanked by long stretches of hydrophobic amino acids (e.g. five); a mixture of charged and hydrophobic amino acids serves as a mitochondrial targeting signal;
  • Signal peptides are stronger determinants than NLSs for protein trafficking. Signal peptides direct proteins to the lumen of the endoplasmic reticulum for their secretion or insertion into cellular membranes (presence of transmembrane domains) (Boulikas, 1994);
  • a number of processes have been found to be regulated by nuclear import including nuclear translocation of the transcription factors NF-KB, rNFIL-6, ISGF3, SRF, c-Fos, GR as well as human cyclins A and BI, casein kinase II, cAMP-dependent protein kinase II, protein kinase C, ERKI and ERK2.
  • Failure of cells to import specific proteins into nuclei can lead to carcinogenesis.
  • BRCA1 is mainly localized in the cytoplasm in breast and ovarian cancer cells, whereas in normal cells the protein is nuclear.
  • mRNA is exported through the same route as a complex with nuclear proteins possessing nuclear export signals (NES).
  • RNA-binding proteins that bind to and escort RNAs to the cytoplasm.
  • CRM1 that binds to the NES sequence on other proteins and interacts with the nuclear pore complex, is an essential mediator of the NES-dependent nuclear export of proteins in eukaryotic cells.
  • Nuclear localization and export signals are found on a number of important molecules, including p53, v-Rel, the transcription factor NF-ATc, the c-Ab1 nonreceptor tyrosine kinase, and the fragile X syndrome mental retardation gene product. The deregulation of their normal import/export trafficking has important implications for human disease.
  • Both nuclear import and export processes can be manipulated by conjugation of proteins with NLS or NES peptides.
  • the foreign DNA needs to enter nuclei for its transcription.
  • a pathway is proposed involving the complexation of plasmids and oligonucleotides with nascent nuclear proteins possessing NLSs as a prerequisite for their nuclear import.
  • Covalent linkage of NLS peptides to oligonucleotides and plasmids or formation of complexes of plasmids with proteins possessing multiple NLS peptides was proposed (Boulikas, 1998b) to increase their import rates and the efficiency of gene expression. Cancer cells were predicted to import more efficiently foreign DNA into nuclei, compared with terminally differentiated cells because of their increased rates of proliferation and protein import.
  • the liposome encapsulated plasmid or oligonucleotide DNA described herein further comprises its use for reducing tumor size or restricting its growth with combination with encapsulated or free antineoplastic agents.
  • Antineoplastic agents preferably are: (i) alkylating agents having the bis-(2-chloroethyl)-amine group such as chlormethine, chlorambucile, melphalan, uramustine, mannomustine, extramustinephosphat, mechlorethaminoxide, cyclophosphamide, ifosfamide, or trifosfamide; (ii) alkylating agents having a substituted aziridine group, for example tretamine, thiotepa, triaziquone, or mitomycine; (iii) alkylating agents of the methanesulfonic ester type such as busulfane; (iv) alkylating N-alkyl-N-nitrosourea derivatives, for example carmustine, lomustine, semustine, or streptozotocine; (v) alkylating agents of the mitobronitole, dacarbazine, or procarbazine type; (
  • tumor suppressor genes p53, RB, BRCA1, E1A, bc1-2, MDR-1, p21, p16, bax, bcl-xs, E2F, IGF-I VEGF, angiostatin, oncostatin, endostatin, GM-CSF, IL-12, IL-2, IL-4, IL-7, IFN- ⁇ , and TNF-a); and (xxiii) antisense oligonucleotides (antisense c-fos, c-myc, K-ras).
  • these drugs are administered in combination with chlormethamine, prednisolone, prednisone, or procarbazine or combined with radiation therapy.
  • Future new anticancer drugs added to the arsenal are expected to be ribozymes, triplex-forming oligonucleotides, gene inactivating oligonucleotides, a number of new genes directed against genes that control the cell proliferation or signaling pathways, and compounds that block signal transduction.
  • Anti-cancer drugs include: acivicin, aclarubicin, acodazole hydrochloride, acronine, adozelesin, adriamycin, aldesleukin, altretamine, ambomycin, ametantrone acetate, aminoglutethimide, amsacrine, anastrozole, anthramycin, asparaginase, asperlin, azacitidine, azetepa, azotomycin, batimastat, benzodepa, bicalutamide, bisantrene hydrochloride, bisnafide dimesylate, bizelesin, bleomycin sulfate, brequinar sodium, bropirimine, busulfan, cactinomycin, calusterone, caracemide, carbetimer, carboplatin, carmustine, carubicin hydrochloride, carzelesin, cedefingol, chloram
  • anti-cancer drugs include: 20-epi-1,25 dihydroxyvitamin D3, 5-ethynyluracil, abiraterone, aclarubicin, acylfulvene, adecypenol, adozelesin, aldesleukin, ALL-TK antagonists, altretamine, ambamustine, amidox, amifostine, aminolevulinic acid, amrubicin, amsacrine, anagrelide, anastrozole, andrographolide, angiogenesis inhibitors, antagonist D, antagonist G, antarelix, anti-dorsalizing morphogenetic protein-1, antiandrogen, antiestrogen, antineoplaston, antisense oligonucleotides, aphidicolin glycinate, apoptosis gene modulators, apoptosis regulators, apurinic acid, ara-CDP-DL-PTBA, arginine deamin
  • the genes in plasmid DNA are brought in interaction with fusogenic peptide/NLS conjugates.
  • the NLS moiety is a stretch of histidyl residues able to assume a net positive charge at a pH of about 5 to 6 and to show a reduction or loose completely this charge at pH above 7.
  • the electrostatic interaction of these positively-charged peptides with the negatively-charged plasmid DNA molecules, established at pH 5-6 is weakened at physiological pH (pH-sensitive peptide-DNA complexes).
  • the first step of the present invention involves complex formation between the plasmid or oligonucleotide DNA with the histidyl/fusogenic peptide conjugate and lipid components in 10-90% ethanol at pH 5.0 to 6.0.
  • the conditions must be where the histidyl residues have a net positive charge and can establish electrostatic interactions with plasmids, oligonucleotides or negatively-charged drugs.
  • the presence of the positively-charged lipid molecules promotes formation of micelles.
  • micelles are converted into liposomes by dilution with water and mixing with pre-made liposomes or lipids at pH 5-6. This is followed by dialysis against pH 7 and extrusion through membranes, entrapping and encapsulating plasmids or oligonucleotides to with a very high yield.
  • composition of peptides and cationic lipids in the first step provides the lipids of the internal bilayer
  • the type of liposomes or lipids added at step 2 provide the external coating of the final liposome formulation (FIG. 1).
  • the formulations of peptides include: HHHHHSPSL 16 (SEQ ID NO:623), and HHHHHSPS(LAI) 5 (SEQ ID NO:624).
  • Coating the outer surface of the complexes with polyethyleneglycol, hyaluronic acids and other polymers conjugated to lipids gives the particles long circulation properties in body fluids and the ability to target solid tumors and their metastases after intravenous injection, and also the ability to cross the tumor cell membrane.
  • An important issue of the present invention is the conversion of micelles formed between the DNA and the cationic lipids, in the presence of ethanol, into liposomes. This is done by the direct addition of the micelle complex into an aqueous solution of preformed liposomes.
  • the liposomes have an average size of 80-160 nm or vice versa, leading to a solution of a final ethanol concentration below 10%.
  • a formulation suitable for pharmaceutical use and for injection into humans and animals will require that the liposomes are of neutral composition (such as cholesterol, PE, PC) coated with PEG.
  • the composition of the aqueous solution of liposomes is any type of liposomes containing cationic lipids and suitable therefore for transfection of cells in culture such as DDAB:DOPE 1: 1.
  • These liposomes are preformed and downsized by sonication or extrusion through membranes to a diameter of 80-160 nm.
  • the ethanolic micelle preparations are then added to the aqueous solution of liposomes with a concomitant dilution of the ethanol solution to below 10%. This step will result in further condensation of DNA or interaction of the negatively-charged phosphate groups on DNA with positively charged groups on lipids. Care must be taken so as only part of the negative charges on DNA are neutralized by lipids in the micelle.
  • the remaining charge neutralization of the DNA is to be provided by the cationic component of the preformed liposomes in the second step.
  • the genes in plasmid DNA are driven by regulatory DNA sequences isolated from nuclear matrix-attached DNA using shotgun selection approaches.
  • the nuclear matrix is composed of DNA, RNA and proteins and serves as the site of DNA replication, gene transcription, DNA repair, and chromosomal attachment in the nucleus.
  • Diverse sets of DNA sequences have been found associated with nuclear matrices and is referred to as matrix attachment regions or MARs.
  • the MARs serve many functions, acting as activators of gene transcription, silencers of gene expression, insulators of transcriptional activity, nuclear retention signals and origins of DNA replication. Current studies indicate that different subsets of MARs are found in different tissue types and may assist in regulating the specific functions of cells.
  • MAR elements within gene transfer vectors could have utility in many experimental and gene therapy applications. Many gene therapy applications require specific expression of one or more genes in targeted cell types for prolonged time periods. MARs within vectors could enhance transcription of the introduced transgene, prolong the retention of that sequence within the nucleus or insulate expression of that transgene from the expression of a cotransduced gene (reviewed by Boulikas, 1995; Bode et al, 1996).
  • the presently disclosed method has the potential of rapidly identifying regulatory control regions.
  • chromatin loops are formed and different attachment regions are used in different cell types or stages of development to modulate the expression of a gene.
  • the presently disclosed method for isolating regulatory regions based on their attachment to the nuclear matrix can identify regulatory regions irrespective of their distance from the gene.
  • Plasmid DNA condenses with various agents, as well as various formulations of cationic liposomes. The condensation affects the level of expression of the reporter beta-galactosidase gene after transfection of K562 human erythroleukemia cell cultures. Liposome compositions are shown in the Table below and in FIG. 2. All lipids were from Avanti Polar Lipids (700 Industrial Park Drive, Alabaster, Ala. 35007). The optimal ratio of lipid to DNA was 7 mmoles total lipid/ ⁇ g DNA.
  • the transfection reagent (10 ⁇ g DNA mixed with 70 mmoles total lipid) was transferred to a small culture flask followed by the addition of 10 ml K562 cell culture (about 2 million cells total); mixing of cells with the transfection reagent was at 5-10 min after mixing DNA with liposomes. Cells were assayed for beta-galactosidase activity several times at 1-30 days post-transfection. The transfected cells were maintained in cell culture as normal cell cultures.
  • SFV Semliki Forest virus expressing beta-galactosidase. The results are shown in FIG. 2.
  • mice tumor targeting in SCID (severe combined immunodeficient) mice were implanted subcutaneously, at two sites, with human MCF-7 breast cancer cells. The cells were allowed to develop into large, measurable solid tumors at about 30 days post-inoculation. Mice were injected intraperitoneously with 0.2 mg plasmid pCMV ⁇ DNA (size of the plasmid is ⁇ 4 kb) per animal carrying the bacterial beta-galactosidase reporter gene.
  • Plasmid DNA (200 ⁇ g, 2.0 mg/ml, 0.1 ml ) was incubated for 5 min with 2001 neutral liposomes of the composition 40% cholesterol, 20% dioleoylphosphatidylethanolamine(DOPE), 12% palmitoyloleoylphosphatidylcholine (POPC), 10% hydrogenated soy phosphatidylcholine (HSPC), 10% distearoylphosphatidylethanolamine (DSPE), 5% sphingomyelin (SM), and 3% derivatized vesicle-forming lipid M-PEG-DSPE.
  • DOPE dioleoylphosphatidylethanolamine
  • POPC palmitoyloleoylphosphatidylcholine
  • HSPC hydrogenated soy phosphatidylcholine
  • DSPE distearoylphosphatidylethanolamine
  • SM sphingomyelin
  • the material was injected (0.35 ml total volume) to the intraperitoneal cavity of the animal.
  • the animal was sacrificed, the skin was removed and the carcass was incubated into X-gal staining solution for about 30 min at 37° C.
  • the animal was incubated in fixative in X-gal staining for about 30 min (addition of 100 ⁇ l concentrated glutaraldehyde to 30 ml X-gal staining solution) and the incubation in staining solution continued. Photos were taken in a time course during the incubation period revealing the preferred organs where beta-galactosidase expression took place.
  • PKKKR M V SEQ ID NO:21
  • Site-directed mutagenesis only slightly impaired nuclear import of large T.
  • PKKKRKVEDP SEQ ID Synthetic NLS peptide from SV40 large T antigen crosslinked to BSA NO:22
  • IgG IgG mediated their nuclear localization after microinjec- tion in Xenopus oocytes.
  • CGYGPKKKRKVGG SEQ ID Synthetic peptide from SV40 large T antigen conjugated to NO:23
  • various proteins and microinjected into the cytoplasm of TC-7 cells.
  • IgM of 970 kD and with an estimated radius of 25-40 nm was retained in the cytoplasm.
  • GAL4 AKCLKx 5 Rx 3 KTKR (SEQ ID gene portion encoding the 74 N-terminal amino acid with E. coli NO:27) ⁇ -galactosidase introduced into yeast cells specify nuclear localization.
  • 74 N-terminal amino acid MKx 11 C RLKKLK CSKEKPKC Yeast GAL4.
  • Acted as an efficient nuclear localization sequence A (SEQ ID NO:28) when fused to invertase but not to ⁇ -galactosidase introduced 29 N-terminal amino acid by transformation into yeast cells. Polyoma large T protein.
  • PKKARED (SEQ ID NO:29) by fusion with pyruvate kinase cDNA and microinjection of Vero VSRKRPR (SEQ ID NO:30) African green monkey cells.
  • Vero VSRKRPR (SEQ ID NO:30) African green monkey cells.
  • CGYGVSRKRPRPG Polyoma virus large T protein. This synthetic peptide crosslinked (SEQ ID NO:31) to chicken serum albumin and microinjected into HeLa cells caused nuclear localization.
  • NLS N terminus determined (SEQ ID NO:32) by infection of monkey kidney cells with a fusion construct containing the 5′ terminal portion of SV40 VP1 gene and the complete cDNA sequence of poliovirus capsid VP1 replacing the VP1 gene of SV40.
  • APKRKSGVSKC (1-11) Polyoma virus major capsid protein VP1 (11 N-terminal amino acid).
  • SEQ ID NO:33 Yeast expression vectors coding for 17 N-terminal amino acid of VP1 fused to ⁇ -galactosidase gave a protein that was transported to the nucleus in yeast cells. Subtractive constructs of VP1 lacking A 1 to C 11 were cytoplasmic.
  • PNKKKRK SEQ ID NO:34
  • SV40 VP2 capsid protein 39 kD
  • the 3′ end of the SV40 VP2-VP3 genes containing this peptide when fused to poliovirus VP1 capsid protein at the gene level resulted in nuclear import of the hybrid VP1 in simian cells infected with the hybrid SV40.
  • EEDGPQKKKRRL (307-318) Polyoma virus capsid protein VP2.
  • a construct having truncated (SEQ ID NO:35) VP2 lacking the 307-318 peptide transfected into COS-7 cells showed cytoplasmic retention of VP2.
  • GKKRSKA SEQ ID NO:36
  • Yeast histone H2B This peptide specified nuclear import when fused to ⁇ -galactosidase.
  • KRPRP SEQ ID NO:37
  • Adenovirus E1a Adenovirus E1a. This pentapeptide, when linked to the C-terminus of E. coli galactokinase, was sufficient to direct its nuclear accumulation after microinjection in Vero monkey cells.
  • CGGLSSKRPRP SEQ ID Adenovirus type 2/5 E1a. This synthetic peptide crosslinked NO:38) to chicken bovine albumin and microinjected into HeLa cells caused nuclear localization.
  • LV RKKRK TE 3 SP NLS 1
  • Xenopus N1 590 amino acid
  • the NLS1 is (SEQ ID NO:40) required but not sufficient for nuclear accumulation of protein N1.
  • NLS 1 and 2 are contiguous at the C-terminus.
  • v-Rel NLS added to the normally cytoplasmic ⁇ -galactosidase directed that protein to the nucleus.
  • the 1st NLS is conserved among all NS1 (SEQ ID NO:43) proteins of influenza A viruses.
  • SVTKKRKLE (SEQ ID NO:44) Human lamin A. Dimerization of lamin A was proposed to give a complex with two NLSs that was transported more efficiently.
  • SASKRRRLE Xenopus lamin A NLS inferred from its similarity to human lamin A (SEQ ID NO:45) NLS. TKGKRKRID Xenopus lamin L I .
  • NLS inferred from its sequence similarity to (SEQ ID NO:46) human lamin A NLS. CVRTTKGKRKRIDV Xenopus lamin L I .
  • RQRRNELKRSP (SEQ ID NO:50) (M2, medium potency NLS) SALIKKKKKMAP Murine c-abl (IV) gene product.
  • the p160 gag/v-abl has a cytoplasmic (SEQ ID NO:51) and plasma membrane localization, whereas the mouse type IV c-abl protein is largely nuclear.
  • PPKKRMRRRIE Adenovirus 5 DBP (DNA-binding protein) found in nuclei of infected (SEQ ID NO:52) cells and involved in virus replication and early and late gene PKKKKKRP (SEQ ID NO:53) expression. Both NLS are needed, and disruption of either site impaired nuclear localization of the 529 amino acid protein.
  • NLS1 glucocorticoid receptor (795 amino acid) NLS1 determined by KIKGIQQATA (497-524 amino fusion with ⁇ -galactosidase (116 kD). NLS1 is 100% conserved acid) between human, mouse and rat GR. Whereas the 407-615 amino acid (SEQ ID NO:54) fragment of GR specifies nuclear location, the 407-740 amino acid fragment was cytoplasmic in the absence of hormone, indicating that sequence 615-740 may inhibit the nuclear location activity. A second (NLS2) is localized in an extensive 256 amino acid C-terminal domain. NLS 2 requires hormone binding for activity.
  • NLS Human ER (estrogen receptor, 595 amino acid) NLS.
  • NLS is between GEGRGEVGSAGDMRAMINO the hormone-binding and DNA-binding regions; ER, in contrast with ACIDNLWPSPLMI KRSKK GR, lacks a second NLS.
  • SEQ ID NO:55 RKFKLKFNK Rabbit PG (progesterone receptor). 100% homology in humans; F ⁇ L (SEQ ID NO:56) change in chickens.
  • PPQKKIKS N-myc gene product; directs puruvate kinase to the nucleus.
  • PQPKKKP SEQ ID NO:60
  • SKRVAKRKL c-erb-A gene product directs puruvate kinase to the nucleus.
  • SEQ ID NO:61 CGGLSSKRPRP Adenovirus type2/5 E1a. This synthetic peptide conjugated with a (SEQ ID NO:62) bifunctional crosslinker to chicken serum albumin (CSA) and microinjected into HeLa cells directed CSA to the nucleus.
  • CSA chicken serum albumin
  • Double-stranded oligonucleotides (SEQ ID NO:63) encoding the 7 amino acid peptides (underlined) and inserted at the N- MTGS KHRKHPG SGA terminus of the p-galactosidase gene resulted in nuclear import.
  • SEQ ID NO:64 RHRKHP (SEQ ID NO:65) Mutated peptides derived from yeast L29 ribosomal protein NLS, KRRKHP (SEQ ID NO:66) found to be efficient NLS.
  • KHKKHP SEQ ID NO:69
  • RHLKHP SEQ ID NO:70
  • KHRKYP SEQ ID NO:71
  • KHRQHP SEQ ID NO:72
  • PETTVV RRRGR SPRRRTPSP Double NLS of hepatitis B virus core antigen.
  • the two underlined RRRRSP RRRR SQS SEQ ID arginine clusters represent distinct and independent NLS.
  • Missense mutations in this domain result in its cytoplasmic retention.
  • DT R EKKKFLK R RLLRLDE Mouse nuclear Mx1 protein (72 kD), Induced by interferons (among (604-620) 20 other proteins) .
  • the cytoplasmic Mx2 has R ⁇ S and R ⁇ E changes in this region.
  • CGYGPKKKRKV SV40 large Synthetic peptides crosslinked to bovine serum albumin (BSA) and T) (SEQ ID NO:77) introduced into MCF 7 or HeLa S3 cells with viral co-internalization
  • CGYGDRNKKKKE human method using adenovirus serotype 3B induced nuclear import of BSA.
  • retinoic acid receptor (SEQ ID NO:78) CGYGARKTKKKIK (human glucocorticoid receptor) (SEQ ID NO:79) CGYGIRKDRRGGR (human estrogen receptor) (SEQ ID NO:80) CGYGARKLKKLGN (human androgen receptor) (SEQ ID NO:81) RKRQRALMLRQAR Human XPAC (xeroderma pigmentosum group A complementing 30-42 protein) involved in DNA excision repair. By site-directed (SEQ ID NO:82) mutagenesis and immunofluorescence. NLS is encoded by exon 1 which is not essential for DNA repair function.
  • EYLSRKGKLEL SEQ ID T-DNA-linked VirD2 endonuclease of the Agrobacterium NO:83 tumefaciens tumor-inducing (T i ) plasmid.
  • T i tumor-inducing
  • a fusion protein with ⁇ - (at the N-terminus) galactosidase is targeted to the nucleus.
  • the T-plasmid integrates into plant nuclear DNA; VirD2 produces a site-specific nick for T integration.
  • VirD2 also contains a bipartite NLS at its C-terminus (see Table 2).
  • KKSKKKRC Putative core NLS of yeast TRM1 (63 kD) that encodes the tRNA (95-102) modification enzyme N 2 , N 2 -dimethylguanosine-specific tRNA methyltransferase. Localizes at the nuclear periphery.
  • the 70-213 amino acid segment of TRM1 causes nuclear localization of ⁇ - galactosidase fusion protein in yeast cells. Site-directed mutagenesis of the 95-102 peptide resulted in its cytoplasmic retention.
  • TRM1 is both nuclear and mitochondrial.
  • the 1-48 amino acid segment specifies mitochondrial import.
  • PQSRKKLR SEQ ID NO:85
  • Max protein specifically interacts with c-Myc protein.
  • This 14 amino acid segment was (SEQ ID NO:89) identified as a minimal nuclear location sequence but was unable to locate puruvate kinase to the nucleus; three more amino acids at either end (shown in parenthesis) were needed.
  • CGQAKKKKLD Xenopus nucleoplasmin-derived synthetic peptide; crossliniked to (SEQ ID NO:90) chicken serum albumin and microinjected to HeLa cells specified nuclear localization. This suggests that nucleoplasmin may possess a simple NLS.
  • HRKYEAPRHx 6 PRKR SEQ ID Yeast L3 ribosomal protein (387 amino acid) N-terminal 21 NO:92) amino acid.
  • Possible bipartite NLS. Ribosomal proteins are transported to the nucleus to assemble with nascent rRNA). Fusion genes with ⁇ -galactosidase were used to transform yeast cells followed by fluorescence staining with b-gal antibody.
  • the 373 amino acid of L3 fused to ⁇ -gal failed to localize to the nucleus, unless a 8 amino acid bridge containing a proline was inserted between L3 and ⁇ -gal.
  • KRKIEEPEPEPKKAK Putative bipartite NLS of Xenopus laevis protein factor xnf7. (SEQ ID NO:95) Inferred by similarity to the bipartite NLS of nucleoplasmin. During oocyte maturation xnf7 is cytoplasmic until mid-blastula- gastrula stage due to high phosphorylation. Partial dephosphorylation results in nuclear accumulation. KKYENVVIKR S P RKR GRPRKD Yeast SWI5 gene product, a transcription factor.
  • Underlined (SEQ ID NO:96) basic amino acid show similarity to bipartite NLS of Xenopus nucleoplasmin.
  • the SWI5 gene is transcribed during S, G2 and M phases, during which the SWI5 protein remains cytoplasmic due to phosphorylation by CDC28-dependent histone H1 kinase at three serine residues two near and one (double underlined) in the NLS.
  • NLS confers cell cycle-regulated nuclear import of SWI5- ⁇ -galactosidase fusion protein.
  • BSI and II functioned interdependently as PPRRRVRQQPP (SEQ ID NO:100) an NLS for the nuclear targeting of AdPol, for which BSIII was 23-33 (BSII) dispensable.
  • BSII-III was more efficient NLS than BSI-II.
  • PARARRRRAP SEQ ID NO:101
  • BSIII KRKx 11 K K KSKK 207-226
  • Human poly(ADP-ribose) polymerase (116 kD).
  • the linear (SEQ ID NO:102) distance between the two basic clusters is not crucial for NLS activity in this bipartite NLS. Lysine 222 (double underlined) is an essential NLS component.
  • DNA binding and poly(ADP- ribosyl)ating active site are independent of NLS.
  • GRKRAFHGDDPFGEGPPDKKGD Herpes simplex virus ICP8 protein (infected-cell protein). This (SEQ ID NO:103) C-terminal portion of ICP8 introduced into pyruvate kinase (PK) caused nuclear targeting in transfected Vero cells. Inclusion of additional ICP8 regions to PK led to inhibition of nuclear localization.
  • Each region independently directs ⁇ - glucuronidase to the nucleus, but both motifs are necessary for maximum efficiency.
  • VirD2 is tightly bound to the 5′ end of the single stranded DNA transfer intermediate T-strand transferred from Agrobacterium to the plant cell genome.
  • Nonpositive NLS lacking clusters of arginines/lysines Signal oligopeptide Protein and features QLVWMACNSAMINO Influenza virus nucleoprotein (NP).
  • SEQ ID NO:105 MN KIPIK DLLNPQ Yeast MAT a2 repressor protein, containing a homeodomain.
  • NLS 1 at N-terminus SEQ ID 1 at N-terminus
  • SEQ ID NO:107 The core pentapeptide containing proline and homeodomain) two other hydrophobic amino acids flanked by lysines or arginines (SEQ ID NO:107) (underlined) was suggested as one type of NLS core.
  • NLS identified by ⁇ - NO:108) galactosidase/HP1 fusion proteins introduced by P-element mediated 152-206 (C-terminal transformation into Drosophila embryos. segment)
  • RLPVRRRRRRVP (SEQ ID NO:110) Adenovirus pTP1 and pTP2 (preterminal proteins, 80 kD) between amino acid residues 362-373.
  • the 140 kD DNA polymerase of adenovirus when it has lost its own NLS can enter the nucleus via its interaction with pTP.
  • the staining was nuclear and nucleolar with some perinuclear staining as well.
  • the NLS fused to the N-terminus of E. coli ⁇ -galactosidase was functional in nuclear targeting.
  • Tat is constitutively nucleolar.
  • RKKRRQRRR(AHQ) Tat positive trans-activator protein of HIV-1 human Nucleolar localization signal immunodeficiency virus type 1.
  • the 3 amino acids shown in (SEQ ID NO:112) parenthesis are essential for the localization of the ⁇ - galactosidase to the nucleolus.
  • the 9 amino acid basic region is able to localize ⁇ -gal to the nucleus but not to the nucleolus.
  • KRVKLDQRRRP (SEQ ID NO:113) Artificial sequence from c-Myc and HIV Tat NLSs that effectively localizes pyruvate kinase to the nucleolus.
  • HSP70 heat shock protein of 70 kD
  • HSP70 localizes pyruvate (SEQ ID NO:114) kinase to the nucleus and nucleolus.
  • HSP70 is physiologically cytoplasmic but with heat-shock HSP70 redistributes to the nucleoli, suggesting that the nucleolar targeting sequence is cryptic at physiological temperature and is revealed under heat- shock.
  • RQA RR N RRRR WRERQR 35-50
  • HIV-1 Rev protein 116 amino acid, nucleolar. Mutations in (SEQ ID NO:115) either of the two regions of arginine clusters severely impair nuclear localization.
  • ⁇ -galactosidase fused to R 4 W was targeted to the nucleus, and fused to the entire 35-50 region, was targeted to the nucleolus.
  • RQA RR NRRRR WRERQRQ 35-51) HIV-1 Rev protein.
  • a fusion of this Rev peptide with ⁇ - (SEQ ID NO:116) galactosidase became nuclear but not nucleolar.
  • the 1-59 amino acid segment of Rev fused to ⁇ -galactosidase localized entirely within the nucleolus. Whereas the NRRRRW (bold) is responsible for nuclear targeting, the RR and WRERQRQ (double underlined) specify nucleolar localization.
  • Rev may function to export HIV structural mRNAs from the nucleus to the cytoplasm.
  • TIK (not conserved) (SEQ ID NO:131) 614PPFKPKIKHRKMC P (not conserved) (SEQ ID NO:132) 148 KKVLQDKRFK Glycogen synthase rat brain Phosphorylates glycogen synthase, NRELQIMRKLD (SEQ kinase 3 c-Jun, c-Myb; two isoforms ID NO:135) GSK-3 ⁇ encoded by discrete genes; highly (483 aa) expressed in brain; both ⁇ and ⁇ forms are cytosolic but also GSK-3 ⁇ associated with the plasma (420 aa) membrane consistent with their role in signal transduction from the cell surface.
  • 289ECLKKFNARRKL Ca 2+ /calmodulin- rat brain Composed of nine 50 kDa ⁇ - KGAIL dependent protein subunits and three 60 kDa ⁇ - (SEQ ID NO:137) kinase II (CaM kinase subunits; both are catalytic; II) ⁇ subunit (542 aa, calmoduim- and ATP-binding 60.3 kDa) domains; highly expressed in forebrain neurons, concentrated in postsynaptic densities; acts as a Ca 2+ -triggered switch and could be involved in long-lasting changes in synapses.
  • 290LKKFNARRKL CaM kinase II (478 rat brain This particular isoform is KGAILTTM (SEQ ID aa, 54 kDa) exclusively expressed in the brain; NO:138) ⁇ -subunit high enzyme levels in specific 450EETRVWHRRDGK brain areas; might be involved in (SEQ ID NO:139) short- and long-term responses to transient stimuli.
  • GFAKRVKGRT CADPK catalytic bovine cardiac By Edman degradation of protein WTLCG subunit (349 aa, 40.6 muscle) fragments; mediates the action of (SEQ ID NO:140) kDa) and is activated by cAMP; consists of two regulatory (R) and two catalytic (C) subunits; cAMP releases the C subunit from the inactive R 2 C 2 cADPK; two cDNAs were cloned encoding two isoforms of the catalytic subunit of cADPK in mouse.
  • 186 GFAKRVKGRTW CADPK bovine cDNA was isolated by screening a TLCG (catalytic subunit) bovine pituitary cDNA library; (SEQ ID NO:141) (350 aa) 93% sequence similarity to known bovine cADPK; represents the second gene for the catalytic subunit of cADPK.
  • EEEIQELKRKLH CGDPK SEQ ID bovine lung By protein sequencing; composed KCQSVLP (SEQ ID NO: 144) of two identical subunits activated NO:142) (670 aa, 76.3 kDa) in an allosteric manner by binding 389 KILKKRHIVDTR of cGMP and not by dissociation (SEQ ID NO:143) of catalytic subunit as in cADPK; sequence similar to cADPK 117 KTLKKHTIVK TPK3 S.
  • cAMP-DPK is a tetrameric protein (SEQ ID NO:145) (398 aa) with two catalytic and two cADPK regulatory subunits; cAMP activates the kinase by dissociating the catalytic subunits from the tetramer; all three TPK 1, 2, 3 are catalytic subunits. 16S 2 H 13 GHG 2 SNF1 (633 aa, 72 kDa) S.
  • PVKKKKIKREIK Casein kinase II ( ⁇ - Drosophila CKIL is composed of a and 3 (SEQ ID NO:148) subunit, catalytic) melanogaster subunits in a a2f32 130-150 kDa 269 DILQRHSRKRW (336 aa) protein; the a-subunit is the ERF (SEQ ID NO:149) catalytic and the f3is 146 PKSSRHHHTDG CKII ( ⁇ -subunit, Drosophila autophosphorylated.
  • LKP SEQ ID NO:168
  • human CDC2 gene can complement both the inviability of a null allele of S. cerevisiae CDC28 and cdc2 mutants of S. pombe
  • CDC2 mRNA appears after that of CDK2.
  • GVVYKARHKLSGR cdc2 (297aa) S. pombe High homology to S. cerevisiae (SEQ ID NO:169) CDC28.
  • CDK2 cell division Human
  • the human CDK2 protein has 65% (SEQ ID NO:170) kinase 2) (298 aa) sequence identity to human p34 cdc2 and 89% sequence identity to Xenopus Eg1 kinase; human CDK2 was able to complement the inviability of a null allele of S. cerevisiae CDC28 but not cdc2 mutants in S. pombe .
  • CDK2 mRNA appears in late G1/early S.
  • FCHSHRVLHRD Eg1 (297 aa) Xenopus Cdk2-related LKP (SEQ ID NO:171) 125 GIAYCHSHRILH CDC28 (298 a) S. cerevisiae The homolog of S. pombe Cdc2 RDLKP (SEQ ID NO:172) 119 HSHRVIHRDLKP cdk3 (305 aa) Human (SEQ ID NO:173) 56 KELKHKNIVR PSSALRE (291 aa) Human cdc2-related kinase.
  • the Wee1 + gene functions as a (SEQ ID NO:192) (877 aa) dose-dependent inhibitor that 388 KQHRPRKNTNFT delays the initiation of mitosis PLPP (SEQ ID NO:193) until the yeast cell has attained a 592 KYAVKKLKVKF certain size;
  • Wee1 has a protein SGP (SEQ ID NO:194) kinase consensus probably regulating cdc2 kinase.
  • 266 PNETRRIKRAN CDC7 (497 aa) S.
  • pombe SEQ ID NO:201
  • SNIKSKCRRVV SEQ ID NO:202
  • PPKRIRTD CTD kinase 528 aa
  • SEQ ID (catalytic) kDa gene gives cells that lack CTD NO:203) kinase, grow slowly, are cold 492 KLARKQKRP sensitive, but have different (SEQ ID NO:204) phosphorylated forms of RNA pol II.
  • GVSSVVRRCIHKP Phosphorylase kinase Rabbit (skeletal (SEQ ID NO:205) (catalytic subunit) muscle) (386 aa) 489 KKYMARRKW Myosin light chain Chicken gizzard Ca 2+ /calmodulin-activated; QKTGHAV kinase (MLCK) (669 phosphorylated by cADPK; first (SEQ ID NO:206) aa) described as responsible for the phosphorylation of a specific class of myosin light chains; required for initiation of contraction in smooth muscle. 314 PWLNNLAEKAK Myosin light chain Rabbit (skeletal By protein sequencing.
  • RCNRRLKSQ kinase (partial 368 muscle) (SEQ ID NO:207) carboxy-terminal aa 334 ILLKKYLMKJRR sequence) WKKNFIAVS (SEQ ID NO:208) 28 GVSSVVRRCIHKP Phosphorylase kinase Mouse (muscle) Glycogenolytic regulatory enzyme; (SEQ ID NO:209) (PhK) (catalytic ⁇ undergoes complex regulation; subunit) (389 aa) composed of 16 subunits containing equimolar ratios of ⁇ , ⁇ , ⁇ and ⁇ subunits; high levels in skeletal muscle; isoforms in cardiac muscle and liver; cDNA probe does not hybridize to X chromosome in mice and is thus distinct from the mutant recessive PhK deficiency that results in glycogen storage disease.
  • cer 782 aa; helicase, component (SEQ ID NO:212) (XPB) Haywire(Dros) of TFIIH essential for cell 522 YVAIKTKKRILLYTM viability; helix-turn-helix, (SEQ ID NO:213) DNA-BD, and helicase (weak NLS if at all, hydrophobic domains environment) 769 PSKHVHPLFKRFRK (SEQ ID NO:214) 84 KKQTLVKRRQRKD ERCC5 RAD2; 1186 aa in human, 1196 in X.
  • helicase, component SEQ ID NO:212
  • XPB Haywire(Dros) of TFIIH essential for cell 522 YVAIKTKKRILLYTM viability
  • helix-turn-helix (SEQ ID NO:213) DNA-BD, and helicase (weak NLS if at all, hydrophobic domains environment) 769 PSKHVHPLFKRFRK (S
  • SEQ ID NO:247 1091 KELEGLINTKRKRLKYF AKLW (SEQ ID NO:248) 422 EKHEGKHQKLL (weak) hMSH2 MSH2 ( S. cer ) human mismatch repair (SEQ ID NO:249) protein; homologous to S. cerevisiae MSH2; associated with the hereditary nonpolyposis colon cancer gene on chromosome 2p16. 397 PDIRRLTKKLNKRG MSH2 (SEQ ID NO:250) (S cer) 547 DAKELRKHKKYIE (SEQ ID NO:251) 869 VKMAKRKANE (SEQ ID NO:252) 95 GELAKRSERRAEAE Human Rad2 Rad2 ( S.
  • cer 709 aa, 81 kDa, structure- MAKD RKSRKK P (SEQ ID specific recognition protein NO:263) 1; involved in recognition of 619 GESSKRDKSKKKKKVKV cisplatin-induced lesions; KMEKK (SEQ ID NO:264) also involved in Ig gene 674 GENKSKKKRRRSEDSEE recombination; one HMG- EE (SEQ ID NO:265) box, similarity to SRY, MTFII, LEF-1, TCF-1a, and ABF2.
  • EMSANNKRKFKTLKRSD weak SEQ ID NO:293
  • WMNSKVRKRRITKDDF GEK SEQ ID NO:294
  • 403 RKVITALHHRKRTKID DYED SEQ ID NO:295)
  • 504 KTGSRCKKVIKRTVGRP SEQ ID NO:296)
  • FHPKRRRIYGFR SEQ ID RAD5 1169 aa; helicase involved in NO:297) postreplication-repair
  • RAD6 215 DSRGRKKASM SEQ ID epistasis group
  • REK SEQ ID NO:299
  • 1 MSTPA RRRLMR DFKRM RAD6 RAD6 mediates the KEDAPP (SEQ ID NO:301) ubiquitination of H2A and H2B histones 15 GVAKLRKEKSGAD RAD10 ERCC1 210 aa; forms an (SEQ ID NO:302) endonuclease with RAD1; 76 DDYNRKRPFRSTRPGK the basic and tyrosine-rich (SEQ ID NO:303) central domain was suggested to bind DNA by ionic interactions and tyrosine intercalation.
  • MARRRLPDRPP RAD54 898 aa recombination-repair (SEQ ID NO:315) protein; ATP-binding motif; 65 GG RSLRKR SA helicase domains; in the (SEQ ID NO:316) same subfamily of helicases 99 QLT KRRK D with MOT1 and SNF2.
  • SEQ ID NO:317 269 DETVFVKSKRVKASSS RAD55 Similarity to RecA, and (extremely weak if at all NLS) lower similarity to RAD51, (SEQ ID NO:318) RAD57, and DMC1 317 GEDRKREGRNLKR (SEQ ID NO:319) 371 PISRQSKKRKFDYRVP RAD57 460 aa; nucleotide-binding (SEQ ID NO:320) domain; limited similarity to RAD51 62 GLKKPRKKTKSSRH SSL2 ERCC3 (XPB) 843 aa; putative helicase that (SEQ ID NO:321) seems to function in repair 688 GRILRAKRRNDEG but also in the removal of (SEQ ID NO:322) secondary structures in the 5′ 784 GRGSNGHKRFKS (weak) untranslated region of mRNA (SEQ ID NO:323) to allow ribosome binding and scanning.
  • Rhp3 or ERCC2 772 aa DNA helicase; 65% 681 DKRYGRSDKRTKLPK rad15 RAD3 identity to RAD3 and 55% (SEQ ID NO:337) identity to ERCC2; essential for viability 464 PPSKRRRVRGG Rad16 RAD 1 Function in repair of UV (SEQ ID NO:338) damage for both cyclobutane dimer and (6-4) photoproduct lesions; Rad 16 interacts with SwilO.
  • meiotic DG (weak because of Y) (SEQ recombination protein; rad32 ID NO:341) mutants are sensitive tog- 575 PSPALLKKTNKRRELP and UV radiation; functions (SEQ ID NO:342) in the same pathway with Rhp51 (RAD51). Rad51 recombination-repair GLAKKYRDHKTHLHIP (weak Hhp1 CKI (mamm) Ser/Thr protein kinase; NLS because of Y and H) (SEQ HRR25 ( S.
  • IRKRRKMK (SEQ ID NO:360) PKKKRLRL (SEQ ID NO:361) GKKKKRKREKL Murine LEF-1 (397 aa). (within the Lymphoid-specific with an HMG-box) HMG1-like box. NLS is identical (SEQ ID NO:362) to that of human TCF-1 ⁇ . GKKKKRKREKL Human TCF-1 ⁇ (399 aa) (within the HMG-box) (T cell-specific transcription factor that HMG-box) activates the T cell receptor (SEQ ID NO:363) C ⁇ ). Contains an HMG box. NLS core is identical to that of murine LEF-1.
  • GKKKRRSREKH Human TCF-1 (within the (uniquely T cell-specific).
  • PKKCRARF SEQ ID NO:365
  • NRRRKKRT SEQ ID NO:367
  • NRRQKEKRI SEQ ID NO:368
  • Five widely (SEQ ID NO:370) spaced zinc-fingers could help AKRSRRS condensation of the chromatin fiber.
  • SEQ ID NO:376 homeodomain protein.
  • DGKRKRKN Human thyroid hormone receptor ⁇ (SEQ ID NO:377) (c-erbA-1 gene). Belongs to the DDSKRVAKRKL family of cytoplasmic proteins that (SEQ ID NO:378) are receptors of hydrophobic NRERRRKEE ligands such as steroids, vitD, (SEQ ID NO:379) retinoic acid, thyroid hormones.
  • WKQRRKF The ligand binding may expose the NLS for nuclear import of the (SEQ ID NO:380) receptor-ligand complex.
  • NRRKRKRS Drosophila gcl (germ cell-less) gene (SEQ ID NO:381) product (569 aa, 65 kD), located PKKKKL in nuclei, required for germ (SEQ ID NO:382) line formation.
  • ARRKRRRL C. elegans Sdc-3 protein (SEQ ID NO:383) (sex-determining protein) LKFKKVRD (2,150 aas).
  • a zinc finger protein is provided.
  • SEQ ID NO:384 FKKFRKF (SEQ ID NO:385) GKQKRRF (SEQ ID NO:386) ERLKRDKEKREKE (SEQ ID NO:387) TRGRPKKVKE (SEQ ID NO:388) SKKRGRRRKKT (SEQ ID NO:389) TRRQKRAKV (SEQ ID NO:390) SRKSKKRLRA (SEQ ID NO:391) LKKIRRKIKNKI Drosophila BBF-2 (related to (SEQ ID NO:392) CREB/ATF) ESRRKKKE (SEQ ID NO:393) Group 0000 DRNKKKKE Xenopus RAR (retinoic acid receptor) (SEQ ID NO:394) ARRRRP (SEQ ID NO:395) GRRRRA Human ATF-2 (the 2nd and (SEQ ID NO:396) 3rd NLS are in basic region DEKRRKV that binds DNA) (SEQ ID NO:397) CRQKRKV (S
  • GRRRRA Human HB16 a cAMP response (SEQ ID NO:402) element-binding protein DEKRRKF (SEQ ID NO:403) SRCRQKRKV (SEQ ID NO:404) SKKKKTKV Human TFIIE- ⁇ (general (SEQ ID NO:405) transcription initiation NRPDKKKI protein factor; forms (SEQ ID NO:406) tetramer ⁇ 2 ⁇ 2 with TFIIE- ⁇ ) QRRKKP (SEQ ID NO:407) QKKRRFKT (SEQ ID NO:408) SRKRKM Human kup transcriptional activator (SEQ ID NO:409) (433 aas). Two distantly spaced zinc fingers. Expressed in hematopoietic cells and testis.
  • ERKRLRNRLA Mouse Jun-B homologue to (SEQ ID NO:410) avian sarcoma virus 17 oncogene v-jun product.
  • One region is similar ATKCRKRKL to yeast GCN4 and to Fos.
  • SEQ ID NO:411) (19 aa stretch) DKRx 6 ERKRRD (N-terminus) Max (specifically associates with (SEQ ID NO:412) c-Myc, N-Myc, L-Myc).
  • the Max-Myc QSRKKLRME complex binds to DNA; neither (C-terminus) Max nor Myc alone exhibit (SEQ ID NO:413) appreciable DNA binding.
  • DKEKKIKLEEDE Chicken VBP (vitellogenin gene- (within an binding protein). Leucine zipper. acidic region) Related to rat DBP. (SEQ ID NO:414) IKKAKKV (SEQ ID NO:415) TRRKKN (SEQ ID NO:416) TRDDKRRA Xenopus borealis B1 factor. Closely (SEQ ID NO:417) related to the mammalian USF. EVERRRRDK Binds to CACGTG in TFIIIA promoter (SEQ ID NO:418) to developmentally regulate its expression.
  • TRDEKRRA Human USF upstream stimulatory (SEQ ID NO:419) factor) activating the major late EVERRRRDK adenovirus promoter (SEQ ID NO:420) YRRYPRRRG YB-1, a protein that binds to the MHC (SEQ ID NO:421) class II Y box.
  • YB-1 is a negative QRRPYRRRRF regulator.
  • SEQ ID NO:422 YRPRFRRG (SEQ ID NO:423) QRRYRRN (SEQ ID NO:424) YRRRRP (SEQ ID NO:425) AKERQKKD Human TFEB Binds to IgH enhancer.
  • ERRRRF (SEQ ID NO:427) LKERQKKD Human TFE3 (536 aa). Binds to ⁇ E3 (SEQ ID NO:428) enhancer of IgH genes.
  • IERRRRFN (SEQ ID NO:429) YFRRRRLEKD (SEQ ID NO:430) KTVALKRRLKASSRL Human Dr1 (176 aa, 19 kD).
  • SEQ ID NO:431 Interacts with TBP (TATA-binding protein) thus inhibiting association of TFIIA and/or TFIIB with TBP. TBP-Dr1 association is affected by Dr1 phosphorylation to repress activated and basal transcription.
  • SEQ ID NO:436 P 7 AP 2 RRRRSADNKD 2 (SEQ ID NO:437) PKKPRHQF (SEQ ID NO:438) EKRKKERN Yeast NPS1 transcription protein (SEQ ID NO:439) factor (1359 aa) involved in cell LLRRLKKEVE growth control at G2 phase.
  • SEQ ID NO:440 Has a catalytic domain of protein kinases.
  • EPLGRIRQKKRVY 2 D 2 (SEQ ID NO:441) (EDAIKKRREARERRRLRQ) (SEQ ID NO:442) DKETTASRSKRRSSRKKRT (SEQ ID NO:443) ESKKKKPKL (SEQ ID NO:444) KKTAAKKTKTKS (SEQ ID NO:445) QRKRQKL Human 243 transcriptional (SEQ ID NO:446) activator (968 aas), induced KAKKQK by mitogens (SEQ ID NO:447) in T cells. N-terminal half is LRRKRQK homologous to oncoprotein Rel and (SEQ ID NO:448) Drosophila Dorsal protein involved in development.
  • the C- terminal half contains repeats found in proteins involved in cell-cycle control of yeast and tissue differentiation in Drosophila.
  • RDIRRRGKNKV Mouse NF-E2 (45 kD), an erythroid (SEQ ID NO:449) transcription factor from mouse erythroleukemia (MEL) cells. Involved in globin gene regulation.
  • QNCRKRKLE Binds to AP-1-1ike sites. (SEQ ID NO:450) Homology to Jun B, GCN4, Fos, ATF1 and CREB in basic region/leucine zipper (see FIG. 2).
  • DRLRKRVE DKIRRKN Human mineralocorticoid receptor (SEQ ID NO:458) ARKSKKL (SEQ ID NO:459) DKIRRKN Human PR (progesterone receptor) (SEQ ID NO:460) GRKFKKF (SEQ ID NO:461) EEVQRKRQKLMP Human and mouse NF ⁇ B 105 kD (SEQ ID NO:462) precursor of p50 (968 aas) (first R is at 361 position). EEVQRKRQKL Human NF- ⁇ B p50 (DNA-binding (SEQ ID NO:463) subunit). Identical to protein KBF1, homologous to rel oncogene product.
  • NF- ⁇ B p65 also contains a NLS (Table 3a).
  • GKTRTRKQ Human TEF-1 (SV40 transcriptional (SEQ ID NO:464) enhancer factor 1). 426 aa.
  • ARRKSRD SEQ ID NO:465) QRKERKSKS Rat, mouse, human IRF-1 (interferon (SEQ ID NO:466) regulatory factor-1). Induced in TKSKTKRKL lymphoma T cells by the pituitary (SEQ ID NO:467) peptide hormone prolactin. Regulates the growth-inhibitory interferon genes.
  • GKCRKKN Ehrlich ascites S-II transcription factor. (SEQ ID NO:468) A general factor that acts at the elongation step.
  • ERSKKRSRE Tobacco TAF-1 transcriptional activator (SEQ ID NO:469) ERELKREKRKQ (SEQ ID NO:470) ARRSRLRKQ (SEQ ID NO:471) YKLDHMRRRIETDE Drosophila TFIIE ⁇ (433 aa), a general (SEQ ID NO:472) transcription factor for RNA polymerase II. Composed of subunits ⁇ and ⁇ . DKNRRKS Human ER (estrogen receptor); 595 aa.
  • IRKDRRG SEQ ID NO:474
  • IKRSKKN SEQ ID NO:475)
  • EQRRHRIE Yeast ADA2 (434 aa)
  • SEQ ID NO:476 transcriptional adaptor required TTRAEKKRLL for the function of certain (SEQ ID NO:477) acidic activation domains.
  • IDKKRSKEAKE SEQ ID NO:478) EAALRRKIRTISK Yeast GCN5 gene product (439 aa), (SEQ ID NO:479) required for the function of GCN4 transcriptional activator and for the activity of the HAP2-3-4 complex.
  • NKKMRRNRF Mouse LFB3 (SEQ ID NO:480) NRRKx 4 RQK (SEQ ID NO:481) TKKGRRNRF Mouse LFB1 (SEQ ID NO:482) NRRKx 4 RHK (SEQ ID NO:483) NKKMRRNRFK rat vHNF1-A (SEQ ID NO:484) NKKMRRNR murine HNF-1 ⁇ (SEQ ID NO:485) TKKGRRNRF mouse HNF-1 (SEQ ID NO:486) NKKMRRNRF human vHNF1 (SEQ ID NO:487) TKKGRRNRF rat liver HNF1 (SEQ ID NO:488) LRRQKRFK rat HNF-3 ⁇ (SEQ ID NO:489) QQH 3 SH 4 Q (SEQ ID NO:490) LRRQKRFK rat HNF-3 ⁇ (SEQ ID NO:491) LRRQKRFK rat HNF-3 ⁇ (SEQ ID NO:492) LKEKERKA rat DBP a protein
  • GRRTRRE human Sp1 (SEQ ID NO:498) DEQKRAEKKAKE yeast SNF2, a transcriptional regulator (SEQ ID NO:499) of many genes.
  • IRRIHKVIRP (SEQ ID NO:500)
  • LLRRLKKDVE (SEQ ID NO:501)
  • Group 0x00x0 AKAKAKKA mouse AGP/EBP (87% similarity to (SEQ ID NO:502) C/EBP), ubiquitously expressed YKMRRERN (SEQ ID NO:503)
  • VRKSRDKA (SEQ ID NO:504)
  • AKAKAKKA rat LAP a 32-kD liver-enriched (SEQ ID NO:505) transcriptional activator, also present YKMRRERN in lung, with 71% sequence similarity (SEQ ID NO:506) to C/EBP.
  • VRKSRDKA Accumulates to maximal levels (SEQ ID NO:507) around birth.
  • YRQRRER Ig/EBP-1 immunoglobulin gene (SEQ ID NO:508) enhancer-binding protein).
  • SEQ ID NO:509 EDPEKEKRIKELE mouse c-Myb (SEQ ID NO:510) MRRKV (SEQ ID NO:511) DYYKVKRPKTD Drosophila eyes absent protein (760 aa), (SEQ ID NO:512) a nuclear protein that functions in GRARGRRHQ early development to prevent (SEQ ID NO:513) programmed cell death and to allow the FRYRKIKDIY event that generate the eye to proceed.
  • SEQ ID NO:514 Mutations cause programmed cell death of eye progenitor cells. Group 0x0x00 AKAKAKKA rat IL-6DBP interacting with (SEQ ID NO:515) interleukin-6 responsive elements. Has a leucine zipper domain.
  • DKRQRNRC mouse H-2RIIBP H-2RIIBP (MHC class I genes (SEQ ID NO:516) H-2 region II binding protein).
  • VRKSRDKA (SEQ ID NO:520) QKKNRNKC mouse PPAR (peroxisome proliferator (SEQ ID NO:521) activated receptor) Group 000xx00 EQIRKLVKKHG yeast RAP1 (SEQ ID NO:522) It binds regulatory sites at FRRSMKRKA yeast mating type silencers.
  • the transcription factor E2F implicated in cell growth, binds to the same pocket of RB.
  • GKGKMRNRRRIQRRG (SEQ ID NO:533) Xenopus laevis L1 ribosomal protein (homologous NKKVKRRELKKN (SEQ ID NO:534) to yeast L2) Encoded by intronless genes.
  • AKTARRKA SEQ ID NO:535) IKAKEKKP (SEQ ID NO:536) GKPKAKKP (SEQ ID NO:537) AKAKKRQ (SEQ ID NO:538) ERKRKS (SEQ ID NO:539) human S6 ribosomal protein (homologous to yeast GKRPRTKA (SEQ ID NO:540) S10) HKRRRI (SEQ ID NO:541) LKKQRTKKNKE (SEQ ID NO:542) PKMRRRTYR (SEQ ID NO:543) Rat L17 ribosomal protein (184 aas) KKKISQKKLKK (SEQ ID NO:544) YMRRRTYRA (SEQ ID NO:545) Podocoryne carnea (hydrozoan, Coelenteratum) EVKKVSKKKL (SEQ ID NO:546) L17 ribosomal protein (184 aas) highly homologous to rat L17.
  • ERNRKDKDAKFR human, rat ribosomal S13 protein ERKRKS (SEQ ID NO:548) yeast S10 ribosomal protein (homologous to human QRLQRKRH (SEQ ID NO:549) S6) IRKRRA (SEQ ID NO:550) GRRRKKHRSRSRSRERRSRSRDRGRG 12 GRER 35 kD subunit of U2 small nuclear DRRRSRDRER (SEQ ID NO:551) ribonucleoprotein auxiliary factor (U2AF), an essential mammalian splicing factor.
  • U2AF 35 interacts with the 65 kD subunit (U2AF 65 ).
  • EFEDPRD human UsnRNP-associated 70 k protein (437 aas)
  • ETREERME SEQ ID NO:553 that is phosphorylated at Arg/Ser-rich domains
  • EAGDAPPDP SEQ ID NO:554 involved in splicing
  • EERMERKRREK SEQ ID NO:555
  • HRDRDRDRERERRESRERDKERERRRSRSRD RRRRSRSRDKEERRRSRERSKDKDRDRKRRS SRSRERARRERERKEE
  • RDRDRERRRSHRSERERRRDRDRDRDRDRDREH KRGER SEQ ID NO:557)
  • QKRNNKKSKKKRCAE yeast TRM1 enzyme for the N 2 , N 2 - EKLRKLKI (near C-terminus) (SEQ ID NO:559) dimethylguanosine
  • TRM1 is both nuclear and mitochondrial.
  • the first motif is within a region (70-213 aa segment) known to cause nuclear localization of ⁇ -galactosidase.
  • NKRKRV SEQ ID NO:560
  • Yeast nucleoporin NUP1 (1076 aa, 113 kD); an SLKINRSNRKRE (SEQ ID NO:561) integral component of the pore complex.
  • Involved EPKRKRRLP (SEQ ID NO:562) in both binding and translocation steps of nuclear ARMRHSKR (C-terminus) (SEQ ID NO:563) import.
  • KAEKEx 3 KVD 2 E 2 (SEQ ID NO:564) Chicken, Xenopus No 38 nucleolar (38 kD); Kx 3 Kx 5 Kx 3 R (SEQ ID NO:565) involved in intranuclear packaging of preribosomal particles.
  • KTEREAEKALEEKx 7 R (SEQ ID NO:566) Chicken, hamster nucleolin (92 kD). Binds Kx 5 Kx 7 Kx 4 RX3EDTTEETLR (SEQ ID NO:567) preribosomal RNA.
  • DHKPQGKKIKFE (SEQ ID NO:568) (C-terminus) WYKHFKKTKD (SEQ ID NO:569) human SATB1 (763 aa) which binds selectively to AT-rich MARs with mixed A, T, C on one strand excluding G. Binds to minor groove with little contact with bases.
  • QKKKQMKAD (SEQ ID NO:570) yeast CBF5p, a centromere-binding protein (KKEKKE) 5 (SEQ ID NO:571) (55kDa, 483aa).
  • the KKEKKRKSED (SEQ ID NO:572) KKE repeat at its C-terminus EEKKSKKSKK (SEQ ID NO:573) occurs in microtubule-binding domains; yeast cells containing only three copies of the KKE repeat of CBF5p delay at G 2 /M; depletion of CBE5p arrests cells at G 1 /S.
  • TKKKSFKL yeast CCE1
  • KSERERMLRESLKEERRRF rat nucleoporin 155 or Nup155 (1390 aas, 155 kDa)
  • a protein of the nuclear pore complex contains 46 consensus sites for various kinases; associated with both the nucleoplasmic and the cytoplasmic region of pores.
  • PKKGSKKA (SEQ ID NO:576) human H2B variant differentially expressed during DGKKRKRSRKES (SEQ ID NO:577) the cell cycle GAKRHRKVLRD (SEQ ID NO:578) Calf thymus histone H4 14-24 (102 aa) PAIRRLARRG (SEQ ID NO:579) 32-41 EHARRKT (SEQ ID NO:580) 74-80 ARRIRGERA 127-135 (SEQ ID NO:581) Calf thymus H3 (135 aa) GSHHKAKGK 121-129 (SEQ ID NO:582) Calf thymus H2A (129 aa) RGKSGKARTKAKSRSSR 3-19 (SEQ ID Sea urchin Psammechinus miliaris H2A (123 aa) NO:583) PKKGSKKA 10-17 (SEQ ID NO:584) Calf thymus H2B QKKDGKKRKRSRKES 22-36 (S
  • Capaccioli S. et al. (1993) “Cationic lipids improve antisense oligonucleotide uptake and prevent degradation in cultured cells and in human serum” Biochem. Biophys. Res. Comm. 197:818-825.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A method is disclosed for encapsulating plasmids, oligonucleotides or negatively-charged drugs into liposomes having a different lipid composition between their inner and outer membrane bilayers and able to reach primary tumors and their metastases after intravenous injection to animals and humans. The formulation method includes complex formation between DNA with cationic lipid molecules and fusogenic/NLS peptide conjugates composed of a hydrophobic chain of about 10-20 amino acids and also containing four or more histidine residues or NLS at their one end. The encapsulated molecules display therapeutic efficacy in eradicating a variety of solid human tumors including but not limited to breast carcinoma and prostate carcinoma. Combination of the plasmids, oligonucleotides or negatively-charged drugs with other anti-neoplastic drugs (the positively-charged cis-platin, doxorubicin) encapsulated into liposomes are of therapeutic value. Also of therapeutic value in cancer eradication are combinations of encapsulated the plasmids, oligonucleotides or negatively-charged drugs with HSV-tk plus encapsulated ganciclovir.

Description

    CROSS-REFERENCE TO RELATED APPLICATIONS
  • This application claims priority under 35 U.S.C. §119(e) to U.S. Provisional Application Serial No. 60/210,925 filed Jun. 9, 2000. The contents of this application is hereby incorporated by reference into the present disclosure.[0001]
    • FIELD OF THE INVENTION
  • The present invention relates to the field of gene therapy and is specifically directed toward methods for producing peptide-lipid-polynucleotide complexes suitable for delivery of polynucleotides to a subject. The peptide-lipid-polynucleotide complexes so produced are useful in a subject for inhibiting the progression of neoplastic disease. [0002]
    • BACKGROUND OF THE INVENTION
  • Throughout this application various publications, patents and published patent specifications are referenced by author and date or by an identifying patent number. Full bibliographical citations for the publications are provided immediately preceding the claims. The disclosures of these publications, patents and published patent specifications are hereby incorporated by reference into the present disclosure to more fully describe the state of the art to which this invention pertains. [0003]
  • Gene therapy is a newly emerging field of biomedical research that holds great promise for the treatment of both acute and chronic diseases and has the potential to bring a revolutionary era to molecular medicine. However, despite numerous preclinical and clinical studies, routine use of gene therapy for the treatment of human disease has not yet been perfected. It remains an important unmet need of gene therapy to create gene delivery systems that effectively target specific cells of interest in a subject while controlling harmful side effects. [0004]
  • Gene therapy is aimed at introducing therapeutically important genes into somatic cells of patients. Diseases already shown to be amenable to therapy with gene transfer in clinical trials include, cancer (melanoma, breast, lymphoma, head and neck, ovarian, colon, prostate, brain, chronic myelogenous leukemia, non-small cell lung, lung adenocarcinoma, colorectal, neuroblastoma, glioma, glioblastoma, astrocytoma, and others), AIDS, cystic fibrosis, adenosine deaminase deficiency, cardiovascular diseases (restenosis, familial hypercholesterolemia, peripheral artery disease), Gaucher disease, α1-antitrypsin deficiency, rheumatoid arthritis and others. Human diseases expected to be the object of clinical trials include hemophilia A and B, Parkinson's disease, ocular diseases, xeroderma pigmentosum, high blood pressure, obesity. ADA deficiency was the disease successfully treated by the first human “gene transfer” experiment conducted by Kenneth Culver in 1990. See, Culver, K. W. (1996) in: Gene Therapy: A Primer for Physicians, Second Ed., Mary Ann Liebert, Inc. Publ, New York, pp. 1-198. [0005]
  • The primary goals of gene therapy are to repair or replace mutated genes, regulate gene expression and signal transduction, manipulate the immune system, or target malignant and other cells for destruction. See, Anderson, W. F. (1992) [0006] Science 256:808-813; Lasic, D. (1997) in: Liposomes in Gene Delivery, CRC Press, pp. 1-295; Boulikas, T. (1998) Gene Ther. Mol. Biol. 1:1-172; Martin, F. and Boulikas, T. (1998) Gene Ther. Mol. Biol. 1:173-214; Ross, G. et al. (1996) Hum. Gene Ther. 7:1781-1790.
  • Human cancer presents a particular disease condition for which effective gene therapy methods would provide a particularly useful clinical benefit. Gene therapy concepts for treatment of such diseases include stimulation of immune responses as well as manipulation of a variety of alternative cellular functions that affect the malignant phenotype. Although many human tumors are non or weakly immunogenic, the immune system can be reinforced and instructed to eliminate cancer cells after transduction of a patient's cells ex vivo with the cytokine genes GM-CSF, IL-12, IL-2, IL-4, IL-7, IFN-γ, and TNF-α, followed by cell vaccination of the patient (e.g. intradermally) to potentiate T-lymphocyte-mediated antitumor effects (cancer immunotherapy). DNA vaccination with genes encoding tumor antigens and immunotherapy with synthetic tumor peptide vaccines are further developments that are currently being tested. The genes used for cancer gene therapy in human clinical trials include a number of tumor suppressor genes (p53, RB, BRCA1, E1A), antisense oncogenes (antisense c-fos, c-myc, K-ras), and suicide genes (HSV-tk, in combination with ganciclovir, cytosine deaminase in combination with 5-fluorocytosine). Other important genes that have been proposed for cancer gene therapy include bcl-2, MDR-1, p21, p16, bax, bcl-xs, E2F, IGF-I, VEGF, angiostatin, CFTR, LDL-R, TGF-β, and leptin. One major hurdle preventing successful implementation of these gene therapies is the difficulty of efficiently delivering an effective dose of polynucleotides to the site of the tumor. Thus, gene delivery systems with enhanced transfection capabilities would be highly advantageous. [0007]
  • A number of different vector technologies and gene delivery methods have been proposed and tested for delivering genes in vivo, including viral vectors and various nucleic acid encapsulation techniques. Alternative viral delivery vehicles for genes include murine retroviruses, recombinant adenoviral vectors, adeno-associated virus, HSV, EBV, HIV vectors, and baculovirus. Nonviral gene delivery methods use cationic or neutral liposomes, direct injection of plasmid DNA, and polymers. Various strategies to enhance efficiency of gene transfer have been tested such as fusogenic peptides in combination with liposomes or polymers to enhance the release of plasmid DNA from endosomes. [0008]
  • Each of the various gene delivery techniques has been found to possess different strengths and weaknesses. Recombinant retroviruses stably integrate into the chromosome but require host DNA synthesis to insert. Adenoviruses can infect non-dividing cells but cause immune reactions leading to the elimination of therapeutically transduced cells. Adeno-associated virus (AAV) is not pathogenic and does not elicit immune responses but new production strategies are required to obtain high AAV titers for preclinical and clinical studies. Wild-type AAVs integrate into chromosome 19, whereas recombinant AAVs are deprived of site-specific integration and may also persist episomally. [0009]
  • Herpes Simplex Virus (HSV) vectors can infect non-replicating cells, such as neuronal cells, and has a high payload capacity for foreign DNA but inflict cytotoxic effects. It seems that each delivery system will be developed independently of the others and that each will demonstrate strengths and weaknesses for certain applications. At present, retroviruses are most commonly used in human clinical trials, followed by adenoviruses, cationic liposomes and AAV. [0010]
  • As the challenges of perfecting gene therapy techniques have become apparent, a variety of additional delivery systems have been proposed to circumvent the difficulties observed with standard technologies. For example, cell-based gene delivery using polymer-encapsulated syngeneic or allogeneic cells implanted into a tissue of a patient can be used to secrete therapeutic proteins. This method is being tested in trials for amyotrophic lateral sclerosis using the ciliary neurotrophic factor gene, and may be extended to Factor VIII and IX for hemophilia, interleukin genes, dopamine-secreting cells to treat Parkinson's disease, nerve growth factor for Alzheimer's disease and other diseases. Other techniques under development include, vectors with the Cre-LoxP recombinase system to rid transfected cells of undesirable viral DNA sequences, use of tissue-specific promoters to express a gene in a particular cell type, or use of ligands recognizing cell surface molecules to direct gene vehicles to a particular cell type. [0011]
  • Additional methods that have been proposed for improving the efficacy of gene therapy technologies include designing p53 “gene bombs” that explode into tumor cells, exploiting the HIV-1 virus to engineer vectors for gene transfer, combining viruses with polymers or cationic lipids to improve gene transfer, the attachment of nuclear localization signal peptides to oligonucleotides to direct genes to nuclei, and the development of molecular switch systems allowing genes to be turned on or off at will. Nevertheless, because of the wide range of disease conditions for which gene therapies are required, and the complexities of developing treatments for such diseases, there remains a need for improved techniques for performing gene therapy. The present invention provides methods and compositions for addressing these issues. [0012]
    • DISCLOSURE OF THE INVENTION
  • A method is disclosed for encapsulating DNA and negatively charged drugs into liposomes having a different lipid composition between their inner and outer membrane bilayers. The liposomes are able to reach primary tumors and their metastases after intravenous injection to animals and humans. The method includes micelle formation between DNA with a mixture of cationic lipid and peptide molecules at molar ratios to nearly neutralization ratios in 10-90% ethanol; the cationic peptides specify nuclear localization and have a hydrophobic moiety endowed with membrane fusion to improve entrance across the cell membrane of the complex. These peptides insert with their cationic portion directed toward condensed DNA and their hydrophobic chain buried together with the hydrophobic chains of the lipids in the micelle membrane monolayer. The DNA/lipid/peptide micelles are converted into liposomes by mixing with pre-made liposomes or lipids followed by dilution in aqueous solutions and dialysis to remove the ethanol and allow liposome formation and extrusion through membranes to a diameter below 160 nm entrapping and encapsulating DNA with a very high yield. The encapsulated DNA has a high therapeutic efficacy in eradicating a variety of solid human tumors including, but not limited to, breast carcinoma and prostate carcinoma. A plasmid is constructed with DNA carrying anticancer genes including, but not limited to p53, RB, BRCA1, E1A, bcl-2, MDR-1, p21, pl6, bax, bcl-xs, E2F, IGF-I VEGF, angiostatin, oncostatin, endostatin, GM-CSF, IL-12, IL-2, IL-4, IL-7, IFN-γ, TNF-α, HSV-tk (in combination with ganciclovir), [0013] E. coli cytosine deaminase (in combination with 5-fluorocytosine) and is combined with encapsulated cisplatin or with other similarly systemically delivered antineoplastic drugs to suppress cancer.
    •  BRIEF DESCRIPTION OF THE DRAWINGS
  • FIG. 1 illustrates the structure of the cancer targeted liposome complex. [0014]
  • FIG. 2 illustrates the results of plasmid DNA condensation with various agents as well as various formulation of cationic liposomes in affecting the level of expression of the reporter beta-galactosidase gene after transfection of K562 human erythroleukemia cell cultures. [0015]
  • FIG. 3 illustrates tumor targeting in SCID mice. FIG. 3A shows a SCID mouse with a large and small human breast tumor before and after staining with X-Gal to test the expression of the transferred gene. Both tumors turn dark blue. The intensity of the blue color is proportional to the expression of the beta-galactosidase gene. [0016]
  • FIG. 3B shows that in the initial staining of the small tumor, the skin and the intestines at the injection area are the first organs to turn blue. FIG. 3C is a view of the back of the animal. The two tumors are clearly visible after removal of the skin (top). Dark staining of the small tumor and light blue staining of the large tumor is evident at an initial stage of staining (bottom). FIG. 3D is a view of the front side of the animal. The two tumors are clearly visible after removal of the skin. On the figure to the bottom the dark staining of both tumors is evident at a later stage during staining. [0017]
  • FIG. 3E shows the front (top) and rear (bottom) higher magnification view of the dark staining of both tumors at a later stage during staining. Staining of the vascular system around the small tumor can also be seen (bottom).[0018]
    • BRIEF DESCRIPTION OF THE TABLES
  • Table 1 is a list of molecules able to form micelles. [0019]
  • Table 2 lists several fusogenic peptides and describes their properties, along with a reference. [0020]
  • Table 3 lists simple Nuclear Localization Signal (NLS) peptides. [0021]
  • Table 4 shows a list of “bipartite” or “split” NLS peptides. [0022]
  • Table 5 lists “nonpositive NLS” peptides lacking clusters of arginines/lysines. [0023]
  • Table 6 lists peptides with nucleolar localization signals (NoLS). [0024]
  • Table 7 lists peptides having karyophilic clusters on non-membrane protein kinases. [0025]
  • Table 8 lists peptide nuclear localization signals on DNA repair proteins. [0026]
  • Table 9 lists NLS peptides in transcription factors. [0027]
  • Table 10 lists NLS peptides in other nuclear proteins. [0028]
    • Modes for Carrying out the Invention
  • Definitions [0029]
  • The practice of the present invention will employ, unless otherwise indicated, conventional techniques of immunology, molecular biology, microbiology, cell biology and recombinant DNA. These methods are described in the following publications. See, e.g., Sambrook, et al. MOLECULAR CLONING: A LABORATORY MANUAL, [0030] 2 d Edition (1989); CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, F. M. Ausubel, et al. eds., (1987); the series METHODS IN ENZYMOLOGY (Academic Press, Inc.); PCR: A PRACTICAL APPROACH, M. MacPherson, et al., IRL Press at Oxford University Press (1991); PCR 2: A PRACTICAL APPROACH, MacPherson et al., eds. (1995); ANTIBODIES, A LABORATORY MANUAL, Harlow and Lane, eds. (1988); and ANIMAL CELL CULTURE, R. I. Freshney, ed. (1987).
  • As used in the specification and claims, the singular form “a,” “an” and “the” include plural references unless the context clearly dictates otherwise. For example, the term “a cell” includes a plurality of cells, including mixtures thereof. [0031]
  • The term “comprising” is intended to mean that the compositions and methods include the recited elements, but not excluding others. “Consisting essentially of” when used to define compositions and methods, shall mean excluding other elements of any essential significance to the combination. Thus, a composition consisting essentially of the elements as defined herein would not exclude trace contaminants from the isolation and purification method and pharmaceutically acceptable carriers, such as phosphate buffered saline, preservatives, and the like. “Consisting of” shall mean excluding more than trace elements of other ingredients and substantial method steps for administering the compositions of this invention. Embodiments defined by each of these transition terms are within the scope of this invention. [0032]
  • The terms “polynucleotide” and “nucleic acid molecule” are used interchangeably to refer to polymeric forms of nucleotides of any length. The polynucleotides may contain deoxyribonucleotides, ribonucleotides, and/or their analogs. Nucleotides may have any three-dimensional structure, and may perform any function, known or unknown. The term “polynucleotide” includes, for example, single-, double-stranded and triple helical molecules, a gene or gene fragment, exons, introns, mRNA, tRNA, rRNA, ribozymes, cDNA, recombinant polynucleotides, branched polynucleotides, plasmids, vectors, isolated DNA of any sequence, isolated RNA of any sequence, nucleic acid probes, and primers. A nucleic acid molecule may also comprise modified nucleic acid molecules. [0033]
  • A “gene” refers to a polynucleotide containing at least one open reading frame that is capable of encoding a particular polypeptide or protein after being transcribed and translated. [0034]
  • A “gene product” refers to the amino acid (e.g., peptide or polypeptide) generated when a gene is transcribed and translated. [0035]
  • The following abbreviations are used herein: DDAB: dimethyldioctadecyl ammonium bromide (same as N,N-distearyl-N,N-dimethylammonium bromide); DODAC: N,N-dioleyl-N,N-dimethylammonium chloride; DODAP: 1,2-dioleoyl-3-dimethylammonium propane; DMRIE: N-[1-(2,3-dimyristyloxy)propyl]-N,N-dimethyl-N-(2-hydroxyethyl) ammonium bromide; DMTAP: 1,2-dimyristoyl-3-trimethylammonium propane; DOGS: Dioctadecylamidoglycylspermine; DOTAP (same as DOTMA): N-(1-(2,3-dioleoyloxy)propyl)-N,N,N-trimethylammonium chloride; DOSPA: N-(1-(2,3-dioleyloxy)propyl)-N-(2-(sperminecarboxamido)ethyl)-N,N-dimethyl ammonium trifluoroacetate; DPTAP: 1,2- dipalmitoyl-3-trimethylammonium propane; DSTAP: 1 ,2-disteroyl-3-trimethylammonium propane; DOPE, 1,2-sn-dioleoylphoshatidylethanolamine; DC-Chol, 3β-(N—(N′,N′-dimethylaminoethane)carbamoyl)cholesterol. See, Gao et al., [0036] Biochem. Biophys. Res. Comm. 179:280-285 (1991).
  • As used herein, the term “pharmaceutically acceptable anion” refers to anions of organic and inorganic acids that provide non-toxic salts in pharmaceutical preparations. Examples of such anions include the halides anions, chloride, bromide, and iodide, inorganic anions such as sulfate, phosphate, and nitrate, and organic anions. Organic anions may be derived from simple organic acids, such as acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, malic acid, malonic acid, succinic acid, maleic, acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methane sulfonic acid, ethane sulfonic acid, p-toluenesulfonic acid, and the like. The preparation of pharmaceutically acceptable salts is described in Berge, et al., [0037] J. Pharm. Sci. 66:1-19 (1977), incorporated herein by reference.
  • Physiologically acceptable carriers, excipients or stabilizers are nontoxic to recipients at the dosages and concentrations employed, and include buffers such as phosphate, citrate, and other organic acids; antioxidants including ascorbic acid; low molecular weight (less than about 10 residues) polypeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, arginine or lysine; monosaccharides, disaccharides, and other carbohydrates including glucose, mannose, or dextrins; chelating agents such as EDTA: sugar alcohols such as mannitol or sorbitol; salt-forming counter ions such as sodium; and/or nonionic surfactants such as Tween, Pluronics or polyethylene glycol (PEG). PEG molecules also contain a fusogenic peptide with an attached Nuclear Localization Signal (NLS) covalently linked to the end of the PEG molecule. [0038]
  • The term “cationic lipid” refers to any of a number of lipid species that carry a net positive charge at physiological pH. Such lipids include, but are not limited to, DDAB, DMRIE, DODAC, DOGS, DOTAP, DOSPA and DC-Chol. Additionally, a number of commercial preparations of cationic lipids are available that can be used in the present invention. These include, for example, LIPOFECTIN (commercially available cationic liposomes comprising DOTMA and DOPE, from GIBCO/BRL, Grand Island, N.Y., USA); LIPOFECTAMINE (commercially available cationic liposomes comprising DOSPA and DOPE, from GIBCO/BRL); and TRANSFECTAM (commercially available cationic lipids comprising DOGS in ethanol from Promega Corp., Madison, Wis., USA). [0039]
  • This invention further provides a number of methods for producing micelles with entrapped therapeutic drugs. The method is particularly useful to produce micelles of drugs or compositions having a net overall negative charge, e.g., DNA, RNA or negatively charged small molecules. For example, the DNA can be comprised within a plasmid vector and encode for a therapeutic protein, e.g., wild-type p53, HSV-tk, p21, Bax, Bad, IL-2, IL-12, GM-CSF, angiostatin, endostatin and oncostatin. In one embodiment, the method requires combining an effective amount of the therapeutic agent with an effective amount of cationic lipids. Cationic lipids useful in the methods of this invention include, but are not limited to, DDAB, dimethyldioctadecyl ammonium bromide; DMRIE: N-[1-(2,3-dimyristyloxy)propyl]-N,N-dimethyl-N-(2-hydroxyethyl) ammonium bromide; DMTAP: 1,2-dimyristoyl-3-trimethylammonium propane; DOGS: Dioctadecylamidoglycylspermine; DOTAP (same as DOTMA): N-(1-(2,3-dioleoyloxy)propyl)-N,N,N-trimethylammonium chloride; DPTAP: 1,2-dipalmitoyl-3-trimethylammonium propane; DSTAP: 1 ,2-disteroyl-3-trimethylammonium propane. [0040]
  • In one aspect, a ratio of from about 30 to about 90% of phosphates contained within the negatively charged therapeutic agent are neutralized by positive charges on lipid molecules (negative charges are in excess) to form an electrostatic micelle complex in an effective concentration of ethanol. In one aspect, the ethanol solution is from about 20% to about 80% ethanol. In a further aspect, the ethanol concentration is about 30%. The ethanol/cationic lipid/therapeutic agent complex is then combined with an effective amount of a fusogenic-karyophilic peptide conjugate. In one aspect, an effective amount of the conjugate is a ratio range from about 0.0 to about 0.3 (positive charges on peptide to negative charges on phosphate groups) to neutralize the majority of the remaining negative charges on the phosphate groups of the therapeutic agents thereby leading to an almost complete neutralization of the complex. The optimal conditions give to the complex a slightly negative charge. However, when the positive charges on cationic lipids exceed the negative charges on the DNA, the excess of positive charges are neutralized by DPPG (dipalmitoyl phosphatidyl glycerol) and its derivatives, or by other anionic lipid molecules in the final micelle complex. [0041]
  • In an alternative embodiment, the above methods can be modified by addition of DNA condensing agents selected from spermine, spermidine, and magnesium or other divalent metal ions neutralizing a certain percentage (1-20%) of phosphate groups. [0042]
  • In a further embodiment, the cationic lipids are combined with an effective amount of fusogenic lipid DOPE at various molar ratios for example, in a molar ratio of from about 1:1 cationic lipid:DOPE. In an alternative embodiment, the cationic lipids are combined with an effective amount of a fusogenic/NLS peptide conjugate. Examples of fusogenic/NLS peptide conjugates include, but are not limited to (KAWLKAF)[0043] 3 (SEQ ID NO:1), GLFKAAAKLLKSLWKLLLKA (SEQ ID NO:2), LLLKAFAKLLKSLWKLLLKA (SEQ ID NO:3), as well as all derivatives of the prototype (Hydrophobic3-Karyophilic1-Hydrophobic2-Karyophilic1)2-3 where Hydrophobic is any of the A, I, L, V, P, G, W, F and Karyophilic is any of the K, R, or H, containing a positively-charged residue every 3rd or 4th amino acid, which form alpha helices and direct a net positive charge to the same direction of the helix. Additional examples include but are not limited to GLFKAIAGFIKNGWKGMIDGGGYC (SEQ ID NO:4) from influenza virus hemagglutinin HA-2; YGRKKRRQRRR (SEQ ID NO:5) from TAT of HIV; MSGTFGGILAGLIGLL(K/R/H)1-6 (SEQ ID NO:6), derived from the N-terminal region of the S protein of duck hepatitis B virus, but with the addition of one to six positively-charged lysine, arginine or histidine residues, and combinations of these, able to interact directly with the phosphate groups of plasmid or oligonucleotide DNA, compensating for part of the positive charges provided by the cationic lipids. GAAIGLAWIPYFGPAA (SEQ ID NO:7) is derived from the fusogenic peptide of the Ebola virus transmembrane protein; residues 53-70 (C-terminal helix) of apolipoprotein (apo) AII peptide; the 23-residue fusogenic N-terminal peptide of HIV-1 transmembrane glycoprotein gp41; the 29-42-residue fragment from Alzheimer's β-amyloid peptide; the fusion peptide and N-terminal heptad repeat of Sendai virus; the 56-68 helical segment of lecithin cholesterol acyltransferase. Included within these embodiments are shorter versions of these peptides, that are known to induce fusion of unilamellar lipid vesicles or all that are similarly derivatized with the addition of one to six positively-charged lysine, arginine or histidine residues (K/R/H)1-6 able to interact directly with the phosphate groups of plasmid or oligonucleotide DNA, compensating for part of the positive charges provided by the cationic lipids. The fusogenic peptides in the fusogenic/NLS conjugates represent hydrophobic amino acid stretches, and smaller fragments of these peptide sequences, that include all signal peptide sequences used in membrane or secreted proteins that insert into the endoplasmic reticulum. Alternatively, the conjugates represent transmembrane domains and smaller fragments of these peptide sequences.
  • In one aspect of the invention, the NLS peptide component in fusogenic/NLS peptide conjugates is derived from the fusogenic hydrophobic peptides. However, there is an addition of 5-6 amino acid karyophilic Nuclear Localization Signals (NLS) derived from a number of known NLS peptides, as well as from searches of the nuclear protein databases, for stretches of five or more karyophilic amino acid stretches in proteins containing at least four positively-charged amino aids flanked by a proline (P) or glycine (G). Examples of NLS peptides are shown in Tables 1-8. The NLS peptide component in fusogenic/NLS peptide conjugates are synthetic peptides containing the above said NLS, but further modified by additional K, R, H residues at the central part of the peptide or with P or G at the N- or C-terminus. [0044]
  • In a further aspect, the fusogenic/NLS peptide conjugates are derived from the said fusogenic hydrophobic peptides but with the addition of a stretch of H[0045] 4-6 (four to six histidine residues) in the place of NLS. Micelle formation takes place at pH 5-6 where histidyl residues are positively charged but lose their charge at the nearly neutral pH of the biological fluids, thus releasing the plasmid or oligonucleotide DNA from their electrostatic interaction.
  • The fusogenic peptide/NLS peptide conjugates are linked to each other with a short amino acid stretch representing an endogenous protease cleavage site. [0046]
  • In a preferred aspect of the invention, the structure of the preferred prototype fusogenic/NLS peptide conjugate used in this invention is: PKKRRGPSP(L/A/I)[0047] 12-20 (SEQ ID NO:8), where (L/A/I)12-20 is a stretch of 12-20 hydrophobic amino acids containing A, L, I, Y, W, F and other hydrophobic amino acids.
  • The micelles made by the above methods are further provided by this invention by conversion into liposomes. An effective amount of liposomes (diameter from about 80 to about 160 nm), or of a lipid solution composed of cholesterol (from about 10% to about 50%), neutral phospholipid such as hydrogenated soy phosphatidylcholine (HSPC) (from about 40% to about 90%), and the derivatized vesicle-forming lipid PEG-DSPE (distearoylphosphatidyl ethanolamine) from about 1-to about 7 mole percent, is added to the micelle solution. [0048]
  • In a specific embodiment, the liposomes are composed of vesicle-forming lipids and between from about 1 to about 7 mole percent of distearoylphosphatidyl ethanolamine (DSPE) derivatized with a polyethyleneglycol. The composition of claim 20, wherein the polyethyleneglycol has a molecular weight is between about 1,000 to 5,000 daltons. Micelles are converted into liposomes with a concomitant decrease of the ethanol concentration which can be accomplished by removal of the ethanol by dialysis of the liposome complexes through permeable membranes or reduced to a diameter of 80-160 nm by extrusion through membranes. [0049]
  • Liposome encapsulated therapeutic agents produced by the above methods are further provided by this invention. [0050]
  • Also provided herein is a method for delivering a therapeutic agent such as plasmid DNA or oligonucleotides to a tissue cell in vivo by intravenous, or other type of injection of the micelles or liposomes. This method specifically targets a primary tumor and the metastases by the long circulating time of the micelle or liposome complex because of the exposure of PEG chains on its surface, its small size (80-160 nm) and the decrease in hydrostatic pressure in the solid tumor from the center to its periphery supporting a preferential extravasation through the tumor vasculature to the extracellular space in tumors. A method for delivering plasmid or oligonucleotide DNA across the cell membrane barrier of the tumors using the micelle or liposome complexes described herein is capable because of the presence of the fusogenic peptides in the complex. In particular, a method for delivering plasmid or oligonucleotide DNA to the liver, spleen and bone marrow after intravenous injection of the complexes is provided. Further provided is a method for delivering therapeutic genes to the liver, spleen and bone marrow of cancer and noncancer patients including but not limited to, factor VIII or IX for the therapy of hemophilias, multidrug resistance, cytokine genes for cancer immunotherapy, genes for the alleviation of pain, genes for the alleviation of diabetes and genes that can be introduced to liver, spleen and bone marrow tissue, to produce a secreted form of a therapeutic protein. [0051]
  • The disclosed therapies also provide methods for reducing tumor size by combining the encapsulated plasmid DNA carrying one or more anticancer genes selected from the group consisting of p53, RB, BRCA1, E1A, bc1-2, MDR-1, p21, p16, bax, bc1-xs, E2F, IGF-I VEGF, angiostatin, oncostatin, endostatin, GM-CSF, IL-12, IL-2, IL-4, IL-7, IFN-γ, TNF-α, HSV-tk (in combination with ganciclovir), [0052] E. coli cytosine deaminase (in combination with 5-fluorocytosine) with encapsulated antisense oligonucleotides (antisense c-fos, c-myc, K-ras), ribozymes or triplex-forming oligonucleotides directed against genes that control the cell cycle or signaling pathways. These methods can be modified by combining the encapsulated plasmid DNA carrying one or more anticancer genes of with encapsulated or free antineoplastic drugs, consisting of the group of adriamycin, angiostatin, azathioprine, bleomycin, busulfane, camptothecin, carboplatin, carmustine, chlorambucile, chlormethamine, chloroquinoxaline sulfonamide, cisplatin, cyclophosphamide, cycloplatam, cytarabine, dacarbazine, dactinomycin, daunorubicin, didox, doxorubicin, endostatin, enloplatin, estramustine, etoposide, extramustinephosphat, flucytosine, fluorodeoxyuridine, fluorouracil, gallium nitrate, hydroxyurea, idoxuridine, interferons, interleukins, leuprolide, lobaplatin, lomustine, mannomustine, mechlorethamine, mechlorethaminoxide, melphalan, mercaptopurine, methotrexate, mithramycin, mitobronitole, mitomycin, mycophenolic acid, nocodazole, oncostatin, oxaliplatin, paclitaxel, pentamustine, platinum-triamine complex, plicamycin, prednisolone, prednisone, procarbazine, protein kinase C inhibitors, puromycine, semustine, signal transduction inhibitors, spiroplatin, streptozotocine, stromelysin inhibitors, taxol, tegafur, telomerase inhibitors, teniposide, thalidomide, thiamiprine, thioguanine, thiotepa, tiamiprine, tretamine, triaziquone, trifosfamide, tyrosine kinase inhibitors, uramustine, vidarabine, vinblastine, vinca alcaloids, vincristine, vindesine, vorozole, zeniplatin, zeniplatin, and zinostatin.
  • The following examples are intended to illustrate, but not limit the invention. [0053]
  • Liposome Composition [0054]
  • Liposomes are microscopic vesicles consisting of concentric lipid bilayers. Structurally, liposomes range in size and shape from long tubes to spheres, with dimensions from a few hundred Angstroms to fractions of a millimeter. Vesicle-forming lipids are selected to achieve a specified degree of fluidity or rigidity of the final complex providing the lipid composition of the outer layer. These are neutral (cholesterol) or bipolar and include phospholipids, such as phosphatidylcholine (PC), phosphatidylethanolamine (PE), phosphatidylinositol (PI), and sphingomyelin (SM) and other type of bipolar lipids including but not limited to dioleoylphosphatidylethanolamine (DOPE), with a hydrocarbon chain length in the range of 14-22, and saturated or with one or more double C═C bonds. Examples of lipids capable of producing a stable liposome, alone, or in combination with other lipid components are phospholipids, such as hydrogenated soy phosphatidylcholine (HSPC), lecithin, phosphatidylethanolamine, lysolecithin, lysophosphatidylethanolamine, phosphatidylserine, phosphatidylinositol, sphingomyelin, cephalin, cardiolipin, phosphatidic acid, cerebrosides, distearoylphosphatidylethanolamine (DSPE), dioleoylphosphatidylcholine (DOPC), dipalmitoylphosphatidylcholine (DPPC), palmitoyloleoylphosphatidylcholine (POPC), palmitoyloleoylphosphatidylethanolamine (POPE) and dioleoylphosphatidylethanolamine 4-(N-maleimido-methyl)cyclohexane-1-carboxylate (DOPE-mal). Additional non-phosphorous containing lipids that can become incorporated into liposomes include stearylamine, dodecylamine, hexadecylamine, isopropyl myristate, triethanolamine-lauryl sulfate, alkyl-aryl sulfate, acetyl palmitate, glycerol ricinoleate, hexadecyl stereate, amphoteric acrylic polymers, polyethyloxylated fatty acid amides, and the cationic lipids mentioned above (DDAB, DODAC, DMRIE, DMTAP, DOGS, DOTAP (DOTMA), DOSPA, DPTAP, DSTAP, DC-Chol). Negatively charged lipids include phosphatidic acid (PA), dipalmitoylphosphatidylglycerol (DPPG), dioleoylphosphatidylglycerol and (DOPG), dicetylphosphate that are able to form vesicles. Preferred lipids for use in the present invention are cholesterol, hydrogenated soy phosphatidylcholine (HSPC) and, the derivatized vesicle-forming lipid PEG-DSPE. [0055]
  • Typically, liposomes can be divided into three categories based on their overall size and the nature of the lamellar structure. The three classifications, as developed by the New York Academy Sciences Meeting, “Liposomes and Their Use in Biology and Medicine,” December 1977, are multi-lamellar vesicles (MLVs), small uni-lamellar vesicles (SUVs) and large uni-lamellar vesicles (LUVs). [0056]
  • SUVs range in diameter from approximately 20 to 50 nm and consist of a single lipid bilayer surrounding an aqueous compartment. Unilamellar vesicles can also be prepared in sizes from about 50 nm to 600 nm in diameter. While unilamellar are single compartmental vesicles of fairly uniform size, MLVs vary greatly in size up to 10,000 nm, or thereabouts, are multi-compartmental in their structure and contain more than one bilayer. LUV liposomes are so named because of their large diameter that ranges from about 600 nm to 30,000 nm; they can contain more than one bilayer. [0057]
  • Liposomes may be prepared by a number of methods not all of which produce the three different types of liposomes. For example, ultrasonic dispersion by means of immersing a metal probe directly into a suspension of MLVs is a common way for preparing SUVs. [0058]
  • Preparing liposomes of the MLV class usually involves dissolving the lipids in an appropriate organic solvent and then removing the solvent under a gas or air stream. This leaves behind a thin film of dry lipid on the surface of the container. An aqueous solution is then introduced into the container with shaking, in order to free lipid material from the sides of the container. This process disperses the lipid, causing it to form into lipid aggregates or liposomes. Liposomes of the LUV variety may be made by slow hydration of a thin layer of lipid with distilled water or an aqueous solution of some sort. Alternatively, liposomes may be prepared by lyophilization. This process comprises drying a solution of lipids to a film under a stream of nitrogen. This film is then dissolved in a volatile solvent, frozen, and placed on a lyophilization apparatus to remove the solvent. To prepare a pharmaceutical formulation containing a drug, a solution of the drug is added to the lyophilized lipids, whereupon liposomes are formed. [0059]
  • Preparing Cationic Liposome/Cationic Peptide/Nucleic Acid Micelles [0060]
  • Cationic lipids, with the exception of sphingosine and some lipids in primitive life forms, do not occur in nature. The present invention uses single-chain amphiphiles which are chloride and bromide salts of the alkyltrimethylammonium surfactants including but not limited to C12 and C16 chains abbreviated DDAB (same as DODAB) or CTAB. The molecular geometry of these molecules determines the critical micelle concentration (ratio between free monomers in solution and molecules in micelles). Lipid exchange between the two states is a highly dynamic process; phospholipids have critical micelle concentration values below 10[0061] −8 M and are more stable in liposomes; however, single chain detergents, such as stearylamine, may emerge from the liposome membrane upon dilution or intravenous injection in milliseconds (Lasic, 1997).
  • Cationic lipids include, but are not limited to, DDAB: dimethyldioctadecyl ammonium bromide (same as N,N-distearyl-N,N-dimethylammonium bromide); DMRIE: N-[1-(2,3-dimyristyloxy)propyl]-N,N-dimethyl-N-(2-hydroxyethyl) ammonium bromide; DODAC: N,N-dioleyl-N,N-dimethylammonium chloride; DMTAP: 1,2-dimyristoyl-3-trimethylammonium propane; DODAP: 1,2-dioleoyl-3-dimethylammonium propane; DOGS: Dioctadecylamidoglycylspermine; DOTAP (same as DOTMA): N-(1-(2,3-dioleoyloxy)propyl)-N,N,N-trimethylammonium chloride; DOSPA: N-(1-(2,3-dioleyloxy)propyl)-N-(2-(sperminecarboxamido)ethyl)-N,N-dimethyl ammonium trifluoroacetate; DPTAP: 1,2-dipalmitoyl-3-trimethylammonium propane; DSTAP: 1,2-disteroyl-3-trimethylammonium propane; DC-Chol, 3β-(N—(N′,N′-dimethylaminoethane)carbamoyl)cholesterol. [0062]
  • Lipid-based vectors used in gene transfer have been formulated in one of two ways. In one method, the nucleic acid is introduced into preformed liposomes made of mixtures of cationic lipids and neutral lipids. The complexes thus formed have undefined and complicated structures and the transfection efficiency is severely reduced by the presence of serum. Preformed liposomes are commercially available as LIPOFECTIN and LIPOFECTAMINE. The second method involves the formation of DNA complexes with mono- or poly-cationic lipids without the presence of a neutral lipid. These complexes are prepared in the presence of ethanol and are not stable in water. Additionally, these complexes are adversely affected by serum (see, Behr, [0063] Acc. Chem. Res. 26:274-78 (1993)). An example of a commercially available poly-cationic lipid is TRANSFECTAM. Other efforts to encapsulate DNA in lipid-based formulations have not overcome these problems (see, Szoka et al., Ann. Rev. Biophys. Bioeng. 9:467 (1980); and Deamer, U.S. Pat. No. 4,515,736).
  • The nucleotide polymers can be single-stranded DNA or RNA, or double-stranded DNA or DNA—RNA hybrids. Examples of double-stranded DNA include structural genes, genes including control and termination regions, and self-replicating systems such as plasmid DNA. Particularly preferred nucleic acids are plasmids. Single-stranded nucleic acids include antisense oligonucleotides (complementary to DNA and RNA), ribozymes and triplex-forming oligonucleotides. In order to increase stability, some single-stranded nucleic acids will preferably have some or all of the nucleotide linkages substituted with stable, non-phosphodiester linkages, including, for example, phosphorothioate, phosphorodithioate, phosphoroselenate, methylphosphonate, or O-alkyl phosphotriester linkages. [0064]
  • Encapsulating Cationic Liposome/Cationic Peptide/Nucleic Acid Micelles into Neutral Liposomes [0065]
  • Cationic lipids used with fusogenic peptide/NLS conjugates to provide the inner layer of the particle can be any of a number of substances selected from the group of DDAB, DODAC, DMRIE, DMTAP, DOGS, DOTAP (DOTMA), DOSPA, DPTAP, DSTAP, DC-Chol. The cationic lipid is combined with DOPE. In one group of embodiments, the preferred cationic lipid is DDAB:DOPE 1: 1. [0066]
  • Neutral lipids used herein to provide the outer layer of the particles can be any of a number of lipid species that exist either in an uncharged or neutral zwitterionic form at physiological pH. Such lipids are selected from a group consisting of diacylphosphatidylcholine, diacylphosphatidylethanolamine, ceramide, sphingomyelin, cephalin, and cerebrosides. In one group of embodiments, lipids containing saturated, mono-, or di-unsaturated fatty acids with carbon chain lengths in the range of C14 to C22 are preferred. In general, less saturated lipids are more easily sized, particularly when the liposomes must be sized below about 0.16 microns, for purposes of filter sterilization. Consideration of liposome size, rigidity and stability of the liposomes in the final preparation, its shelf life without leakage of the encapsulated DNA, and stability in the bloodstream generally guide the selection of neutral lipids for providing the outer coating of our gene vehicles. Lipids having a variety of acyl chain groups of varying chain length and degree of saturation are available or may be isolated or synthesized by well-known techniques. In another group of embodiments, lipids with carbon chain lengths in the range of C14 to C22 are used. Preferably, the neutral lipids used in the present invention are hydrogenated soy phosphatidylcholine (HSPC), cholesterol, and PEG-distearoylphosphatidyl ethanolamine (DSPE) or PEG-ceramide. [0067]
  • Methods for Preparing Liposomes [0068]
  • A variety of methods for preparing various liposome forms have been described in several issued patents, for example, U.S. Pat. Nos. 4,229,360; 4,224,179; 4,241,046; 4,737,323; 4,078,052; 4,235,871; 4,501,728; and 4,837,028, as well as in the articles Szoka et al., [0069] Ann. Rev. Biophys. Bioeng. 9:467 (1980) and Hope et al., Chem. Phys. Lip. 40:89 (1986). These methods do not produce all three different types of liposomes (MLVs, SUVs, LUVs). For example, ultrasonic dispersion by means of immersing a metal probe directly into a suspension of MLVs is a common way for preparing SUVs.
  • Preparing liposomes of the MLV class usually involves dissolving the lipids in an appropriate organic solvent and then removing the solvent under a gas or air stream. This leaves behind a thin film of dry lipid on the surface of the container. An aqueous solution is then introduced into the container with shaking, in order to free lipid material from the sides of the container. This process disperses the lipid, causing it to form into lipid aggregates or liposomes. Liposomes of the LUV variety may be made by slow hydration of a thin layer of lipid with distilled water or an aqueous solution of some sort. Alternatively, liposomes may be prepared by lyophilization. This process comprises drying a solution of lipids to a film under a stream of nitrogen. The film is then dissolved in a volatile solvent, frozen, and placed on a lyophilization apparatus to remove the solvent. To prepare a pharmaceutical formulation containing a drug, a solution of the drug is added to the lyophilized lipids, whereupon liposomes are formed. [0070]
  • Following liposome preparation, the liposomes may be sized to achieve a desired size range and relatively narrow distribution of liposome sizes. Preferably, the preformed liposomes are sized to a mean diameter of about 80 to 160 nm (the upper size limit for filter sterilization before in vivo administration). Several techniques are available for sizing liposomes to a desired size. Sonicating a liposome suspension either by bath or probe sonication produces a progressive size reduction down to small unilamellar vesicles less than about 0.05 microns (50 nm) in size. Extrusion of liposome through a small-pore polycarbonate is our preferred method for reducing liposome sizes to a relatively well-defined size distribution. The liposomes may be extruded through successively smaller-pore membranes, to achieve a gradual reduction in liposome size. [0071]
  • One way used to coat DNA with lipid is by controlled detergent depletion from a cationic lipid/DNA/detergent complex. This method can give complexes with stability in plasma. Hofland et al. (1996), have prepared such complexes by dialysis of a mixture of DOSPA/DOPE/DNA/octylglucoside. [0072]
  • Pharmaceutical compositions comprising the cationic liposome/nucleic acid complexes of the invention are prepared according to standard techniques and further comprise a pharmaceutically acceptable carrier. Generally, normal saline will be employed as the pharmaceutically acceptable carrier. [0073]
  • For in vivo administration, the pharmaceutical compositions are preferably administered parenterally, i.e., intravenously, intraperitoneally, subcutaneously, intrathecally, injection to the spinal cord, intramuscularly, intraarticularly, portal vein injection, or intratumorally. More preferably, the pharmaceutical compositions are administered intravenously or intratumorally by a bolus injection. In other methods, the pharmaceutical preparations may be contacted with the target tissue by direct application of the preparation to the tissue. The application may be made by topical “open” or “closed” procedures. The term “topical” means the direct application of the pharmaceutical preparation to a tissue exposed to the environment, such as the skin, to any surface of the body, nasopharynx, external auditory canal, ocular administration and administration to the surface of any body cavities, inhalation to the lung, genital mucosa and the like. [0074]
  • “Open” procedures are those procedures that include incising the skin of a patient and directly visualizing the underlying tissue to which the pharmaceutical preparations are applied. This is generally accomplished by a surgical procedure, such as a thoracotomy to access the lungs, abdominal laparotomy to access abdominal viscera, or other direct surgical approach to the target tissue. [0075]
  • “Closed” procedures are invasive procedures in which the internal target tissues are not directly visualized, but accessed via insertion of instruments through small wounds in the skin. For example, the preparations may be administered to the peritoneum by needle lavage. Likewise, the pharmaceutical preparations may be administered to the meninges or spinal cord by infusion during a lumbar puncture followed by appropriate positioning of the patient as commonly practiced for spinal anesthesia or metrazamide imaging of the spinal cord. Alternatively, the preparations may be administered through endoscopic devices. [0076]
    • EXAMPLES
  • Materials and Methods [0077]
  • DDAB, DOPE (dioleoylphosphatidylethanolamine) and most other lipids used here were purchased from Avanti Polar Lipids; PEG-DSPE was from Syngena. [0078]
  • Engineering of Plasmid pLF [0079]
  • The pGL3-C (Promega) was cut with XbaI and blunt-end ligated using the Klenow fragment of [0080] E. coli DNA polymerase. It was then cut with HindIII and the 1689-bp fragment, carrying the luciferase gene, was gel-purified. The pGFP-N1 plasmid (Clontech) was cut with SmaI and HindIII and the 4.7 kb fragment, isolated from an agarose gel, was ligated with the luciferase fragment. JM109 E. Coli cells were transformed and 20 colonies were selected; about half of them showed the presence of inserts; 8 clones with inserts were cut with BamHI and XhoI to further confirm the presence of the luciferase gene; seven of them were positive.
  • Radiolabeled plasmid pLF was generated by culturing [0081] Escherichia coli in 3H-thymidine-5′-triphosphate or 32P inorganic phosphate (5 mCi) (Dupont/NEN, Boston, Mass.) and purified using standard techniques as described above.
  • DLS Measurements [0082]
  • A Coulter N4M light scattering instrument was used, at a 90° angle, set at a run time of 200 sec, using 4 to 25 microsec sample time. The scan of the particle size distribution was obtained in 1 ml sample volume using plastic cuvettes, at 20° C. and at 0.01 poise viscosity. [0083]
  • In one aspect, this invention provides a method for entrapping DNA into lipids that enhances the content of plasmid per volume unit, and reduces the toxicity of the cationic lipids used to trap plasmid or oligonucleotide DNA. The DNA becomes hidden in the inner membrane bilayer of the final complex. Furthermore, the gene transfer complex is endowed with long circulation time in body fluids and extravasates preferentially into solid tumors and their metastatic foci and nodules. The extravasation occurs through their vasculature at most sites of the human or animal body after intravenous injection of the gene-carrying vehicles. This occurs because of their small size (100-160 nm), their content in neutral to slightly negatively-charged lipids in their outer membrane bilayers, and their coating with PEG. These gene delivery vehicles are able to cross the cell membrane barrier after they reach the extracellular tumor space because of the presence of fusogenic peptides conjugated with karyophilic peptides. The vehicles assume a certain predefined orientation in the lipid membrane with their positive ends directed toward DNA and their hydrophobic tail buried inside the hydrophobic lipid bilayer. The labile NLS-fusogenic peptide linkage is cleaved after endocytosis and the remaining NLS peptide bound to plasmid DNA aids its nuclear uptake. This occurs especially when non-dividing cells are targeted, such as liver, spleen or bone marrow cells that represent the major sites for extravasation and concentration of these vehicles other than solid tumors. [0084]
  • Organic Solvent [0085]
  • A suitable solvent for preparing a micelle from the desired lipid components is ethanol, methanol, or other aliphatic alcohols such as propanol, isopropanol, butanol, tert-butanol, iso-butanol, pentanol and hexanol. Mixtures of two or more solvents may be used in the practice of the invention. It is also to be understood that any solvent that is miscible with an ethanol solution, even in small amounts, can be used to improve micelle formation and its subsequent conversion into liposomes, including chloroform, dichloromethane, diethylether, cyclohexane, cyclopentane, benzene, and toluene. [0086]
  • Cationic Lipids [0087]
  • In a further embodiment, the liposome encapsulated DNA described herein further comprises an effective amount of cationic lipids. Cationic lipids have been widely used for gene transfer; a number of clinical trials (34 out of 220 total RAC-approved protocols as of December, 1997) use cationic lipids. Although many cell culture studies have been documented, systemic delivery of genes with cationic lipids in vivo has been very limited. All clinical protocols use subcutaneous, intradermal, intratumoral, and intracranial injection as well as intranasal, intrapleural, or aerosol administration but not I.V. delivery, because of the toxicity of the cationic lipids and DOPE (see, Martin and Boulikas, 1998). Liposomes formulated from DOPE and cationic lipids based on diacyltrimethylammonium propane (dioleoyl-, dimyristoyl-, dipalmitoyl-, disteroyl-trimethylammonium propane or DOTAP, DMTAP, DPTAP, DSTAP, respectively) or DDAB were highly toxic when incubated in vitro with phagocytic cells (macrophages and U937 cells), but not towards non-phagocytic T lymphocytes. The rank order of toxicity was DOPE/DDAB >DOPE/DOTAP >DOPE/DMTAP >DOPE/DPTAP >DOPE/DSTAP; and the toxicity was determined from the effect of the cationic liposomes on the synthesis of nitric oxide (NO) and TNF-α produced by activated macrophages (Filion and Phillips, 1997). [0088]
  • Another aspect to be considered before I.V. injection is undertaken, is that negatively charged serum proteins can interact and cause inactivation of cationic liposomes (Yang and Huang, 1997). Condensing agents used for plasmid delivery including polylysine, transferrin-polylysine, a fifth-generation poly(amidoamine) (PAMAM) dendrimer, poly(ethyleneimine), and several cationic lipids (DOTAP, DC-Chol/DOPE, DOGS/DOPE, and DOTMA/DOPE), were found to activate the complement system to varying extents. Strong complement activation was seen with long-chain polylysines, the dendrimer, poly(ethyleneimine), and DOGS. Modifying the surface of preformed DNA complexes with polyethyleneglycol (Plank et al., 1996) considerably reduced complement activation. [0089]
  • Cationic lipids increase the transfection efficiency by destabilizing the biological membranes, including plasma, endosomal, and lysosomal membranes. Incubation of isolated lysosomes with low concentrations of DOTAP caused a striking increase in free activity of β-galactosidase, and even a release of the enzyme into the medium. This demonstrates that the lysosomal membrane is deeply destabilized by the lipid. The mechanism of destabilization was thought to involve an interaction between cationic liposomes and anionic lipids of the lysosomal membrane, thus allowing a fusion between the lipid bilayers. The process was less pronounced at pH 5 than at pH 7.4, and anionic amphipathic lipids were able to prevent partially this membrane destabilization (Wattiaux et al., 1997). [0090]
  • In contrast to DOTAP and DMRIE that were 100% charged at pH 7.4, DC-CHOL was only about 50% charged as monitored by a pH-sensitive fluorophore. This difference decreases the charge on the external surfaces of the liposomes, and was proposed to promote an easier dissociation of bilayers containing DC-CHOL from the plasmid DNA, and an increase in release of the DNA-lipid complex into the cytosol from the endosomes (Zuidam and Barenholz, 1997). [0091]
  • Although cationic lipids have been used widely for the delivery of genes, very few studies have used systemic I.V. injection of cationic liposome-plasmid complexes. This is because of the toxicity of the lipid component in animal models, not humans. Administration by I.V. injection of two types of cationic lipids of similar structure, DOTMA and DOTAP, shows that the transfection efficiency is determined mainly by the structure of the cationic lipid and the ratio of cationic lipid to DNA; the luciferase and GFP gene expression in different organs was transient, with a peak level between 4 and 24 hr, dropping to less than 1% of the peak level by day 4 (Song et al., 1997). [0092]
  • A number of different organs in vivo can be targeted after liposomal delivery of genes or oligonucleotides. Intravenous injection of cationic liposome-plasmid complexes by tail vein in mice, targeted mainly the lung and to a smaller extent the liver, spleen, heart, kidney and other organs (Zhu et al., 1993). Intraperitoneal injection of a plasmid-liposome complex expressing antisense K-ras RNA in nude mice inoculated i.p. with AsPC-1 pancreatic cancer cells harboring K-ras point mutations and PCR analysis indicated that the injected DNA was delivered to various organs except brain (Aoki et al., 1995). [0093]
  • A number of factors for DOTAP:cholesterol/DNA complex preparation including the DNA:liposome ratio, mild sonication, heating, and extrusion were found to be crucial for improved systemic delivery; maximal gene expression was obtained when a homogeneous population of DNA:liposome complexes between 200 to 450 nm in size were used. Cryo-electron microscopy showed that the DNA was condensed on the interior of invaginated liposomes between two lipid bilayers in these formulations, a factor that was thought to be responsible for the high transfection efficiency in vivo and for the broad tissue distribution (Templeton et al., 1997). [0094]
  • Steps to improve liposome-mediated gene delivery to somatic cells include, persistence of the plasmid in blood circulation, port of entry and transport across the cell membrane, release from endosomal compartments into the cytoplasm, nuclear import by docking through the pore complexes of the nuclear envelope, expression driven by the appropriate promoter/enhancer control elements, and persistence of the plasmid in the nucleus for long periods (Boulikas, 1998a). [0095]
  • Plasmid Condensation With Spermine [0096]
  • In a further embodiment, the liposome encapsulated DNA described herein is condensed with spermine and/or spermidine. DNA can be presented to cells in culture as a complex with polycations such as polylysine, or basic proteins such as protamine, total histones or specific histone fractions, protamine (Boulikas and Martin, 1997). The interaction of plasmid DNA with protamine sulfate, followed by the addition of DOTAP cationic liposomes, offered a better protection of plasmid DNA against enzymatic digestion. The method gave consistently higher gene expression in mice via tail vein injection as compared with DOTAP/DNA complexes. 50 μg of luciferase-plasmid per mouse gave 20 ng luciferase protein per mg extracted tissue protein in the lung, that was detected as early as 1 h after injection, peaked at 6 h and declined thereafter. Intraportal injection of protamine/DOTAP/DNA led to about a 100-fold decrease in gene expression in the lung as compared with I.V. injection. Endothelial cells were the primary locus of lacZ transgene expression (Li and Huang, 1997). Protamine sulfate enhanced plasmid delivery into several different types of cells in vitro, using the monovalent cationic liposomal formulations (DC-Chol and lipofectin). This effect was less pronounced with the multivalent cationic liposome formulation, lipofectamine (Sorgi et al., 1997). [0097]
  • Spermine is found to enhance the transfection efficiency of DNA-cationic liposome complexes in cell culture and in animal studies. This biogenic polyamine at high concentrations caused liposome fusion most likely promoted by the simultaneous interaction of one molecule of spermine (four positively charged amino groups) with the polar head groups of two or more molecules of lipids. At low concentrations (0.03-0.1 mM) it promoted anchorage of the liposome-DNA complex to the surface of cells and enhanced significantly transfection efficiency (Boulikas, unpublished). [0098]
  • The polycations polybrene, protamine, DEAE-dextran, and poly-L-lysine significantly increased the efficiency of adenovirus-mediated gene transfer in cell culture. This was thought to act by neutralizing the negative charges presented by membrane glycoproteins that reduce the efficiency of adenovirus-mediated gene transfer (Arcasoy et al., 1997). [0099]
  • Oligonucleotide Transfer [0100]
  • In a further embodiment, the liposome encapsulates oligonucleotide DNA. Encapsulation of oligonucleotides into liposomes increased their therapeutic index, prevented degradation in cultured cells, and in human serum and reduced toxicity to cells (Thierry and Dritschilo, 1992; Capaccioli et al., 1993; Lewis et al., 1996). However, most studies have been performed in cell culture, and very few in animals in vivo. There are still an important number of improvements needed before these approaches can move into clinical studies. [0101]
  • Zelphati and Szoka (1997), have found that complexes of fluorescently labeled oligonucleotides with DOTAP liposomes, entered the cell using an endocytic pathway mainly involving uncoated vesicles. Oligonucleotides were redistributed from punctate cytoplasmic regions into the nucleus. This process was independent of acidification of the endosomal vesicles. The nuclear uptake of oligonucleotides depended on several factors, such as charge of the particle, where positively charged complexes were required for enhanced nuclear uptake. DOTAP increased over 100 fold the antisense activity of a specific anti-luciferase oligonucleotide. Physicochemical studies of oligonucleotide-liposome complexes of different cationic lipid compositions indicated that either phosphatidylethanolamine or negative charges on other lipids in the cell membrane are required for efficient fusion with cationic liposome-oligonucleotide complexes to promote entry to the cell (Jaaskelainen et al., 1994). [0102]
  • Similar results were reported by Lappalainen et al. (1997). Digoxigenin-labeled oligodeoxynucleotides (ODNs) complexed with the polycationic DOSPA and the monocationic DDAB (with DOPE as a helper lipid) were taken up by CaSki cells in culture by endocytosis. The nuclear membrane was found to pose a barrier against nuclear import of ODNs that accumulated in the perinuclear area. Although DOSPA/DOPE liposomes could deliver ODNs into the cytosol, they were unable to mediate nuclear import of ODNs. On the contrary, oligonucleotide-DDAB/DOPE complexes with a net positive charge were released from vesicles into the cytoplasm. It was determined that DDAB/DOPE mediated nuclear import of the oligonucleotides. [0103]
  • DOPE-heme (ferric protoporphyrin IX) conjugates, inserted in cationic lipid particles with DOTAP, protected oligoribonucleotides from degradation in human serum and increased oligoribonucleotide uptake into 2.2.15 human hepatoma cells. The enhancing effect of heme was evident only at a net negative charge in the particles (Takle et al., 1997). Uptake of liposomes labeled with [0104] 111In and composed of DC-Chol and DOPE was primarily by liver, with some accumulation in spleen and skin and very little in the lung after I.V. tail injection. Preincubation of cationic liposomes with phosphorothioate oligonucleotide induced a dramatic, yet transient, accumulation of the lipid in lung that gradually redistributed to liver. The mechanism of lung uptake involved entrapment of large aggregates of oligonucleotides within pulmonary capillaries at 15 min post-injection via embolism. Labeled oligonucleotide was localized primarily to phagocytic vacuoles of Kupffer cells at 24 h post-injection. Nuclear uptake of oligonucleotides in vivo was not observed (Litzinger et al., 1996).
  • Polyethylene Glycol (PEG)-Coated Liposomes [0105]
  • In a further embodiment, the liposome encapsulated DNA described herein, further comprise coating of the final complex in step [0106] 2 (FIG. 1) with PEG. It is often desirable to conjugate a lipid to a polymer that confers extended half-life, such as polyethylene glycol (PEG). Derivatized lipids that are employed, include PEG-modified DSPE or PEG-ceramide. Addition of PEG components prevents complex aggregation, increases circulation lifetime of particles (liposomes, proteins, other complexes, drugs) and increases the delivery of lipid-nucleic acid complexes to the target tissues. See, Maxfield et al., Polymer 16:505-509 (1975); Bailey, F. E. et al., in: Nonionic Surfactants, Schick, M. J., ed., pp. 794-821 (1967); Abuchowski, A. et al., J. Biol. Chem. 252:3582-3586 (1977); Abuchowski, A. et al., Cancer Biochem. Biophys. 7:175-186 (1984); Katre, N. V. et al., Proc. Natl. Acad. Sci. USA 84:1487-1491 (1987); Goodson, R. et al. Bio Technology 8:343-346 (1990).
  • Conjugation to PEG is reported to have reduced immunogenicity and toxicity. See, Abuchowski et al., [0107] J. Biol. Chem. 252:3578-3581 (1977). The extent of enhancement of blood circulation time of liposomes, by coating with PEG is described in U.S. Pat. No. 5,013,556. Typically, the concentration of the PEG-modified phospholipids, or PEG-ceramide in the complex will be about 1-7%. In a particularly preferred embodiment, the PEG-modified lipid is a PEG-DSPE.
  • Coating the surface of liposomes with inert materials designed to camouflage the liposome from the body's host defense systems was shown to increase remarkably the plasma longevity of liposomes. The biological paradigm for this “surface modified” sub-branch was the erythrocyte, a cell that is coated with a dense layer of carbohydrate groups, and that manages to evade immune system detection and to circulate for several months (before being removed by the same type of cell responsible for removing liposomes). [0108]
  • The first breakthrough came in 1987 when a glycolipid (the brain tissue-derived ganglioside GM 1), was identified that, when incorporated within the lipid matrix, allowed liposomes to circulate for many hours in the blood stream (Allen and Chonn, 1987). A second glycolipid, phosphatidylinositol, was also found to impart long plasma residence times to liposomes and, since it was extracted from soybeans, not brain tissue, was believed to be a more pharmaceutically acceptable excipient (Gabizon et al., 1989). [0109]
  • A major advance in the surface-modified sub-branch was the development of polymer-coated liposomes (Allen et al. 1991). Polyethylene glycol (PEG) modification had been used for many years to prolong the half-lives of biological proteins (such as enzymes and growth factors) and to reduce their immunogenicity (e.g. Beauchamp et al., 1983). It was reported in the early 1990s that PEG-coated liposomes circulated for remarkably long times after intravenous administration. Half-lives on the order of 24 h were seen in mice and rats, and over 30 hours in dogs. The term “stealth” was applied to these liposomes because of their ability of evade interception by the immune system. The PEG hydrophilic polymers form dense “conformational clouds” to prevent other macromolecules from interaction with the surface, even at low concentrations of the protecting polymer (Gabizon and Papahadjopoulos, 1988; Papahadjopoulos et al., 1991; reviewed by Torchilin, 1998). The increased hydrophilicity of the liposomes after their coating with the amphipathic PEG5000 leads to a reduction in nonspecific uptake by the reticuloendothelial system. [0110]
  • Whereas the half-life of antimyosin immunoliposomes was 40 min, by coating with PEG, they increased their half-life to 1000 min after intravenous injection to rabbits (Torchilin et al., 1992). [0111]
  • Micelles, Surfactants and Small Unilamellar Vesicles [0112]
  • In a further embodiment, the liposome encapsulated DNA described herein, further comprise an initial step of micelle formation between cationic lipids and condensed plasmid or oligonucleotide DNA in ethanol solutions. Micelles are small amphiphilic colloidal particles formed by certain kinds of lipid molecules, detergents or surfactants under defined conditions of concentration, solvent and temperature. They are composed of a single lipid layer. Micelles can have their hydrophilic head groups assembled exposing their hydrophobic tails to the solvent (for example in 30-60% aqueous ethanol solution) or can reverse their structures exposing their polar heads toward the solvent such as by lowering the concentration of the ethanol to below 10% (reverse micelles). Micelle systems are in thermodynamic equilibrium with the solvent molecules and environment. This results in constant phase changes, especially upon contact with biological materials, such as upon introduction to cell culture, injection to animals, dilution, contact with proteins or other macromolecules. These changes result in rapid micelle disassembly or flocculation. This is in contrast to the much higher stability of liposome bilayers. [0113]
  • Single-chain surfactants are able to form micelles (see Table 1, below). These include the anionic (sodium dodecyl sulfate, cholate or oleate) or cationic (cetyl-trimethylammonium bromide, CTAB) surfactants. CTAB, CTAC, and DOIC micelles yielded larger solubility gaps (lower concentration of colloidally suspended DNA) than corresponding SUV particles containing neutral lipid and CTAB (1:1) (Lasic, 1997). [0114]
    TABLE 1
    Molecules able to form micelles
    Molecule Reference
    CTAB, CTAC, DOIC Lasic, 1997
    Detergent/phospholipid micelles Lusa et al., ```1998
    Dodecyl betaine (amphoteric surfactant) de la Maza et al., 1998
    Dodecylphosphocholine cholate Lasic, 1997
    Glycine-conjugated bile salt (anionic Leonard and Cohen, 1998
    steroid detergent-like molecule)
    Lipid-dodecyl maltoside micelles Lambert et al., 1998
    mixed micelles (Triton X-100 & Lopez et al., 1998
    phosphatidylcholine)
    Octylglucoside (non-ionic straight Leonard and Cohen, 1998
    chain detergent)
    Oleate Lasic, 1997
    PEG-dialkylphosphatidic Tirosh et al., 1998
    acid (dihexadecylphosphatidyl
    (DHP)-PEG2000)
    Phosphatidylcholine (neutral zwitterionic) Schroeder et al., 1990
    Polyethyleneglycol (MW 5000)-distearoyl Weissig et al., 1998
    phosphatidyl ethanolamine (PEG-DSPE)
    sodium dodecyl sulfate (anionic straight Leonard and Cohen, 1998
    chain detergent)
    Sodium taurofusidate (conjugated fungal Leonard and Cohen, 1998
    bile salt analog)
    Taurine-conjugated bile salts (anionic Leonard and Cohen, 1998
    steroid detergent-like molecule)
    Triton X-100 surfactant Lasic, 1997
  • There is a critical detergent/phospholipid ratio at which lamellar-to-micellar transition occurs. For example, the vesicle-micelle transition was observed for dodecyl maltoside with large unilamellar liposomes. A striking feature of the solubilization process by dodecyl maltoside was the discovery of a new phase, consisting of a very viscous “gel-like” structure composed of long filamentous thread-like micelles, over 1 to 2 microns in length. [0115]
  • A long circulating complex needs to be slightly anionic. Therefore the liposomes used for the conversion of the micelles into liposomes contain bipolar lipids (PC, PE) and 1-30% negatively charged lipids (DPPG). The cationic lipids which are toxic, are hidden in the inner liposome membrane bilayer. Those reaching the solid tumor will exert their toxic effects causing apoptosis. Apoptosis will be caused by the delivery of the toxic drug or anti-neoplastic gene or oligonucleotide to the cancer cell but also by the nuclear localization of the cationic lipids (along with plasmid DNA) to the nucleus. Indeed, a number of studies suggest that plasmid DNA is imported to nuclei; its translocation docks cationic lipid molecules electrostatically attached to the DNA. These cationic lipid molecules exert their toxicity by interfering with the nucleosome and domain structure of the chromatin causing local destabilization. This disturbance or aberrant chromatin reorganization could be exerted at the level of the nuclear matrix where plasmid DNA is attached for transcription, autonomous replication, or integration via recombination. [0116]
  • Surfactants have found wide application in formulations such as emulsions (including microemulsions) and liposomes. The most common way of classifying and ranking the properties of the many different types of surfactants, both natural and synthetic, is by the use of the hydrophile/lipophile balance (HLB). The use of surfactants in drug products, formulations and in emulsions has been reviewed (Rieger, in: Pharmaceutical Dosage Forms, Marcel Dekker, Inc., New York, 1988, p. 285). [0117]
  • Nonionic surfactants find wide application in pharmaceutical and cosmetic products and are usable over a wide range of pH values. In general, their HLB values range from 2 to about 18, depending on their structure. Nonionic surfactants include, nonionic esters such as ethylene glycol esters, propylene glycol esters, glyceryl esters, polyglyceryl esters, sorbitan esters, sucrose esters, and ethoxylated esters. Nonionic alkanolamides and ethers, such as fatty alcohol ethoxylates, propoxylated alcohols, and ethoxylated/propoxylated, block polymers are also included in this class. The polyoxyethylene surfactants are the most popular members of the nonionic surfactant class. [0118]
  • Anionic surfactants include carboxylates such as soaps, acyl lactylates, acyl amides of amino acids, esters of sulfuric acid such as alkyl sulfates and ethoxylated alkyl sulfates, sulfonates such as alkyl benzene sulfonates, acyl isethionates, acyl taurates and sulfosuccinates, and phosphates. The most important members of the anionic surfactant class are the alkyl sulfates and the soaps. [0119]
  • Cationic surfactants include quaternary ammonium salts and ethoxylated amines. The quaternary ammonium salts are the most used members of this class. If the surfactant molecule has the ability to carry either a positive or negative charge, the surfactant is classified as amphoteric. Amphoteric surfactants include acrylic acid derivatives, substituted alkylamides, N-alkylbetaines and phosphatides. [0120]
  • Classical micelles may not be effective as gene transfer vehicles, but important intermediates in the formation of liposome complexes encapsulating drugs or nucleic acids. The stability of single chain surfactants-DNA-colloidal systems is lower than SUV particles containing neutral lipid and CTAB (1:1). However, second generation micelles are able to target tumors in vivo. Weissig and co-workers (1998) used the soybean trypsin inhibitor (STI) as a model protein to target tumors. STI was modified with a hydrophobic residue of N-glutaryl-phosphatidyl-ethanolamine (NGPE) and incorporated into both polyethyleneglycol (MW 5000)-distearoyl phosphatidyl ethanolamine (PEG-DSPE) micelles (<20 nm) and PEG-DSPE-modified long-circulating liposomes (ca. 100 μm). As determined from the protein label by using ilIn attached to soybean trypsin inhibitor via protein-attached diethylene triamine pentaacetic acid, DTPA, PEG-lipid micelles accumulated better than the same protein anchored in long-circulating PEG-liposomes in subcutaneously established Lewis lung carcinoma in mice after tail vein injection. [0121]
  • Loading a liposomal dispersion with an amphiphilic drug may cause a phase transformation into a micellar solution. The transition from high ratios of phospholipid to drug (from 2:1 to 1:1 downwards) were accompanied by the conversion of liposomal dispersions of milky-white appearance (particle size 200 m) to nearly transparent micelles (particle size below 25 nm). See, Schutze and Muller-Goymann (1998). [0122]
  • Fusogenic Peptides [0123]
  • In a further embodiment, the liposome encapsulated DNA described herein further comprises an effective amount of a fusogenic peptide. Fusogenic peptides belong to a class of helical amphipathic peptides characterized by a hydrophobicity gradient along the long helical axis. This hydrophobicity gradient causes the tilted insertion of the peptides in membranes, thus destabilizing the lipid core and, thereby, enhancing membrane fusion (Decout et al., 1999). [0124]
  • Hemagglutinin (HA) is a homotrimeric surface glycoprotein of the influenza virus. In infection, it induces membrane fusion between viral and endosomal membranes at low pH. Each monomer consists of the receptor-binding HA1 domain and the membrane-interacting HA2 domain. The NH2-terminal region of the HA2 domain (amino acids 1 to 127), the so-called “fusion peptide,” inserts into the target membrane and plays a crucial role in triggering fusion between the viral and endosomal membranes. Based on the substitution of eight amino acids in region 5-14 with cysteines and spin-labeling electron paramagnetic resonance, it was concluded that the peptide forms an alpha-helix tilted approximately 25 degrees from the horizontal plane of the membrane with a maximum depth of 15 Å from the phosphate group (Macosko et al., 1997). Use of fusogenic peptides from influenza virus hemagglutinin HA-2 enhanced greatly the efficiency of transferrin-polylysine-DNA complex uptake by cells. The peptide was linked to polylysine and the complex was delivered by the transferrin receptor-mediated endocytosis (reviewed by Boulikas, 1998a). This peptide has the sequence: GLFEAIAGFI ENGWEGMIDG GGYC (SEQ ID NO:9) and is able to induce the release of the fluorescent dye calcein from liposomes prepared with egg yolk phosphatidylcholine, which was higher at acidic pH. This peptide was also able to increase up to 10-fold the anti-HIV potency of antisense oligonucleotides, at a concentration of 0.1-1 mM, using CEM-SS lymphocytes in culture. This peptide changes conformation at the slightly more acidic environment of the endosome, destabilizing and breaking the endosomal membrane (reviewed by Boulikas, 1998a). [0125]
  • The presence of negatively charged lipids in the membrane is important for the manifestation of the fusogenic properties of some peptides, but not of others. Whereas the fusogenic action of a peptide, representing a putative fusion domain of fertilin, a sperm surface protein involved in sperm-egg fusion, was dependent upon the presence of negatively charged lipids, that of the HIV2 peptide was not (Martin and Ruysschaert, 1997). [0126]
  • For example, to analyze the two domains on the fusogenic peptides of influenza virus hemagglutinin HA, HA-chimeras were designed in which the cytoplasmic tail and/or transmembrane domain of HA was replaced with the corresponding domains of the fusogenic glycoprotein F of Sendai virus. Constructs of HA were made in which the cytoplasmic tail was replaced by peptides of human neurofibromin type 1 (NF1) (residues 1441 to 1518) or c-Raf-1, (residues 51 to 131) and were expressed in CV-1 cells by using the vaccinia virus-T7 polymerase transient-expression system. Membrane fusion between CV-1 cells and bound human erythrocytes (RBCS) mediated by parental or chimeric HA proteins showed that, after the pH was lowered, a flow of the aqueous fluorophore calcein from preloaded RBCs into the cytoplasm of the protein-expressing CV-1 cells took place. This indicated that membrane fusion involves both leaflets of the lipid bilayers and leads to formation of an aqueous fusion pore (Schroth-Diaz et al., 1998). [0127]
  • A remarkable discovery was that the TAT protein of HIV is able to cross cell membranes (Green and Loewenstein, 1998) and that a 36-amino acid domain of TAT, when chemically cross-linked to heterologous proteins, conferred the ability to transduce into cells. The 11-amino acid fusogenic peptide of TAT (YGRKKRRQRRR (SEQ ID NO:10)) is a nucleolar localization signal (see Boulikas, 1998b). [0128]
  • Another protein of HIV, the glycoprotein gp41, contains fusogenic peptides. Linear peptides derived from the membrane proximal region of the gp41 ectodomain have potential applications as anti-HIV agents and inhibit infectivity by adopting a helical conformation (Judice et al., 1997). The 23 amino acid residue, N-terminal peptide of HIV-1 gp41 has the capacity to destabilize negatively charged large unilamellar vesicles. In the absence of cations, the main structure was a pore-forming alpha-helix, whereas in the presence of Ca[0129] 2+ the conformation switched to a fusogenic, predominantly extended beta-type structure. The fusion activity of HIV(ala) (bearing the R22→A substitution) was reduced by 70%, whereas fusogenicity was completely abolished when a second substitution (V2→E) was included, arguing that it is not an alpha-helical but an extended structure adopted by the HIV-1 fusion peptide that actively destabilizes cholesterol-containing, electrically neutral membranes (Pereira et al., 1997).
  • The prion protein (PrP) is a glycoprotein of unknown function normally found at the surface of neurons and of glial cells. It is involved in diseases such as bovine spongiform encephalopathy, and Creutzfeldt-Jakob disease in humans, where PrP is converted into an altered form (termed PrPSc). According to computer modeling calculations, the 120 to 133 and 118 to 135 domains of PrP are tilted lipid-associating peptides inserting in a oblique way into a lipid bilayer and able to interact with liposomes to induce leakage of encapsulated calcein (Pillot et al., 1997b). [0130]
  • The C-terminal fragments of the Alzheimer amyloid peptide (amino acids 29-40 and 29-42) have properties related to those of the fusion peptides of viral proteins inducing fusion of liposomes in vitro. These properties could mediate a direct interaction of the amyloid peptide with cell membranes and account for part of the cytotoxicity of the amyloid peptide. In view of the epidemiologic and biochemical linkages between the pathology of Alzheimer's disease and apolipoprotein E (apoE) polymorphism, examination of the potential interaction between the three common apoE isoforms and the C-terminal fragments of the amyloid peptide showed that only apoE2 and apoE3, not apoE4, are potent inhibitors of the amyloid peptide fusogenic and aggregational properties. The protective effect of apoE against the formation of amyloid aggregates was thought to be mediated by the formation of stable apoE/amyloid peptide complexes (Pillot et al., 1997a; Lins et al., 1999). [0131]
  • The fusogenic properties of an amphipathic net-negative peptide (WAE 11), consisting of 11 amino acid residues were strongly promoted when the peptide was anchored to a liposomal membrane. The fusion activity of the peptide appeared to be independent of pH and membrane merging, and the target membranes required a positive charge that was provided by incorporating lysine-coupled phosphatidylethanolamine (PE-K). Whereas the coupled peptide could cause vesicle aggregation via nonspecific electrostatic interaction with PE-K, the free peptide failed to induce aggregation of PE-K vesicles (Pecheur et al., 1997). [0132]
  • A number of studies suggest that stabilization of an alpha-helical secondary structure of the peptide after insertion in lipid bilayers in membranes of cells or liposomes is responsible for the membrane fusion properties of peptides. Zn[0133] 2+, enhances the fusogenic activity of peptides because it stabilizes the alpha-helical structure. For example, the HEXXH (SEQ ID NO:11) domain of the salivary antimicrobial peptide, located in the C-terminal functional domain of histatin-5, a recognized zinc-binding motif is in a helicoidal conformation (Martin et al., 1999; Melino et al., 1999; Curtain et al., 1999).
  • Fusion peptides have been formulated with DNA plasmids to create peptide-based gene delivery systems. A combination of the YKAKnWK (SEQ ID NO:12) peptide, used to condense plasmids into 40 to 200 nm nanoparticles, with the GLFEALLELLESLWELLLEA (SEQ ID NO: 13) amphipathic peptide, that is a pH-sensitive lytic agent designed to facilitate release of the plasmid from endosomes enhanced expression systems containing the beta-galactosidase reporter gene (Duguid et al., 1998). See Table 2, below. [0134]
    TABLE 2
    Fusogenic peptides
    Fusogenic peptide Source Protein Properties Reference
    GLFEAIAGFIENGWEG Influenza virus Endowed with membrane Bongartz et al., 1994
    MIDGGGYC (SEQ ID hemagglutinin fusion properties
    NO:9) HA-2
    YGRKKRRQRRR (SEQ TAT of HIV Endowed with membrane Green and
    ID NO:5) fusion properties Loewenstein, 1988
    23-residue fusogenic N- HIV-1 trans- Was able to insert as an Curtain et al., 1999
    terminal peptide membrane alpha-helix into neutral
    glycoprotein gp41 phospholipid bilayers
    70 residue peptide (SV- Fusion peptide Induced lipid mixing of egg Ghosh and Shai,
    117) and N-terminal phosphatidylcholine- 1999
    heptad repeat of phosphatidyl`glycerol
    Sendai virus (PC/PG) large unilamellar
    vesicles (LUVs)
    23 hydrophobic amino S protein of A high degree of similarity Rodriguez-Crespo et
    acids in the amino-terminal hepatitis B virus with known fusogenic al., 1994
    region (HBV) peptides from other viruses.
    MSGTFGGILAGLIGLL N-terminal region Was inserted into the Rodriguez-Crespo et
    (SEQ ID NO:6) of the S protein of hydrophobic core of the al., 1999
    duck hepatitis B lipid bilayer and induced
    Virus (DHBV) leakage of internal aqueous
    contents from both neutral
    and negatively charged
    liposomes
    MSPSSLLGLLAGLQVV S protein of Was inserted into the Rodriguez-Crespo et
    (SEQ ID NO:14) woodchuck hydrophobic core of the al., 1999
    hepatitis B virus lipid bilayer and induced
    (WHV) leakage of internal aqueous
    contents from both neutral
    and negatively charged
    liposomes
    N-terminus of Nef Nef protein of Membrane-perturbing and Macreadie et al.,
    human fusogenic activities in 1997
    inimuno- artificial membranes; causes
    deficiency cell killing in E. coli and
    type 1 (HIV-1) yeast
    Amino-terminal sequence F1 polypeptide of Can be used as a carrier Partidos et al., 1996
    F1 polypeptide measles virus system for CTL epitopes
    (MV)
    19-27 amino acid segment Glycoprotein Adopts an amphiphilic Voneche et al., 1992
    gp51 of bovine structure and plays a key
    leukemia virus role in the fusion events
    induced by bovine leukemia
    virus
    120 to 133 and 118 to 135 Prion protein Tilted lipid-associating Pillot et al., 1997b
    domains peptide; interact with
    liposomes to induce leakage
    of encapsulated calcein
    29-42-residue fragment Alzheimer's beta- Endowed with capacities Lins et al., 1999
    amyloid peptide resembling those of the
    tilted fragment of viral
    fusion proteins
    Non-aggregated amyloid Alzheimer's beta- Induces apoptotic neuronal Pillot et al., 1999
    beta-peptide (1-40) amyloid peptide cell death
    LCAT 56-68 helical Lecithin Forms stable beta-sheets in Peelman et al., 1999;
    segment cholesterol lipids Decout et al., 1999
    acyltransferase
    (LCAT)
    Peptide sequence B18 Membrane- Triggers fusion between Ulrich et al., 1999
    associated sea lipid vesicles; a histidine-
    urchin sperm nch motif for binding zinc
    protein binding is required for the fusogenic
    function
    53-70 (C-terminal helix) Apolipoprotein Induces fusion of Lambert et al., 1998
    (apo) AII unilamellar lipid vesicles
    and displaces apo AI from
    HDL and r-HDL
    Residues 90-111 PH-30 alpha (a Membrane-fusogenic Nudome et al., 1997
    protein activity to acidic
    functioning in phospholipid bilayers
    sperm-egg fusion)
    Casein signal peptides Alpha s2- and Interact with Creuzenet et al., 1997
    beta-casein dimyristoylphosphatidyl-
    glycerol and -choline
    liposomes; show both lytic
    and fusogenic activities
    Pardaxin Amphipathic Forms voltage-gated, Lelkes and
    polypeptide, cation-selective pores; Lazarovici, 1988
    purified from the mediated the aggregation of
    gland secretion of liposomes composed of
    the Red Sea phosphatidylserine but not
    Moses sole of phosphatidylcholine
    flatfish
    Pardachirus
    marmoratus
    Histatin-5 Salivary Aggregates and fuses Melino et al., 1999
    antimicrobial negatively charged small
    peptide unilamellar vesicles in the
    presence of Zn2+
    Gramicidin (linear Antibiotic Induces aggregation and Massari and Colonna,
    hydrophobic polypeptide) fusion of vesicles 1986; Toumois et
    al., 1990
    Amphipathic negatively Synthetic Forms an alpha-helix Martin et al., 1999
    charged peptide consisting inserted and anchored into
    of 11 residues (WAE) the membrane (favored at
    37° C.) oriented almost
    parallel to the lipid acyl
    chains; promotes fusion of
    large unilamellar liposomes
    (LUV)
    A polymer of polylysine Synthetic Histidyl residues become Midoux and
    (average 190) partially cationic upon protonation of Monsigny, 1999
    substituted with histidyl the imidazole groups at pH
    residues below 6.0.; disrupt
    endosomal membranes
    GLFEALLELLESLWELL Synthetic Amphipathic peptide; a pH- Duguid et al., 1998
    LEA (SEQ ID NO:4) sensitive lytic agent to
    facilitate release of the
    plasmid from endosomes
    (LKKL)4 (SEQ ID NO: 15) Synthetic Amphiphilic fusogenic Gupta and Kothekar,
    peptide, able to interact with 1997
    four molecules of DMPC
    Ac-(Leu-Ala-Arg-Leu)3- Synthetic; basic Caused a leakage of Suenaga et al., 1989;
    NHCH3 (SEQ ID NO: 16) amphipathic contents from small Lee et al., 1992
    peptides unilamellar vesicles
    composed of egg yolk
    phosphatidylcholine and egg
    yolk phosphatidic acid (3:1)
    Amphiphilic anionic Synthetic Can mimic the fusogenic Murata et al., 1991
    peptides E5 and E5L activity of influenza
    hemagglutinin (HA)
    30-amino acid peptide with Synthetic; Becomes an amphipathic Parente et al., 1988
    the major repeat unit Glu- designed alpha-helix as the pH is
    Ala-Leu-Ala (GALA)7 to mimic lowered to 5.0; fusion of
    (SEQ ID NO:17) the behavior of phosphatidylcholine small
    the fusogenic unilamellar vesicles induced
    sequences of viral by GALA requires a peptide
    fusion proteins length greater than 16 amino
    acids
    Poly Glu-Aib-Leu-Aib Synthetic Amphiphilic structure upon Kono et al., 1993
    (SEQ ID NO:18) Aib the formation of alpha-
    represents 2- helix; caused fusion of
    aminoisobutyric acid EYPC liposomes and
    dipalmitoylphosphatidylcholine
    liposomes more strongly
    with decreasing pH
  • Fusogenic Lipids [0135]
  • DOPE is a fusogenic lipid; elastase cleavage of N-methoxy-succinyl-Ala-Ala-Pro-Val-DOPE (SEQ ID NO:19) converted this derivative to DOPE (overall positive charge) to deliver an encapsulated fluorescent probe, calcein, into the cell cytoplasm (Pak et al., 1999). An oligodeoxynucleic sequence of 30 bases complementary to a region of beta-endorphin mRNA elicited a concentration-dependent inhibition of beta-endorphin production in cell culture after it was encapsulated within small unilamellar vesicles (50 nm) containing dipalmitoyl-DL-alpha-phosphatidyl-L-serine endowed with fusogenic properties (Fresta et al., 1998). [0136]
  • Nuclear Localization Signals (NLS) [0137]
  • In a further embodiment, the liposome encapsulated plasmid or oligonucleotide DNA described herein further comprise an effective amount of nuclear localization signal (NLS) peptides. Trafficking of nuclear proteins from the site of their synthesis in the cytoplasm to the sites of function in the nucleus through pore complexes is mediated by NLSs on proteins to be imported into nuclei (Tables 3-10, below). Protein translocation from the cytoplasm to the nucleoplasm involves: (i) the formation of a complex of karyopherin α with NLS-protein; (ii) subsequent binding of karyopherin β; (iii) binding of the complex to FXFG peptide repeats on nucleoporins; (iv) docking of Ran-GDP to nucleoporin and to karyopherin heterodimer by p10; (v) a number of association-dissociation reactions on nucleoporins that dock the import substrate toward the nucleoplasmic side with a concomitant GDP-GTP exchange reaction transforming Ran-GDP into Ran-GTP and catalyzed by karyopherin α; and (vi) dissociation from karyopherin β and release of the karyopherin α/NLS-protein by Ran-GTP to the nucleoplasm. [0138]
  • Karyophilic and acidic clusters were found in most non-membrane serine/threonine protein kinases whose primary structure has been examined (Table 6). These karyophilic clusters might mediate the anchoring of the kinase molecules to transporter proteins for their regulated nuclear import and might constitute the nuclear localization signals. In contrast to protein transcription factors that are exclusively nuclear possessing strong karyophilic peptides composed of at least four arginines, (R), and lysines, (K), within an hexapeptide flanked by proline and glycine helix-breakers, protein kinases often contain one histidine and three K+R residues (Boulikas, 1996). This was proposed to specify a weak NLS structure resulting in the nuclear import of a fraction of the total cytoplasmic kinase molecules, as well as in their weak retention in the different ionic strength nuclear environment. Putative NLS peptides in protein kinases may also contain hydrophobic or bulky aromatic amino acids proposed to further diminish their capacity to act as strong NLS. [0139]
  • Most mammalian proteins that participate in DNA repair pathways seem to possess strong karyophilic clusters containing at least four R+K over a stretch of six amino acids (Table 7). [0140]
  • Rules to predict nuclear localization of an unknown protein Several simple rules have been proposed for the prediction of the nuclear localization of a protein of an unknown function from its amino acid sequence: [0141]
  • (i) An NLS is defined as four arginines (R) plus lysines (K) within an hexapeptide; the presence of one or more histidines (H) in the tetrad of the karyophilic hexapeptide, often found in protein kinases that have a cytoplasmic and a nuclear function, may specify a weak NLS whose function might be regulated by phosphorylation or may specify proteins that function in both the cytoplasm and the nucleus (Boulikas, 1996); [0142]
  • (ii) The K/R clusters are flanked by the a-helix breakers G and P thus placing the NLS at a helix-turn-helix or end of a a-helix. Negatively-charged amino acids (D, E) are often found at the flank of the NLS and on some occasions may interrupt the positively-charged NLS cluster; [0143]
  • (iii) Bulky amino acids (W, F, Y) are not present within the NLS hexapeptide; [0144]
  • (iv) NLS signals may not be flanked by long stretches of hydrophobic amino acids (e.g. five); a mixture of charged and hydrophobic amino acids serves as a mitochondrial targeting signal; [0145]
  • (v) The higher the number of NLSs, the more readily a molecule is imported to the nucleus (Dworetzky et al., 1988). Even small proteins, for example histones (10-22 kDa), need to be actively imported to increase their import rates compared with the slow rate of diffusion of small molecules through pores; [0146]
  • (vi) Signal peptides are stronger determinants than NLSs for protein trafficking. Signal peptides direct proteins to the lumen of the endoplasmic reticulum for their secretion or insertion into cellular membranes (presence of transmembrane domains) (Boulikas, 1994); [0147]
  • (vii) Signals for the mitochondrial import of proteins (a mixture of hydrophobic and karyophilic amino acids) may antagonize nuclear import signals and proteins possessing both type of signals may be translocated to both mitochondria and nuclei; [0148]
  • (viii) Strong association of a protein with large cytoplasmic structures (membrane proteins, intermediate filaments) make such proteins unavailable for import even though they posses NLS-like peptides (Boulikas, 1994); [0149]
  • (ix). Transcription factors and other nuclear proteins posses a great different number of putative NLS stretches. Of the sixteen possible forms of putative NLS structures the most abundant types are the 00×00, 000×0, 0000, and 00×0×0, where 0 is R or K, together accounting for about 70% of all karyophilic clusters on transcription factors (Boulikas, 1994); [0150]
  • (x) A small number of nuclear proteins seem to be void of a typical karyophilic NLS. Either non karyophilic peptides function for their nuclear import, as such molecules possess bipartite NLSs, or these NLS-less proteins depend absolutely for import on their strong complexation in the cytoplasm with a nuclear protein partner able to be imported (Boulikas, 1994). This mechanism may ensure a certain stoichiometric ratio of the two molecules in the nucleus, and might be of physiological significance; and [0151]
  • (xi) A number of proteins may be imported via other mechanisms not dependent on classical NLS. [0152]
  • A number of processes have been found to be regulated by nuclear import including nuclear translocation of the transcription factors NF-KB, rNFIL-6, ISGF3, SRF, c-Fos, GR as well as human cyclins A and BI, casein kinase II, cAMP-dependent protein kinase II, protein kinase C, ERKI and ERK2. Failure of cells to import specific proteins into nuclei can lead to carcinogenesis. For example, BRCA1 is mainly localized in the cytoplasm in breast and ovarian cancer cells, whereas in normal cells the protein is nuclear. mRNA is exported through the same route as a complex with nuclear proteins possessing nuclear export signals (NES). The majority of proteins with NES are RNA-binding proteins that bind to and escort RNAs to the cytoplasm. However, other proteins with NES function in the export of proteins; CRM1, that binds to the NES sequence on other proteins and interacts with the nuclear pore complex, is an essential mediator of the NES-dependent nuclear export of proteins in eukaryotic cells. Nuclear localization and export signals (NLS and NES) are found on a number of important molecules, including p53, v-Rel, the transcription factor NF-ATc, the c-Ab1 nonreceptor tyrosine kinase, and the fragile X syndrome mental retardation gene product. The deregulation of their normal import/export trafficking has important implications for human disease. Both nuclear import and export processes can be manipulated by conjugation of proteins with NLS or NES peptides. During gene therapy, the foreign DNA needs to enter nuclei for its transcription. A pathway is proposed involving the complexation of plasmids and oligonucleotides with nascent nuclear proteins possessing NLSs as a prerequisite for their nuclear import. Covalent linkage of NLS peptides to oligonucleotides and plasmids or formation of complexes of plasmids with proteins possessing multiple NLS peptides was proposed (Boulikas, 1998b) to increase their import rates and the efficiency of gene expression. Cancer cells were predicted to import more efficiently foreign DNA into nuclei, compared with terminally differentiated cells because of their increased rates of proliferation and protein import. [0153]
  • Antineoplastic Drugs [0154]
  • In a further embodiment, the liposome encapsulated plasmid or oligonucleotide DNA described herein, further comprises its use for reducing tumor size or restricting its growth with combination with encapsulated or free antineoplastic agents. Antineoplastic agents preferably are: (i) alkylating agents having the bis-(2-chloroethyl)-amine group such as chlormethine, chlorambucile, melphalan, uramustine, mannomustine, extramustinephosphat, mechlorethaminoxide, cyclophosphamide, ifosfamide, or trifosfamide; (ii) alkylating agents having a substituted aziridine group, for example tretamine, thiotepa, triaziquone, or mitomycine; (iii) alkylating agents of the methanesulfonic ester type such as busulfane; (iv) alkylating N-alkyl-N-nitrosourea derivatives, for example carmustine, lomustine, semustine, or streptozotocine; (v) alkylating agents of the mitobronitole, dacarbazine, or procarbazine type; (vi) complexing agents such as cis-platin; (vii) antimetabolites of the folic acid type, for example methotrexate; (viii) purine derivatives such as mercaptopurine, thioguanine, azathioprine, tiamiprine, vidarabine, or puromycine and purine nucleoside phosphorylase inhibitors; (ix) pyrimidine derivatives, for example fluorouracil, floxuridine, tegafur, cytarabine, idoxuridine, flucytosine; (x) antibiotics such as dactinomycin, daunorubicin, doxorubicin, mithramycin, bleomycin or etoposide; (xi) vinca alkaloids; (xii) inhibitors of proteins overexpressed in cancer cells such as telomerase inhibitors, glutathione inhibitors, proteasome inhibitors; (xiii) modulators or inhibitors of signal transduction pathways such as phosphatase inhibitors, protein kinase C inhibitors, casein kinase inhibitors, insulin-like growth factor-1 receptor inhibitor, ras inhibitors, ras-GAP inhibitor, protein tyrosine phosphatase inhibitors; (xiv) tumor angiogenesis inhibitors such as angiostatin, oncostatin, endostatin, thalidomide; (xv) modulators of the immune response and cytokines such as interferons, interleukins, TNF-alpha; (xvi) modulators of the extracellular matrix such as matrix metalloproteinase inhibitors, stromelysin inhibitors, plasminogen activator inhibitor; (xvii) hormone modulators for hormone-dependent cancers (breast cancer, prostate cancer) such as antiandrogen, estrogens; (xviii) apoptosis regulators; (xix) bFGF inhibitor; (xx) multiple drug resistance gene inhibitor; (xxi) monoclonal antibodies or antibody fragments against antigenes overexpressed in cancer cells (anti-Her2/neu for breast cancer); (xxii) anticancer genes whose expression will cause apoptosis, arrest the cell cycle, induce an immune response against cancer cells, inhibit tumor angiogenesis i.e. formation of blood vessels, tumor suppressor genes (p53, RB, BRCA1, E1A, bc1-2, MDR-1, p21, p16, bax, bcl-xs, E2F, IGF-I VEGF, angiostatin, oncostatin, endostatin, GM-CSF, IL-12, IL-2, IL-4, IL-7, IFN-γ, and TNF-a); and (xxiii) antisense oligonucleotides (antisense c-fos, c-myc, K-ras). Optionally these drugs are administered in combination with chlormethamine, prednisolone, prednisone, or procarbazine or combined with radiation therapy. Future new anticancer drugs added to the arsenal are expected to be ribozymes, triplex-forming oligonucleotides, gene inactivating oligonucleotides, a number of new genes directed against genes that control the cell proliferation or signaling pathways, and compounds that block signal transduction. [0155]
  • Anti-cancer drugs include: acivicin, aclarubicin, acodazole hydrochloride, acronine, adozelesin, adriamycin, aldesleukin, altretamine, ambomycin, ametantrone acetate, aminoglutethimide, amsacrine, anastrozole, anthramycin, asparaginase, asperlin, azacitidine, azetepa, azotomycin, batimastat, benzodepa, bicalutamide, bisantrene hydrochloride, bisnafide dimesylate, bizelesin, bleomycin sulfate, brequinar sodium, bropirimine, busulfan, cactinomycin, calusterone, caracemide, carbetimer, carboplatin, carmustine, carubicin hydrochloride, carzelesin, cedefingol, chlorambucil, cirolemycin, cisplatin, cladribine, crisnatol mesylate, cyclophosphamide, cytarabine, dacarbazine, dactinomycin, daunorubicin hydrochloride, decitabine, dexormaplatin, dezaguanine, dezaguanine mesylate, diaziquone, docetaxel, doxorubicin, doxorubicin hydrochloride, droloxifene, droloxifene citrate, dromostanolone propionate, duazomycin, edatrexate, eflomithine hydrochloride, elsamitrucin, enloplatin, enpromate, epipropidine, epirubicin hydrochloride, erbulozole, esorubicin hydrochloride, estramustine, estramustine phosphate sodium, etanidazole, etoposide, etoposide phosphate, etoprine, fadrozole hydrochloride, fazarabine, fenretinide, floxuridine, fludarabine phosphate, fluorouracil, flurocitabine, fosquidone, fostriecin sodium, gemcitabine, gemcitabine hydrochloride, hydroxyurea, idarubicin hydrochloride, ifosfamide, ilmofosine, interferon alfa-2a, interferon α-2b, interferon α-n1, interferon α-n3, interferon β-i a, interferon γ-i b, iproplatin, irinotecan hydrochloride, lanreotide acetate, letrozole, leuprolide acetate, liarozole hydrochloride, lometrexol sodium, lomustine, losoxantrone hydrochloride, masoprocol, maytansine, mechlorethamine hydrochloride, megestrol acetate, melengestrol acetate, melphalan, menogaril, mercaptopurine, methotrexate, methotrexate sodium, metoprine, meturedepa, mitindomide, mitocarcin, mitocromin, mitogillin, mitomalcin, mitomycin, mitosper, mitotane, mitoxantrone hydrochloride, mycophenolic acid, nocodazole, nogalamycin, ormaplatin, oxisuran, paclitaxel, pegaspargase, peliomycin, pentamustine, peplomycin sulfate, perfosfamide, pipobroman, piposulfan, piroxantrone hydrochloride, plicamycin, plomestane, porfimer sodium, porfiromycin, prednimustine, prednisone, procarbazine hydrochloride, puromycin, puromycin hydrochloride, pyrazofurin, riboprine, rogletimide, safingol, safingol hydrochloride, semustine, simtrazene, sparfosate sodium, sparsomycin, spirogermanium hydrochloride, spiromustine, spiroplatin, streptonigrin, streptozocin, sulofenur, talisomycin, taxol, tecogalan sodium, tegaflir, teloxantrone hydrochloride, temoporfin, teniposide, teroxirone, testolactone, thiamiprine, thioguanine, thiotepa, tiazofurin, tirapazamine, topotecan hydrochloride, toremifene citrate, trestolone acetate, triciribine phosphate, trimetrexate, trimetrexate glucuronate, triptorelin, tubulozole hydrochloride, uracil mustard, uredepa, vapreotide, verteporfin, vinblastine sulfate, vincristine sulfate, vindesine, vindesine sulfate, vinepidine sulfate, vinglycinate sulfate, vinleurosine sulfate, vinorelbine tartrate, vinrosidine sulfate, vinzolidine sulfate, vorozole, zeniplatin, zinostatin, zorubicin hydrochloride. [0156]
  • Other anti-cancer drugs include: 20-epi-1,25 dihydroxyvitamin D3, 5-ethynyluracil, abiraterone, aclarubicin, acylfulvene, adecypenol, adozelesin, aldesleukin, ALL-TK antagonists, altretamine, ambamustine, amidox, amifostine, aminolevulinic acid, amrubicin, amsacrine, anagrelide, anastrozole, andrographolide, angiogenesis inhibitors, antagonist D, antagonist G, antarelix, anti-dorsalizing morphogenetic protein-1, antiandrogen, antiestrogen, antineoplaston, antisense oligonucleotides, aphidicolin glycinate, apoptosis gene modulators, apoptosis regulators, apurinic acid, ara-CDP-DL-PTBA, arginine deaminase, asulacrine, atamestane, atrimustine, axinastatin 1, axinastatin 2, axinastatin 3, azasetron, azatoxin, azatyrosine, baccatin III derivatives, balanol, batimastat, BCR/ABL antagonists, benzochlorins, benzoylstaurosporine, beta lactam derivatives, beta-alethine, betaclamycin B, betulinic acid, bFGF inhibitor, bicalutamide, bisantrene, bisaziridinylspermine, bisnafide, bistratene A, bizelesin, breflate, bropirimine, budotitane, buthionine sulfoximine, calcipotriol, calphostin C, camptothecin derivatives, canarypox IL-2, capecitabine, carboxamide-amino-triazole, carboxyamidotriazole, CaRest M3, CARN 700, cartilage derived inhibitor, carzelesin, casein kinase inhibitors (ICOS), castanospermine, cecropin B, cetrorelix, chlorlns, chloroquinoxaline sulfonamide, cicaprost, cis-porphyrin, cladribine, clomifene analogues, clotrimazole, collismycin A, collismycin B, combretastatin A4, combretastatin analogue, conagenin, crambescidin 816, crisnatol, cryptophycin 8, cryptophycin A derivatives, curacin A, cyclopentanthraquinones, cycloplatam, cypemycin, cytarabine ocfosfate, cytolytic factor, cytostatin, dacliximab, decitabine, dehydrodidemnin B, deslorelin, dexifosfamide, dexrazoxane, dexverapamil, diaziquone, didemnin B, didox, diethylnorspermine, dihydro-5-azacytidine, dihydrotaxol, 9-dioxamycin, diphenyl spiromustine, docosanol, dolasetron, doxifluridine, droloxifene, dronabinol, duocarmycin SA, ebselen, ecomustine, edelfosine, edrecolomab, eflornithine, elemene, emitefur, epirubicin, epristeride, estramustine analogue, estrogen agonists, estrogen antagonists, etanidazole, etoposide phosphate, exemestane, fadrozole, fazarabine, fenretinide, filgrastim, finasteride, flavopiridol, flezelastine, fluasterone, fludarabine, fluorodaunorunicin hydrochloride, forfenimex, formestane, fostriecin, fotemustine, gadolinium gallium nitrate texaphyrin, galocitabine, ganirelix, gelatinase inhibitors, gemcitabine, glutathione inhibitors, hepsulfam, heregulin, hexamethylene bisacetamide, hypericin, ibandronic acid, idarubicin, idoxifene, idramantone, ilmofosine, ilomastat, imidazoacridones, imiquimod, immunostimulant peptides, insulin-like growth factor-1 receptor inhibitor, interferon agonists, interferons, interleukins, iobenguane, iododoxorubicin, ipomeanol, 4-, irinotecan, iroplact, irsogladine, isobengazole, isohomohalicondrin B, itasetron, jasplakinolide, kahalalide F, lamellarin-N triacetate, lanreotide, leinamycin, lenograstim, lentinan sulfate, leptolstatin, letrozole, leukemia inhibiting factor, leukocyte alpha interferon, leuprolide+estrogen+progesterone, leuprorelin, levamisole, liarozole, linear polyamine analogue, lipophilic disaccharide peptide, lipophilic platinum compounds, lissoclinamide 7, lobaplatin, lombricine, lometrexol, lonidamine, losoxantrone, lovastatin, loxoribine, lurtotecan, lutetium texaphyrin, lysofylline, lytic peptides, maitansine, mannostatin A, marimastat, masoprocol, maspin, matrilysin inhibitors, matrix metalloproteinase inhibitors, menogaril, merbarone, meterelin, methioninase, metoclopramide, MIF inhibitor, mifepristone, miltefosine, mirimostim, mismatched double stranded RNA, mitoguazone, mitolactol, mitomycin analogues, mitonafide, mitotoxin fibroblast growth factor-saporin, mitoxantrone, mofarotene, molgramostim, monoclonal antibody, human chorionic gonadotrophin, monophosphoryl lipid A+myobacterium cell wall sk, mopidamol, multiple drug resistance gene inhibitor, multiple tumor suppressor 1-based therapy, mustard anticancer agent, mycaperoxide B, mycobacterial cell wall extract, myriaporone, N-acetyldinaline, N-substituted benzamides, nafarelin, nagrestip, naloxone +pentazocine, napavin, naphterpin, nartograstim, nedaplatin, nemorubicin, neridronic acid, neutral endopeptidase, nilutamide, nisamycin, nitric oxide modulators, nitroxide antioxidant, nitrullyn, 06-benzylguanine, octreotide, okicenone, oligonucleotides, onapristone, ondansetron, ondansetron, oracin, oral cytokine inducer, ormaplatin, osaterone, oxaliplatin, oxaunomycin, paclitaxel analogues, paclitaxel derivatives, palauamine, palmitoylrhizoxin, pamidronic acid, panaxytriol, panomifene, parabactin, pazelliptine, pegaspargase, peldesine, pentosan polysulfate sodium, pentostatin, pentrozole, perflubron, perfosfamide, perillyl alcohol, phenazinomycin, phenylacetate, phosphatase inhibitors, picibanil, pilocarpine hydrochloride, pirarubicin, piritrexim, placetin A, placetin B, plasminogen activator inhibitor, platinum complex, platinum compounds, platinum-triamine complex, porfimer sodium, porfiromycin, propyl bis-acridone, prostaglandin J2, proteasome inhibitors, protein A-based immune modulator, protein kinase C inhibitor, protein kinase C inhibitors, microalgal., protein tyrosine phosphatase inhibitors, purine nucleoside phosphorylase inhibitors, purpurins, pyrazoloacridine, pyridoxylated hemoglobin polyoxyethylene conjugate, raf antagonists, raltitrexed, ramosetron, ras famesyl protein transferase inhibitors, ras inhibitors, ras-GAP inhibitor, retelliptine demethylated, rhenium Re 186 etidronate, rhizoxin, ribozymes, RII retinamide, rogletimide, rohitukine, romurtide, roquinimex, rubiginone B 1, ruboxyl, safingol, saintopin, SarCNU, sarcophytol A, sargramostim, Sdi 1 mimetics, semustine, senescence derived inhibitor 1, sense oligonucleotides, signal transduction inhibitors, signal transduction modulators, single chain antigen binding protein, sizofiran, sobuzoxane, sodium borocaptate, sodium phenylacetate, solverol, somatomedin binding protein, sonermin, sparfosic acid, spicamycin D, spiromustine, splenopentin, spongistatin 1, squalamine, stem cell inhibitor, stem-cell division inhibitors, stipiamide, stromelysin inhibitors, sulfinosine, superactive vasoactive intestinal peptide antagonist, suradista, suramin, swainsonine, synthetic glycosaminoglycans, tallimustine, tamoxifen methiodide, tauromustine, tazarotene, tecogalan sodium, tegafur, tellurapyrylium, telomerase inhibitors, temoporfin, temozolomide, teniposide, tetrachlorodecaoxide, tetrazomine, thaliblastine, thalidomide, thiocoraline, thrombopoietin, thrombopoietin mimetic, thymalfasin, thymopoietin receptor agonist, thymotrinan, thyroid stimulating hormone, tin ethyl etiopurpurin, tirapazamine, titanocene dichloride, topotecan, topsentin, toremifene, totipotent stem cell factor, translation inhibitors, tretinoin, triacetyluridine, triciribine, trimetrexate, triptorelin, tropisetron, turosteride, tyrosine kinase inhibitors, tyrphostins, UBC inhibitors, ubenimex, urogenital sinus-derived growth inhibitory factor, urokinase receptor antagonists, vapreotide, variolin B, velaresol, veramine, verdins, verteporfin, vinorelbine, vinxaltine, vitaxin, vorozole, zanoterone, zeniplatin, zilascorb, zinostatin stimalamer. [0157]
  • pH-Sensitive Peptide-DNA Complexes [0158]
  • In a further embodiment of the invention, the genes in plasmid DNA are brought in interaction with fusogenic peptide/NLS conjugates. In a further embodiment the NLS moiety is a stretch of histidyl residues able to assume a net positive charge at a pH of about 5 to 6 and to show a reduction or loose completely this charge at pH above 7. The electrostatic interaction of these positively-charged peptides with the negatively-charged plasmid DNA molecules, established at pH 5-6 is weakened at physiological pH (pH-sensitive peptide-DNA complexes). [0159]
  • The first step of the present invention involves complex formation between the plasmid or oligonucleotide DNA with the histidyl/fusogenic peptide conjugate and lipid components in 10-90% ethanol at pH 5.0 to 6.0. The conditions must be where the histidyl residues have a net positive charge and can establish electrostatic interactions with plasmids, oligonucleotides or negatively-charged drugs. At the same time, the presence of the positively-charged lipid molecules promotes formation of micelles. At the second step, micelles are converted into liposomes by dilution with water and mixing with pre-made liposomes or lipids at pH 5-6. This is followed by dialysis against pH 7 and extrusion through membranes, entrapping and encapsulating plasmids or oligonucleotides to with a very high yield. [0160]
  • Whereas the composition of peptides and cationic lipids in the first step provides the lipids of the internal bilayer, the type of liposomes or lipids added at step [0161] 2 provide the external coating of the final liposome formulation (FIG. 1). Examples for the formulations of peptides include: HHHHHSPSL16 (SEQ ID NO:623), and HHHHHSPS(LAI)5 (SEQ ID NO:624).
  • These are added at a 1:0.5:0.5 molar ratio (negative charge on DNA: cationic liposome: histidine peptide). The peptide inserts in an alpha-helical conformation inside the lipid bilayer and not only carries out DNA condensation but also endows membrane fusion properties to the complex to improve entrance across the cell membrane. The type of hydrophobic amino acids (for example, content in aromatic amino acids), in the peptide chain is very important as is the length of the peptide chain in ensuring integrity and rigidity of the complexes. Coating the outer surface of the complexes with polyethyleneglycol, hyaluronic acids and other polymers conjugated to lipids gives the particles long circulation properties in body fluids and the ability to target solid tumors and their metastases after intravenous injection, and also the ability to cross the tumor cell membrane. [0162]
  • Protease-Sensitive Linkages in Peptides Between the NLS and Fusogenic Moieties [0163]
  • Conversion of Micelles Into Liposomes [0164]
  • An important issue of the present invention is the conversion of micelles formed between the DNA and the cationic lipids, in the presence of ethanol, into liposomes. This is done by the direct addition of the micelle complex into an aqueous solution of preformed liposomes. The liposomes have an average size of 80-160 nm or vice versa, leading to a solution of a final ethanol concentration below 10%. A formulation suitable for pharmaceutical use and for injection into humans and animals will require that the liposomes are of neutral composition (such as cholesterol, PE, PC) coated with PEG. [0165]
  • However, another important aspect is the research application of the present invention, such as for transfection of cells in culture. The composition of the aqueous solution of liposomes is any type of liposomes containing cationic lipids and suitable therefore for transfection of cells in culture such as DDAB:DOPE 1: 1. These liposomes are preformed and downsized by sonication or extrusion through membranes to a diameter of 80-160 nm. The ethanolic micelle preparations are then added to the aqueous solution of liposomes with a concomitant dilution of the ethanol solution to below 10%. This step will result in further condensation of DNA or interaction of the negatively-charged phosphate groups on DNA with positively charged groups on lipids. Care must be taken so as only part of the negative charges on DNA are neutralized by lipids in the micelle. The remaining charge neutralization of the DNA is to be provided by the cationic component of the preformed liposomes in the second step. [0166]
  • Regulatory DNA and Nuclear Matrix-Attached DNA [0167]
  • In a further embodiment of the present invention, the genes in plasmid DNA are driven by regulatory DNA sequences isolated from nuclear matrix-attached DNA using shotgun selection approaches. [0168]
  • The compact structural organization of chromatin and the proper spatial orientation of individual chromosomes within a cell are partially provided by the nuclear matrix. The nuclear matrix is composed of DNA, RNA and proteins and serves as the site of DNA replication, gene transcription, DNA repair, and chromosomal attachment in the nucleus. Diverse sets of DNA sequences have been found associated with nuclear matrices and is referred to as matrix attachment regions or MARs. The MARs serve many functions, acting as activators of gene transcription, silencers of gene expression, insulators of transcriptional activity, nuclear retention signals and origins of DNA replication. Current studies indicate that different subsets of MARs are found in different tissue types and may assist in regulating the specific functions of cells. The presence of this complex assortment of structural and regulatory molecules in the matrix, as well as the in situ localization of DNA replication and transcription complexes to the matrix strongly suggest that the nuclear matrix plays a fundamental, unique role in nuclear processes. The structuring of genomes into domains has a functional significance. The inclusion of specific MAR elements within gene transfer vectors could have utility in many experimental and gene therapy applications. Many gene therapy applications require specific expression of one or more genes in targeted cell types for prolonged time periods. MARs within vectors could enhance transcription of the introduced transgene, prolong the retention of that sequence within the nucleus or insulate expression of that transgene from the expression of a cotransduced gene (reviewed by Boulikas, 1995; Bode et al, 1996). [0169]
  • Various biochemical procedures have been used to identify regulatory regions within genes. Traditionally, identification and selection of regulatory DNA sequences depend on tedious procedures such as transcription factor footprinting in vitro or in vivo, or subcloning of smaller fragments from larger genomic DNA sequences upstream of reporter genes. These methods have been used primarily to identify regions proximal to the 5′ end of genes. However, in many instances, regulatory regions are found at considerable distances from the proximal 5′ end of the gene, and confer cell type- or developmental stage- specificity. For example, studies from the groups of Grosveld and Engel (Lakshmanan et al., 1999) have shown that over 625 kb of genomic sequences surrounding the GATA-3 locus are required for the correct developmental expression of the gene in transgenic mice. Extensive DNA stretches at distances 5-20 kb upstream of the gene were found to be responsible for the central nervous system-specificity of expression. The region between 20 to 130 kb upstream of the gene harbored regulatory regions for urogenital-specific expression of GATA-3, whereas sequences 90-180 kb downstream of the gene conferred endocardial-specific expression. [0170]
  • The presently disclosed method has the potential of rapidly identifying regulatory control regions. In cells, chromatin loops are formed and different attachment regions are used in different cell types or stages of development to modulate the expression of a gene. The presently disclosed method for isolating regulatory regions based on their attachment to the nuclear matrix can identify regulatory regions irrespective of their distance from the gene. Although the human genome project is expected to be almost complete by the year 2000, information on the location and nature of the vast majority of the estimated 500,000 regulatory regions will not be available. [0171]
    • Example 1
  • Plasmid DNA condenses with various agents, as well as various formulations of cationic liposomes. The condensation affects the level of expression of the reporter beta-galactosidase gene after transfection of K562 human erythroleukemia cell cultures. Liposome compositions are shown in the Table below and in FIG. 2. All lipids were from Avanti Polar Lipids (700 Industrial Park Drive, Alabaster, Ala. 35007). The optimal ratio of lipid to DNA was 7 mmoles total lipid/μg DNA. The transfection reagent (10 μg DNA mixed with 70 mmoles total lipid) was transferred to a small culture flask followed by the addition of 10 ml K562 cell culture (about 2 million cells total); mixing of cells with the transfection reagent was at 5-10 min after mixing DNA with liposomes. Cells were assayed for beta-galactosidase activity several times at 1-30 days post-transfection. The transfected cells were maintained in cell culture as normal cell cultures. [0172]
  • Best results were obtained when the cells used for transfection were at low number, not near confluence. In all experiments the transfection material was added directly in the presence of serum and antibiotics without removal of the transfection reagent or washings of the cells. This simplifies the transfection procedure and is suitable for lymphoid and other type of cell cultures that do not attach to the dish, but grow in suspension. All DNA condensing agents were purchased from Sigma. They were suspended at 0.1 mg/ml in water. Plasmid pCMVβ was purchased from Clontech and was purified using the Anaconda kit of Althea Technologies (San Diego, Calif.). PolyK is polylysine, mw 9,400. PolyR is polyarginine. PolyH is polyhistidine. [0173]
  • To 100 μl plasmid solution (10 μg total plasmid DNA) 20 μl or 50 μl of polyK, polyR, polyH, were added; the volume was adjusted to 250 μl with water followed by addition of about 70 μl liposomes (7 mnoles /μg DNA). After incubation for 10 mm to 1 h at 20° C. the transfection mixture was brought in contact with the cell culture. The best DNA condensing reagent was polyhistidine compared with the popular polylysine. The best cationic lipid was DC-cholesterol (DC-CHOL: [0174]
  • 3β[N—(N′,N′-dimethylaminoethane)carbamoyl]cholesterol). SFV is Semliki Forest virus expressing beta-galactosidase. The results are shown in FIG. 2. [0175]
    Liposome Molecular weight Composition Preparation
    L2 DDAB mw 631 DDAB 4.2 μmoles/ml 15 mg DDAB +
    DOPE mw 744 DOPE 4.2 μmoles/ml 0.88 ml 20 mg/ml
    DOPE
    L3 DOGS-NTA mw 1015.4 DOGS-NTA 1 μmole/ml 5 mg DOGS
    DOPE 1 μmole/ml 0.185 ml DOPE
    L4 DC-Chol (mw 537) DC-Chol 1 μmole/ml 0.106 ml DC-Chol (25
    DOPE (mw 744) DOPE 1 μmole/ml mg/ml) +
    0.185 ml DOPE (20
    mg/ml)
    L5 DOTAP (mw 698) DOTAP 1.4 μmole/ml 0.5 ml 10 mg/
    ml DOTAP +
    DOPE (mw 744) DOPE 1.3 μmole/ml 0.25 ml DOPE (20
    mg/ml)
    L6 DODAP (mw 648) DODAP 1.54 μmoles/ml 0.5 ml 10 mg/ml
    DOPE 1.3 μmole/ml DODAP = 5 mg = 7.72
    μmoles +
    0.25 ml DOPE (20
    mg/ml)
    • Example 2
  • Targeting Genes to Tumors Using Gene Vehicles (Lipogenes). [0176]
  • As shown in FIG. 3, tumor targeting in SCID (severe combined immunodeficient) mice were implanted subcutaneously, at two sites, with human MCF-7 breast cancer cells. The cells were allowed to develop into large, measurable solid tumors at about 30 days post-inoculation. Mice were injected intraperitoneously with 0.2 mg plasmid pCMVβ DNA (size of the plasmid is ˜4 kb) per animal carrying the bacterial beta-galactosidase reporter gene. Plasmid DNA (200 μg, 2.0 mg/ml, 0.1 ml ) was incubated for 5 min with 2001 neutral liposomes of the composition 40% cholesterol, 20% dioleoylphosphatidylethanolamine(DOPE), 12% palmitoyloleoylphosphatidylcholine (POPC), 10% hydrogenated soy phosphatidylcholine (HSPC), 10% distearoylphosphatidylethanolamine (DSPE), 5% sphingomyelin (SM), and 3% derivatized vesicle-forming lipid M-PEG-DSPE. [0177]
  • At this stage, weak complexation of plasmid DNA with neutral (zwitterionic) liposomes takes place. This ensures homogeneous distribution of plasmid DNA to liposomes at the subsequent step of addition of cationic liposomes. After complexation of plasmid DNA with zwitterionic liposomes, 50 μl of cationic liposomes (DC-Chol 1 μmole/ml:DOPE 1.4 μmole/ml) were added and incubated at room temperature for 10 min. At this stage, a mixed liposome population is present and, most likely, formation of a type of liposome-DNA complexes containing lipids from the zwitterionic and cationic lipids takes place. The material was injected (0.35 ml total volume) to the intraperitoneal cavity of the animal. At 5 days post-injection the animal was sacrificed, the skin was removed and the carcass was incubated into X-gal staining solution for about 30 min at 37° C. The animal was incubated in fixative in X-gal staining for about 30 min (addition of 100 μl concentrated glutaraldehyde to 30 ml X-gal staining solution) and the incubation in staining solution continued. Photos were taken in a time course during the incubation period revealing the preferred organs where beta-galactosidase expression took place. [0178]
  • Because of the tumor vasculature targeting shown in FIG. 3E, the data imply that transfer of the genes of angiostatin, endostatin, or oncostatin to the tumors (whose gene products restrict vascular growth and inhibit blood supply to the tumor) is expected to be a rational approach for cancer treatment. Also, a combination therapy using anticancer lipogenes with encapsulated drugs into tumor targeting liposomes appears as a rational cancer therapy. [0179]
  • It is to be understood that while the invention has been described in conjunction with the above embodiments, that the foregoing description and the following examples are intended to illustrate and not limit the scope of the invention. Other aspects, advantages and modifications within the scope of the invention will be apparent to those skilled in the art to which the invention pertains. [0180]
    TABLE 3
    Simple NLS
    Signal oligopeptide Protein and features
    PKKKRKV (SEQ ID NO:20) Wild-type SV40 large T protein A point mutation converting lysine-
    128 (double underlined) to threonine results in the retention of large T
    in the cytoplasm. Transfer of this peptide to the N-terminus of β-
    galactosidase or pyruvate kinase at the gene level and microinjection
    of plasmids into Vero cells showed nuclear location of chimeric
    proteins.
    PKKKRMV (SEQ ID NO:21) SV40 large T with a K→M change. Site-directed mutagenesis only
    slightly impaired nuclear import of large T.
    PKKKRKVEDP (SEQ ID Synthetic NLS peptide from SV40 large T antigen crosslinked to BSA
    NO:22) or IgG mediated their nuclear localization after microinjec-
    tion in Xenopus oocytes. The PKKGSKKA from Xenopus H2B was in-
    effective and PKTKRKV was less effective.
    CGYGPKKKRKVGG (SEQ ID Synthetic peptide from SV40 large T antigen conjugated to
    NO:23) various proteins and microinjected into the cytoplasm of TC-7
    cells. Specified nuclear localization up to protein sizes of 465 kD
    (ferritin). IgM of 970 kD and with an estimated radius of 25-40 nm
    was retained in the cytoplasm.
    CYDDEATADSQHSTPPKKK SV40 large T protein long NLS. The long NLS but not the short NLS,
    RKVEDPKDFESELLS was able to localize the bulky IgM (970 kD) into the nucleus.
    (SEQ ID NO:24) Mutagenesis at the four possible sites of phosphorylation
    (double underlined) impaired nuclear import.
    CGGPKKKRKVG SV40 large T protein. This synthetic peptide crosslinked to chicken
    (SEQ ID NO:25) serum albumin and microinjected into HeLa cells caused
    nuclear localization.
    PKKKIKV (SEQ ID NO:26) A mutated (R→I) version of SV40 large T NLS. Effective NLS.
    MKx11CRLKKLKCSKEKPKC Yeast GAL4 (99 kD). Fusions of the GAL4
    AKCLKx5Rx3KTKR (SEQ ID gene portion encoding the 74 N-terminal amino acid with E. coli
    NO:27) β-galactosidase introduced into yeast cells specify nuclear localization.
    74 N-terminal amino acid
    MKx11CRLKKLKCSKEKPKC Yeast GAL4. Acted as an efficient nuclear localization sequence
    A (SEQ ID NO:28) when fused to invertase but not to β-galactosidase introduced
    29 N-terminal amino acid by transformation into yeast cells. Polyoma large T protein. Identified
    PKKARED (SEQ ID NO:29) by fusion with pyruvate kinase cDNA and microinjection of Vero
    VSRKRPR (SEQ ID NO:30) African green monkey cells. Mutually independent NLS.
    Can exert cooperative effects.
    CGYGVSRKRPRPG Polyoma virus large T protein. This synthetic peptide crosslinked
    (SEQ ID NO:31) to chicken serum albumin and microinjected into HeLa cells caused
    nuclear localization.
    APTKRKGS SV40 VP1 capsid polypeptide (46 kD). NLS (N terminus) determined
    (SEQ ID NO:32) by infection of monkey kidney cells with a fusion construct containing
    the 5′ terminal portion of SV40 VP1 gene and the complete cDNA
    sequence of poliovirus capsid VP1 replacing the VP1 gene of SV40.
    APKRKSGVSKC (1-11) Polyoma virus major capsid protein VP1 (11 N-terminal amino acid).
    (SEQ ID NO:33) Yeast expression vectors coding for 17 N-terminal amino acid of VP1
    fused to β-galactosidase gave a protein that was transported to the
    nucleus in yeast cells. Subtractive constructs of VP1 lacking A1 to
    C11 were cytoplasmic. This, FITC-labeled, synthetic peptide crosslinked
    to BSA or IgG, caused nuclear import after microinjection into 3T6
    cells. Replacement of K3 with T did not.
    PNKKKRK (SEQ ID NO:34) SV40 VP2 capsid protein (39 kD). The 3′ end of the SV40 VP2-VP3
    (amino acid position 317-323) genes containing this peptide when fused to poliovirus VP1 capsid
    protein at the gene level resulted in nuclear import of the hybrid VP1
    in simian cells infected with the hybrid SV40.
    EEDGPQKKKRRL (307-318) Polyoma virus capsid protein VP2. A construct having truncated
    (SEQ ID NO:35) VP2 lacking the 307-318 peptide transfected into COS-7 cells showed
    cytoplasmic retention of VP2. The 307-318 peptide crosslinked to
    BSA or IgG specified nuclear import following their microinjection
    into NIH 3T6 cells.
    GKKRSKA (SEQ ID NO:36) Yeast histone H2B. This peptide specified nuclear import when fused to
    β-galactosidase.
    KRPRP (SEQ ID NO:37) Adenovirus E1a. This pentapeptide, when linked to the C-terminus of
    E. coli galactokinase, was sufficient to direct its nuclear
    accumulation after microinjection in Vero monkey cells.
    CGGLSSKRPRP (SEQ ID Adenovirus type 2/5 E1a. This synthetic peptide crosslinked
    NO:38) to chicken bovine albumin and microinjected into HeLa cells caused
    nuclear localization.
    LVRKKRKTE3SP (NLS 1) Xenopus N1 (590 amino acid). Abundant in X. laevis oocytes,
    (SEQ ID NO:39) forming complexes with histones H3, H4 via two acidic domains
    LKDKDAKKSKQE (NLS2) each containing 21 and 9 (D + E), respectively. The NLS1 is
    (SEQ ID NO:40) required but not sufficient for nuclear accumulation of protein
    N1. NLS 1 and 2 are contiguous at the C-terminus.
    GNKAKRQRST v-Rel or p59v-rel the transforming protein, product of the v-rel
    (SEQ ID NO:41) oncogene of the avian reticuloendotheliosis retrovirus strain T (Rev-T).
    v-Rel NLS added to the normally cytoplasmic β-galactosidase directed
    that protein to the nucleus.
    PFLDRLRRDQK NS1 protein of influenza A virus, that accumulates in nuclei of virus-
    (SEQ ID NO:42) infected cells. Determined to be an NLS by deletion mutagenesis of
    PKQKRKMAR NS1 in recombinant SV40. The 1st NLS is conserved among all NS1
    (SEQ ID NO:43) proteins of influenza A viruses.
    SVTKKRKLE (SEQ ID NO:44) Human lamin A. Dimerization of lamin A was proposed to give a
    complex with two NLSs that was transported more efficiently.
    SASKRRRLE Xenopus lamin A. NLS inferred from its similarity to human lamin A
    (SEQ ID NO:45) NLS.
    TKGKRKRID Xenopus lamin LI. NLS inferred from its sequence similarity to
    (SEQ ID NO:46) human lamin A NLS.
    CVRTTKGKRKRIDV Xenopus lamin LI. This synthetic peptide crosslinked to chicken
    (SEQ ID NO:47) bovine albumin and microinjected into HeLa cells caused nuclear
    localization.
    ACIDKRVKLD Human c-myc oncoprotein. This synthetic peptide crosslinked to
    (SEQ ID NO:48) chicken bovine albumin and microinjected into HeLa cells caused
    nuclear localization.
    ACIDKRVKLD Human c-myc oncoprotein. Conjugation of the M1 peptide to human
    (SEQ ID NO:49) serum albumin and microinjection of Vero cells gives complete
    (M1, fully potent NLS) nuclear accumulation. M2 gave slower and only partial nuclear
    localization.
    RQRRNELKRSP
    (SEQ ID NO:50)
    (M2, medium potency NLS)
    SALIKKKKKMAP Murine c-abl (IV) gene product. The p160gag/v-abl has a cytoplasmic
    (SEQ ID NO:51) and plasma membrane localization, whereas the mouse type IV c-abl
    protein is largely nuclear.
    PPKKRMRRRIE Adenovirus 5 DBP (DNA-binding protein) found in nuclei of infected
    (SEQ ID NO:52) cells and involved in virus replication and early and late gene
    PKKKKKRP (SEQ ID NO:53) expression. Both NLS are needed, and disruption of either site
    impaired nuclear localization of the 529 amino acid protein.
    YRKCLQAGMNLEARKTKK Rat GR, glucocorticoid receptor (795 amino acid) NLS1 determined by
    KIKGIQQATA (497-524 amino fusion with β-galactosidase (116 kD). NLS1 is 100% conserved
    acid) between human, mouse and rat GR. Whereas the 407-615 amino acid
    (SEQ ID NO:54) fragment of GR specifies nuclear location, the 407-740 amino acid
    fragment was cytoplasmic in the absence of hormone, indicating that
    sequence 615-740 may inhibit the nuclear location activity. A second
    (NLS2) is localized in an extensive 256 amino acid C-terminal
    domain. NLS 2 requires hormone binding for activity.
    RKDRRGGRMLKHKRQRDD Human ER (estrogen receptor, 595 amino acid) NLS. NLS is between
    GEGRGEVGSAGDMRAMINO the hormone-binding and DNA-binding regions; ER, in contrast with
    ACIDNLWPSPLMIKRSKK GR, lacks a second NLS. Can direct a fusion product with β-
    (amino acid 256-303) galactosidase to the nucleus.
    (SEQ ID NO:55)
    RKFKLKFNK Rabbit PG (progesterone receptor). 100% homology in humans; F→L
    (SEQ ID NO:56) change in chickens. When this sequence was deleted, the receptor
    became cytoplasmic but could be shifted into the nucleus by addition
    of hormone; in this case the hormone mediated the dimerization of a
    mutant PG with a wild type PG molecule.
    GKRKNKPK (SEQ ID NO:57) Chicken Ets1 core NLS. Within a 77 amino acid C-terminal segment
    90% homologous to Ets2. When deleted by deletion mutagenesis at the
    gene level the mutant Ets1 became cytoplasmic.
    PLLKKIKQ (SEQ ID NO;58) c-myb gene product; directs puruvate kinase to the nucleus.
    PPQKKIKS (SEQ ID NO:59) N-myc gene product; directs puruvate kinase to the nucleus.
    PQPKKKP (SEQ ID NO:60) p53; directs puruvate kinase to the nucleus.
    SKRVAKRKL c-erb-A gene product; directs puruvate kinase to the nucleus.
    (SEQ ID NO:61)
    CGGLSSKRPRP Adenovirus type2/5 E1a. This synthetic peptide conjugated with a
    (SEQ ID NO:62) bifunctional crosslinker to chicken serum albumin (CSA) and
    microinjected into HeLa cells directed CSA to the nucleus.
    MTGSKTRKHRGSGA Yeast ribosomal protein L29. Double-stranded oligonucleotides
    (SEQ ID NO:63) encoding the 7 amino acid peptides (underlined) and inserted at the N-
    MTGSKHRKHPGSGA terminus of the p-galactosidase gene resulted in nuclear import.
    (SEQ ID NO:64)
    RHRKHP (SEQ ID NO:65) Mutated peptides derived from yeast L29 ribosomal protein NLS,
    KRRKHP (SEQ ID NO:66) found to be efficient NLS. The last two are less effective NLS,
    KYRKHP (SEQ ID NO:67) resulting in both nuclear and cytoplasmic location of β-galactosidase
    KHRRHP (SEQ ID NO:68) fusion protein.
    KHKKHP (SEQ ID NO:69)
    RHLKHP (SEQ ID NO:70)
    KHRKYP (SEQ ID NO:71)
    KHRQHP (SEQ ID NO:72)
    PETTVVRRRGRSPRRRTPSP Double NLS of hepatitis B virus core antigen. The two underlined
    RRRRSPRRRRSQS (SEQ ID arginine clusters represent distinct and independent NLS. Mutagenesis
    NO:73) showed that the antigen fails to accumulate in the nucleus only when
    (One sequence, C-terminus) both NLS are simultaneously deleted or mutated.
    ASKSRKRKL Viral Jun, a transcription factor of the AP-1 complex. Accumulates in
    (SEQ ID NO:74) nuclei most rapidly during G2 and slowly during G1 and S. The cell
    cycle dependence of viral but not of cellular Jun is due to a C→S
    mutation in NLS of viral Jun. This NLS conjugated to rabbit IgG can
    mediate cell cycle-dependent translocation.
    GGLCSARLHRHALLAT Human T-cell leukemia virus Tax trans-activator protein. The most
    (SEQ ID NO:75) basic region within the 48 N-terminal segment. Missense mutations in
    this domain result in its cytoplasmic retention.
    DTREKKKFLKRRLLRLDE Mouse nuclear Mx1 protein (72 kD), Induced by interferons (among
    (604-620) 20 other proteins) . Selectively inhibits influenza virus mRNA
    (SEQ ID NO:76) synthesis in the nucleus and virus multiplication. The cytoplasmic Mx2
    has R→S and R→E changes in this region.
    CGYGPKKKRKV (SV40 large Synthetic peptides crosslinked to bovine serum albumin (BSA) and
    T) (SEQ ID NO:77) introduced into MCF 7 or HeLa S3 cells with viral co-internalization
    CGYGDRNKKKKE (human method using adenovirus serotype 3B induced nuclear import of BSA.
    retinoic acid receptor)
    (SEQ ID NO:78)
    CGYGARKTKKKIK
    (human glucocorticoid receptor)
    (SEQ ID NO:79)
    CGYGIRKDRRGGR
    (human estrogen receptor)
    (SEQ ID NO:80)
    CGYGARKLKKLGN
    (human androgen receptor)
    (SEQ ID NO:81)
    RKRQRALMLRQAR Human XPAC (xeroderma pigmentosum group A complementing
    30-42 protein) involved in DNA excision repair. By site-directed
    (SEQ ID NO:82) mutagenesis and immunofluorescence. NLS is encoded by exon 1
    which is not essential for DNA repair function.
    EYLSRKGKLEL (SEQ ID T-DNA-linked VirD2 endonuclease of the Agrobacterium
    NO:83) tumefaciens tumor-inducing (Ti) plasmid. A fusion protein with β-
    (at the N-terminus) galactosidase is targeted to the nucleus. The T-plasmid integrates into
    plant nuclear DNA; VirD2 produces a site-specific nick for T
    integration. VirD2 also contains a bipartite NLS at its C-terminus (see
    Table 2).
    KKSKKKRC (SEQ ID NO:84) Putative core NLS of yeast TRM1 (63 kD) that encodes the tRNA
    (95-102) modification enzyme N2, N2-dimethylguanosine-specific tRNA
    methyltransferase. Localizes at the nuclear periphery. The 70-213
    amino acid segment of TRM1 causes nuclear localization of β-
    galactosidase fusion protein in yeast cells. Site-directed mutagenesis of
    the 95-102 peptide resulted in its cytoplasmic retention. TRM1 is both
    nuclear and mitochondrial. The 1-48 amino acid segment specifies
    mitochondrial import.
    PQSRKKLR (SEQ ID NO:85) Max protein; specifically interacts with c-Myc protein. Fusion of 126-
    151 segment of Max to chicken pyruvate kinase (PK) gene, including
    this putative NLS, followed by transfection of COS-1 cells and indirect
    immunofluorescence with anti-PK showed nuclear targeting.
    QPQRYGGGRGRRW (SEQ ID Gag protein of human foamy retrovirus; a mutant that completely lacks
    NO:86) this box exhibits very little nuclear localization; binds DNA and RNA
    in vitro.
  • [0181]
    TABLE 4
    “Bipartite” or “split” NLS
    Signal Oligopeptide Protein and features
    C-terminus Xenopus nucleoplasmin. Deletion analysis demonstrated the
    presence of a signal responsible for nuclear location.
    TKKAGQAKKK (SEQ ID NO:87) Xenopus nucleoplasmin
    TKKAGQAKKKKLD Xenopus nucleoplasmin. Whereas these 17 amino acids had NLS
    (SEQ ID NO:88) activity, shorter versions of the 17 amino acid sequences were
    unable to locate pyruvate kinase to the nucleus.
    TKKAGQAKKK(KLD) Xenopus nucleoplasmin. This 14 amino acid segment was
    (SEQ ID NO:89) identified as a minimal nuclear location sequence but was unable
    to locate puruvate kinase to the nucleus; three more amino acids
    at either end (shown in parenthesis) were needed.
    CGQAKKKKLD Xenopus nucleoplasmin-derived synthetic peptide; crossliniked to
    (SEQ ID NO:90) chicken serum albumin and microinjected to HeLa cells specified
    nuclear localization. This suggests that nucleoplasmin may
    possess a simple NLS.
    KRPAMINO ACID Xenopus nucleoplasmin bipartite NLS. Two clusters of basic
    TKKAGQAKKKK (SEQ ID NO:91) amino acids (underlined) separated by 10 amino acid are half
    NLS components.
    HRKYEAPRHx6PRKR (SEQ ID Yeast L3 ribosomal protein (387 amino acid) N-terminal 21
    NO:92) amino acid. Possible bipartite NLS. (Ribosomal proteins are
    transported to the nucleus to assemble with nascent rRNA).
    Fusion genes with β-galactosidase were used to transform yeast
    cells followed by fluorescence staining with b-gal antibody. The
    373 amino acid of L3 fused to β-gal failed to localize to the
    nucleus, unless a 8 amino acid bridge containing a proline was
    inserted between L3 and β-gal.
    NKKKRKLSRGSSQKTKGTSASAK SV40 Vp3 structural protein. (35 amino acid C-terminus). By
    ARHKRRNRSSRS (one sequence) DEAE-dextran-mediated transfection of TC7 cells with mutated
    (SEQ ID NO:93) constructs.
    RVTIRTVRVRRPPKGKHRK Simian sarcoma virus v-sis gene product (p28sis). The cellular
    (SEQ ID NO:94) counterpart c-sis gene encodes a precursor of the PDGF B-chain
    (platelet-derived growth factor). The NLS is 100% conserved
    between v-sis gene product and PDGF. This protein is normally
    transported across the ER; introduction of a charged ammo acid
    within the hydrophobic signal peptide results in a mutant protein
    that is translocated into the nucleus. Puruvate kinase-NLS fusion
    product is transported less efficiently than cytoplasmic v-sis
    mutant proteins to the nucleus.
    KRKIEEPEPEPKKAK Putative bipartite NLS of Xenopus laevis protein factor xnf7.
    (SEQ ID NO:95) Inferred by similarity to the bipartite NLS of nucleoplasmin.
    During oocyte maturation xnf7 is cytoplasmic until mid-blastula-
    gastrula stage due to high phosphorylation. Partial
    dephosphorylation results in nuclear accumulation.
    KKYENVVIKRSPRKRGRPRKD Yeast SWI5 gene product, a transcription factor. Underlined
    (SEQ ID NO:96) basic amino acid show similarity to bipartite NLS of Xenopus
    nucleoplasmin. The SWI5 gene is transcribed during S, G2 and
    M phases, during which the SWI5 protein remains cytoplasmic
    due to phosphorylation by CDC28-dependent histone H1 kinase
    at three serine residues two near and one (double underlined) in
    the NLS. Translocated at the end of anaphase/G1 due to
    dephosphorylation of NLS. NLS confers cell cycle-regulated
    nuclear import of SWI5-β-galactosidase fusion protein.
    MKRKRNS 735-741 Bipartite NLS of influenza virus polymerase basic protein 2
    (SEQ ID NO:97) (PB2). Mutational analysis of PB2 and transfection of BHK cells
    GIESIDNVMGMIGILPDMTPSTEM showed that both regions are involved in nuclear import.
    SMRGVRISKMGVDETSSAEKIV Deletion of 449-495 region gives perinuclear localization to the
    449-495 (SEQ ID NO:98) cytoplasmic side.
    AHRARRLH (SEQ ID NO:99) “Tripartite” or “doubly bipartite” NLS of adenovirus DNA
    6-13 (BSI) polymerase (AdPol). BSI and II functioned interdependently as
    PPRRRVRQQPP (SEQ ID NO:100) an NLS for the nuclear targeting of AdPol, for which BSIII was
    23-33 (BSII) dispensable. BSII-III was more efficient NLS than BSI-II.
    PARARRRRAP (SEQ ID NO:101)
    39-48 (BSIII)
    KRKx11KKKSKK 207-226 Human poly(ADP-ribose) polymerase (116 kD). The linear
    (SEQ ID NO:102) distance between the two basic clusters is not crucial for NLS
    activity in this bipartite NLS. Lysine 222 (double underlined) is
    an essential NLS component. DNA binding and poly(ADP-
    ribosyl)ating active site are independent of NLS.
    GRKRAFHGDDPFGEGPPDKKGD Herpes simplex virus ICP8 protein (infected-cell protein). This
    (SEQ ID NO:103) C-terminal portion of ICP8 introduced into pyruvate kinase (PK)
    caused nuclear targeting in transfected Vero cells. Inclusion of
    additional ICP8 regions to PK led to inhibition of nuclear
    localization.
    KRPREDDDGEPSERKRARDDR Bipartite NLS of VirD2 endonuclease of rhizogenes strains of
    (SEQ ID NO:104) Agrobacterium tumefaciens. Within the C-terminal 34 amino
    acid. Each region (underlined) independently directs β-
    glucuronidase to the nucleus, but both motifs are necessary for
    maximum efficiency. VirD2 is tightly bound to the 5′ end of the
    single stranded DNA transfer intermediate T-strand transferred
    from Agrobacterium to the plant cell genome.
  • [0182]
    TABLE 5
    “Nonpositive NLS” lacking clusters of arginines/lysines
    Signal oligopeptide Protein and features
    QLVWMACNSAMINO Influenza virus nucleoprotein (NP). The underlined region
    ACIDFEDLRVLSFIRGTKVS (327-345) when fused to chimpanzee a1-globin at the cDNA level and
    PRG 327-356 microinjected into Xenopus oocytes specifies nuclear localization.
    (SEQ ID NO:105)
    MNKIPIKDLLNPQ Yeast MAT a2 repressor protein, containing a homeodomain.
    (NLS 1 at N-terminus) (SEQ ID The two NLS are distinct, each capable of targeting β-galactosidase to
    NO:106) the nucleus. However, deletion of NLS2 results in a2 accumulation at
    VRILESWFAKNIEN the pores. NLS1 and 2 may act at different steps in a localization
    PYLDT (NLS2 at amino acid pathway. Part of the homeodomain mediates nuclear localization in
    141-159, part of the addition to DNA binding. The core pentapeptide containing proline and
    homeodomain) two other hydrophobic amino acids flanked by lysines or arginines
    (SEQ ID NO:107) (underlined) was suggested as one type of NLS core.
    Rx7Kx15KIPRx3HFY Drosophila HP1 (206 amino acids) that binds to
    EERLSWYSDNED (SEQ ID heterochromatin and is involved in gene silencing. NLS identified by β-
    NO:108) galactosidase/HP1 fusion proteins introduced by P-element mediated
    152-206 (C-terminal transformation into Drosophila embryos.
    segment)
    FVx7- Adenovirus type 5 E1A internal, developmentally-regulated
    20MxSLxYMx4MF NLS. This NLS functions in Xenopus oocytes but not in somatic cells.
    This NLS can be utilized up to the early neurula stage.
  • [0183]
    TABLE 6
    Nucleolar localization signals (NoLS)
    Signal oligopeptide Protein and features
    MPKTRRRP R RSQRKRPPTP Nucleolus localization signal in amino terminus of human p27x-
    (SEQ ID NO:109) III protein (also called Rex) of T cell leukemia virus type I
    (HTLV-I). When this peptide is fused to N-terminus of β-
    galactosidase, directs it to the nucleolus. Deletion of residues 2-
    8 (underlined), 12-18 (double-underline) or substitution of the
    central RR (dotted-underlined) with TT abolish nucleolar
    localization. Other amino acids between positions 20-80
    increase nucleolar localization efficiency.
    RLPVRRRRRRVP (SEQ ID NO:110) Adenovirus pTP1 and pTP2 (preterminal proteins, 80 kD)
    between amino acid residues 362-373. The 140 kD DNA
    polymerase of adenovirus when it has lost its own NLS can
    enter the nucleus via its interaction with pTP. The staining was
    nuclear and nucleolar with some perinuclear staining as well.
    The NLS fused to the N-terminus of E. coli β-galactosidase was
    functional in nuclear targeting.
    GRKKRRQRRRP HIV (human immunodeficiency virus) Tat protein; localizes
    (SEQ ID NO:111) pyruvate kinase to the nucleolus. Tat is constitutively nucleolar.
    RKKRRQRRR(AHQ) Tat positive trans-activator protein of HIV-1 (human
    Nucleolar localization signal immunodeficiency virus type 1). The 3 amino acids shown in
    (SEQ ID NO:112) parenthesis are essential for the localization of the β-
    galactosidase to the nucleolus. The 9 amino acid basic region is
    able to localize β-gal to the nucleus but not to the nucleolus.
    KRVKLDQRRRP (SEQ ID NO:113) Artificial sequence from c-Myc and HIV Tat NLSs that
    effectively localizes pyruvate kinase to the nucleolus.
    FKRKHKKDISQNKRAVRR Human HSP70 (heat shock protein of 70 kD); localizes pyruvate
    (SEQ ID NO:114) kinase to the nucleus and nucleolus. HSP70 is physiologically
    cytoplasmic but with heat-shock HSP70 redistributes to the
    nucleoli, suggesting that the nucleolar targeting sequence is
    cryptic at physiological temperature and is revealed under heat-
    shock.
    RQARRNRRRRWRERQR (35-50) HIV-1 Rev protein (116 amino acid, nucleolar). Mutations in
    (SEQ ID NO:115) either of the two regions of arginine clusters severely impair
    nuclear localization. β-galactosidase fused to R4W was targeted
    to the nucleus, and fused to the entire 35-50 region, was targeted
    to the nucleolus.
    RQARRNRRRRWRERQRQ (35-51) HIV-1 Rev protein. A fusion of this Rev peptide with β-
    (SEQ ID NO:116) galactosidase became nuclear but not nucleolar. The 1-59 amino
    acid segment of Rev fused to β-galactosidase localized entirely
    within the nucleolus. Whereas the NRRRRW (bold) is
    responsible for nuclear targeting, the RR and WRERQRQ
    (double underlined) specify nucleolar localization. Rev may
    function to export HIV structural mRNAs from the nucleus to
    the cytoplasm.
  • [0184]
    TABLE 7
    Karyophilic clusters on non-membrane protein kinases
    Non-membrane
    Karyophilic peptides protein kinase Species Features
    73 FVVHKRCHE Protein kinase C (673 Bovine, human Known to translocate to the
    (SEQ ID NO:117) aa) β type nucleus following treatment of
    96 DDPRSKHKFKIH cells with mitogens.
    (SEQ ID NO:118)
    577 TKHPGKRLG
    (SEQ ID NO:119)
    71 FVVHRRCHEF Protein kinase C (697 bovine, human γ
    (SEQ ID NO:120) aa) type
    95 DDPRNKHKFRLH
    (SEQ ID NO:121)
    591 TKHPAKRLG
    (SEQ ID NO:122)
    72 FVVHKRCHE Protein kinase C (673 rabbit type α and
    (SEQ ID NO:123) aa) β
    96 DDPRSKHKFKIH
    (SEQ ID NO:124)
    577 TKHPGKRLG
    (SEQ ID NO:125)
    71 FVVHRRCHE PKC-I (701 aa) rat brain
    (SEQ ID NO:126)
    95 DDPRNKHKFRLH
    (SEQ ID NO:127)
    594 TKHPGKRLG
    (SEQ ID NO:128)
    22 GENKMKSRLRKG Protein kinase C Drosophila 14 exons, 20 kb; 3 transcripts in
    (not conserved) (639 aa, 75 kDa) adult flies; not expressed in 0-3 h
    (SEQ ID NO:129) Drosophila embryos; the
    80SYVVHKRCHEYVT VVHKRCHE (SEQ ID
    (conserved) NO: 133)motif (or VVHRRCHE
    (SEQ ID NO:130) (SEQ ID NO:134)) is conserved
    211PDDKDQSKKKTR among all PKC known.
    TIK (not conserved)
    (SEQ ID NO:131)
    614PPFKPKIKHRKMC
    P (not conserved)
    (SEQ ID NO:132)
    148 KKVLQDKRFK Glycogen synthase rat brain Phosphorylates glycogen synthase,
    NRELQIMRKLD (SEQ kinase 3 c-Jun, c-Myb; two isoforms
    ID NO:135) GSK-3α encoded by discrete genes; highly
    (483 aa) expressed in brain; both α and β
    forms are cytosolic but also
    GSK-3β associated with the plasma
    (420 aa) membrane consistent with their
    role in signal transduction from the
    cell surface.
    LQDRRFKNRELQ Zw3 Drosophila Product of the segment polarity
    (SEQ ID NO:136) zeste-white 3 gene zw3; the protein encoded has
    34% homology to cdc2; mutations
    in zw3 give embryos that lack
    most of the ventral denticles,
    differentiated structures derived
    from the most anterior region of
    each segment.
    289ECLKKFNARRKL Ca2+/calmodulin- rat brain Composed of nine 50 kDa α-
    KGAIL dependent protein subunits and three 60 kDa β-
    (SEQ ID NO:137) kinase II (CaM kinase subunits; both are catalytic;
    II) β subunit (542 aa, calmoduim- and ATP-binding
    60.3 kDa) domains; highly expressed in
    forebrain neurons, concentrated in
    postsynaptic densities; acts as a
    Ca2+-triggered switch and could be
    involved in long-lasting changes in
    synapses.
    290LKKFNARRKL CaM kinase II (478 rat brain This particular isoform is
    KGAILTTM (SEQ ID aa, 54 kDa) exclusively expressed in the brain;
    NO:138) α-subunit high enzyme levels in specific
    450EETRVWHRRDGK brain areas; might be involved in
    (SEQ ID NO:139) short- and long-term responses to
    transient stimuli.
    185 GFAKRVKGRT CADPK catalytic bovine (cardiac By Edman degradation of protein
    WTLCG subunit (349 aa, 40.6 muscle) fragments; mediates the action of
    (SEQ ID NO:140) kDa) and is activated by cAMP; consists
    of two regulatory (R) and two
    catalytic (C) subunits; cAMP
    releases the C subunit from the
    inactive R2C2 cADPK; two
    cDNAs were cloned encoding two
    isoforms of the catalytic subunit of
    cADPK in mouse.
    186 GFAKRVKGRTW CADPK bovine cDNA was isolated by screening a
    TLCG (catalytic subunit) bovine pituitary cDNA library;
    (SEQ ID NO:141) (350 aa) 93% sequence similarity to known
    bovine cADPK; represents the
    second gene for the catalytic
    subunit of cADPK.
    29 EEEIQELKRKLH CGDPK (SEQ ID bovine lung By protein sequencing; composed
    KCQSVLP (SEQ ID NO: 144) of two identical subunits activated
    NO:142) (670 aa, 76.3 kDa) in an allosteric manner by binding
    389 KILKKRHIVDTR of cGMP and not by dissociation
    (SEQ ID NO:143) of catalytic subunit as in cADPK;
    sequence similar to cADPK
    117 KTLKKHTIVK TPK3 S. cerevisiae cAMP-DPK is a tetrameric protein
    (SEQ ID NO:145) (398 aa) with two catalytic and two
    cADPK regulatory subunits; cAMP
    activates the kinase by dissociating
    the catalytic subunits from the
    tetramer; all three TPK 1, 2, 3 are
    catalytic subunits.
    16S2H13GHG2 SNF1 (633 aa, 72 kDa) S. cerevisiae Ser/Thr kinase;
    166 EYCHRHKIVHRD autophosphorylated; plays a
    LKP (SEQ ID NO:146) central role is carbon catabolite
    495 PLVTKKSKTRWH repression in yeast required for
    FG (SEQ ID NO:147) expression of glucose-repressible
    genes; region 60-250 shows high
    sequence similarity to cAMP-
    dependent protein kinase
    (cADPK).
    70 PVKKKKIKREIK Casein kinase II (α- Drosophila CKIL is composed of a and 3
    (SEQ ID NO:148) subunit, catalytic) melanogaster subunits in a a2f32 130-150 kDa
    269 DILQRHSRKRW (336 aa) protein; the a-subunit is the
    ERF (SEQ ID NO:149) catalytic and the f3is
    146 PKSSRHHHTDG CKII (β-subunit, Drosophila autophosphorylated.
    (SEQ ID NO:150) regulatory) (215 aa) melanogaster
    142 PKSSRHHHTDG CKII (β-subunit, bovine (lung)
    (SEQ ID NO:151) regulatory) (209 aa,
    24.2 kDa)
    108 PKQRHRKSLG KIN1 (1064 aa, 117 S. cereviszae 30% aa similarity to bovine
    (SEQ ID NO:152) kDa) cADPK and 27% (KINi) or 25%
    129 GSMCKVKLAK (KJN2) aa similarity to v-Src
    HRYTNE within the kinase domain; the
    (SEQ ID NO:153) catalytic domains of KINi and
    506 DRKHAKIRNQ KIN2 are near the N-terminus and
    (SEQ ID NO:154) are structural mosaics with features
    638 GNIFRKLSQRR characteristic of both Tyr and
    KKTIEQ Ser/Thr kinases.
    (SEQ ID NO:155)
    773 PPLNVAKGRKL
    HP (SEQ ID NO:156)
    87 ELRQFHRRSLG KIN2 (1152 aa, 126 S. cerevisiae
    (SEQ ID NO:157) kDa)
    111 GKVKLVKHRQ
    TKE (SEQ ID NO:158)
    217 GSLKEHHARKF
    ARG (SEQ ID NO:159)
    807 LSVPKGRKLHP
    (SEQ ID NO:160)
    60FLRRGIKKKLTLD STE7 (515 aa) S. cerevisiae Implicated in the control of the
    (SEQ ID NO:161) three cell types in yeast: (a, a,and
    472 PSKDDKFRHWC ala) of which a and a cells are
    RKIKSKIKEDKRIKRE haploid and are specialized for
    (SEQ ID NO:162) mating whereas a/a cells are
    diploid and are specialized for
    meiosis and sporulation; with the
    exception of the mating type locus,
    MAT, all cells contain the same
    DNA sequences. STE7 gene
    produces insensitivity to cell-
    division arrest induced by the yeast
    mating hormone, a-factor.
    722 QRRVKKLPSTTL S6KIIα (733 aa) Xenopus
    (SEQ ID NO:163)
    QRRVKKLPSITL S6KII β Xenopus
    (SEQ ID NO:164)
    742 QRRVKKLPSTTL S6KII (752 aa) Chicken
    (SEQ ID NO:165)
    713QRRVRKLPSTTL S6KII (724 aa) Mouse
    (SEQ ID NO:166)
    16GVVYKGRHKTTG CDC2Hs Human Isolated by expressing a human
    (SEQ ID NO:167) (297 aa) cDNA library in S. pombe and
    120 FCHSRRVLHRD p34cdc2 selecting for clones that
    LKP (SEQ ID NO:168) complement a mutation in the cdc2
    yeast gene; the human CDC2 gene
    can complement both the
    inviability of a null allele of S.
    cerevisiae CDC28 and cdc2
    mutants of S. pombe; CDC2
    mRNA appears after that of
    CDK2.
    GVVYKARHKLSGR cdc2 (297aa) S. pombe High homology to S. cerevisiae
    (SEQ ID NO:169) CDC28.
    119HSHRVLHRDLKP CDK2 (cell division Human The human CDK2 protein has 65%
    (SEQ ID NO:170) kinase 2) (298 aa) sequence identity to human
    p34cdc2 and 89% sequence
    identity to Xenopus Eg1 kinase;
    human CDK2 was able to
    complement the inviability of a
    null allele of S. cerevisiae CDC28
    but not cdc2 mutants in S. pombe.
    CDK2 mRNA appears in late
    G1/early S.
    109 FCHSHRVLHRD Eg1 (297 aa) Xenopus Cdk2-related
    LKP (SEQ ID NO:171)
    125 GIAYCHSHRILH CDC28 (298 a) S. cerevisiae The homolog of S. pombe Cdc2
    RDLKP
    (SEQ ID NO:172)
    119 HSHRVIHRDLKP cdk3 (305 aa) Human
    (SEQ ID NO:173)
    56 KELKHKNIVR PSSALRE (291 aa) Human cdc2-related kinase.
    (SEQ ID NO:174) (SEQ ID NO:175)
    1 MDRMKKIKRQ (N- PCTAIRE-1 (496 aa) Human cdc2-related kinase.
    terminus) (SEQ ID
    NO:176)
    141 DKPLSRRLRRV
    (SEQ ID NO:177)
    1 MKKFKRR PCTAIRE-2 (523 aa) Human cdc2 related kinase.
    (SEQ ID NO:178)
    129 RNRIHRRIS
    (SEQ ID NO:179)
    172 SRRSRRAS
    (SEQ ID NO:180)
    304 HRRKVLHR
    (SEQ ID NO:181)
    512 GHGKNRRQSM
    LF (SEQ ID NO:182)
    163 HTRKILHR PCTAIRE-3 Human cdc2 related kinase.
    (SEQ ID NO:183) (380 aa)
    369 PGRGKNRRQSIF
    (SEQ ID NO:184)
    69 EVFRRKRRLH KKIALRE (358 aa) Human cdc2-related kinase.
    (SEQ ID NO:185) (SEQ ID NO:187)
    302 DKPTRKTLRKSR
    KHH (SEQ ID NO:186)
    1 MVKRHKNT nim1+ gene product S. pombe
    (SEQ ID NO:188) (new inducer of
    87 DGELFHYIRKHGP mitosis); protein
    (SEQ ID NO: 189) kinase (370 aa)
    114 DAVAHCHRFRFR
    HRD (SEQ ID NO:190)
    295 KKSSSKKVVRRL
    QQRDD
    (SEQ ID NO:191)
    194 PAQKLRKKNNFD Wee1+ gene product S. pombe The Wee1+ gene functions as a
    (SEQ ID NO:192) (877 aa) dose-dependent inhibitor that
    388 KQHRPRKNTNFT delays the initiation of mitosis
    PLPP (SEQ ID NO:193) until the yeast cell has attained a
    592 KYAVKKLKVKF certain size; Wee1 has a protein
    SGP (SEQ ID NO:194) kinase consensus probably
    regulating cdc2 kinase.
    266 PNETRRIKRAN CDC7 (497 aa) S. cerevisiae Required for mitotic but not
    RAG (SEQ IDNO:195) meiotic DNA replication
    presumably to phosphorylate
    specific replication protein factors;
    implicated in DNA repair and
    meiotic recombination; some
    homology with CDC28 and
    oncogene protein kinases but
    differs in a large region within the
    phosphorylation receptor domain.
    48YDHVRKTRVAIKK ERK1 (MAP kinase) Rat Known to translocate to the
    (SEQ ID NO:196) (367 aa; 42 kDa) nucleus following their activation
    by phosphorylation at T-190, and
    Y-192 (T-183, Y-185 in ERK2).
    59 ILKHFKHE FUS3 (353 aa) S. cerevisiae MAP-(ERK1)-related.
    (SEQ ID NO:197)
    252 QIKSKRAKEY KSS1 (368 aa) S. cerevisiae MAP-(ERK1)-related.
    (SEQ ID NO:198)
    ELVKHLVKHGSN SW16 S. cerevisiae Activator of CACGA-box with
    (SEQ ID NO:199) (803aa, 90 kDa) sequence similarity to cdc10;
    GKAKKIRSQLL required at START of cell cycle.
    (SEQ ID NO:200)
    EQRIKRHRJDVSDED cdc10 S. pombe
    (SEQ ID NO:201)
    SNIKSKCRRVV
    (SEQ ID NO:202)
    37 PPKRIRTD CTD kinase (528 aa) S. cerevisiae Consists of 3 subunits of 58, 38,
    (suggested by the 58 kDa subunit and 32 kDa; disruption of the 58
    authors) (SEQ ID (catalytic) kDa gene gives cells that lack CTD
    NO:203) kinase, grow slowly, are cold
    492 KLARKQKRP sensitive, but have different
    (SEQ ID NO:204) phosphorylated forms of RNA pol
    II.
    29 GVSSVVRRCIHKP Phosphorylase kinase Rabbit (skeletal
    (SEQ ID NO:205) (catalytic subunit) muscle)
    (386 aa)
    489 KKYMARRKW Myosin light chain Chicken gizzard Ca2+/calmodulin-activated;
    QKTGHAV kinase (MLCK) (669 phosphorylated by cADPK; first
    (SEQ ID NO:206) aa) described as responsible for the
    phosphorylation of a specific class
    of myosin light chains; required
    for initiation of contraction in
    smooth muscle.
    314 PWLNNLAEKAK Myosin light chain Rabbit (skeletal By protein sequencing.
    RCNRRLKSQ kinase (partial 368 muscle)
    (SEQ ID NO:207) carboxy-terminal aa
    334 ILLKKYLMKJRR sequence)
    WKKNFIAVS
    (SEQ ID NO:208)
    28 GVSSVVRRCIHKP Phosphorylase kinase Mouse (muscle) Glycogenolytic regulatory enzyme;
    (SEQ ID NO:209) (PhK) (catalytic γ undergoes complex regulation;
    subunit) (389 aa) composed of 16 subunits
    containing equimolar ratios of α, β,
    γ and δ subunits; high levels in
    skeletal muscle; isoforms in
    cardiac muscle and liver; cDNA
    probe does not hybridize to X
    chromosome in mice and is thus
    distinct from the mutant recessive
    PhK deficiency that results in
    glycogen storage disease.
  • [0185]
    TABLE 8
    Nuclear localization signals on DNA repair proteins
    Gene Equivalent protein
    Putative NLS product in other species Features
    HIGHER EUKARYOTES
    None ERCC1 RAD10 297 aa; DBD; interacts
    (N-terminus) strongly with ERCC4 (XPF)
    MDPGKDKEGvpqpsgppaRKKF to form an excision
    (bipartite NLS) endonuclease; unless the
    (SEQ ID NO:210) KDKx11RKK is a bipartite
    NLS it may depend upon its
    binding with ERCC4 for its
    nuclear import.
    None ERCC2 RAD3 (S. cer) 760 aa; DNA helicase
    681DKRFARGDKRGKLPR (XPD) component of TFIIH,
    (near the C-terminus) (four essential for cell viability;
    positive, one negative over a contains one nucleotide-
    heptapeptide stretch) binding, one DNA-binding,
    (SEQ ID NO:211) and seven domains
    characteristic of helicases;
    52% identity with S. cer
    RAD3 at the amino acid
    level.
    8 DRDKKKSRKRHYEDEE ERCC3 SSL2 (S. cer) 782 aa; helicase, component
    (SEQ ID NO:212) (XPB) Haywire(Dros) of TFIIH essential for cell
    522 YVAIKTKKRILLYTM viability; helix-turn-helix,
    (SEQ ID NO:213) DNA-BD, and helicase
    (weak NLS if at all, hydrophobic domains
    environment)
    769 PSKHVHPLFKRFRK
    (SEQ ID NO:214)
    84 KKQTLVKRRQRKD ERCC5 RAD2; 1186 aa in human, 1196 in X.
    (SEQ ID NO:215) (XPG) Rad13 laevis; 3′ incision
    210 EFTKRRRTL endonuclease; involved in
    (SEQ ID NO:216) homologous recombination;
    390 DESMIKDRKDRLP strongly nuclear
    (SEQ ID NO:217)
    1170 GKKRRKLRRARGRK
    RKT (SEQ ID NO:218)
    253PQKQEKKPRKIMLNEASG ERCC6 RAD26 1493 aa; involved in the
    (SEQ ID NO:219) CS-B preferential repair of active
    314 PNKKARVLSKKEERLKK genes; nonessential for cell
    HIKKLQKR (SEQ ID NO:220) viability
    406 PLPKGGKRQKKVP
    (SEQ ID NO:221)
    455 DGDEDYYKQRLRRWNK
    LRLQDKEKRLKLEDDSEESD
    (SEQ ID NO:222)
    1028 DVQTPKCHLKRRIQP
    X8PKRKKFP (SEQ ID NO:223)
    1180 KHKSKTKHHSVAEEETL
    EKHLRPKQKPKX15PHLVKK
    RRY (SEQ ID NO:224)
    1324 PAGKKSRFGKKRN
    (SEQ ID NO:225)
    21 PASVRASIERKRQRALM XPA RAD14 273 aa; zinc finger domain;
    LRGAR (SEQ ID NO:226) involved in lesion
    160 PPLKFIVKKNPHHSQW recognition
    GD (weak) (SEQ ID NO:227)
    210 NREKMKQKKFDKKVKE
    (weak because of F)
    (SEQ ID NO:228)
    72 YLRRAMKRFN (weak) XPC RAD4 (23% identity, 823 aas, 92.9 kDa; very
    (SEQ ID NO:229) 44% similarity) hydrophilic protein; might be
    262 PSAKGKRNKGGRKKRSK involved in lesion
    PSSSEEDEGPG (SEQ ID recognition since XPC cells
    NO:230) (40% of all XP cases) can
    297 QRRPHGRERR (weak) repair active parts of the
    (SEQ ID NO:231) genome whereas inactive and
    368 RTHRGSHRKDP (weak) the nontranscribed strand of
    (SEQ ID NO:232) active genes are not repaired
    384 SSSSSSSKRGKKMCSDG
    (SEQ ID NO:233)
    531 ALKRHLLKYE (weak)
    (SEQ ID NO:234)
    594 SNRARKARLAEP
    (SEQ ID NO:235)
    660 PNLHRVARKLD (weak)
    (SEQ ID NO:236)
    716 ERKEKEKKEKR
    (SEQ ID NO:237)
    740 IRERLKRRYG
    (SEQ ID NO:238)
    801 GGPKKTKRERK
    (SEQ ID NO:239)
    20 KSKAKSKARREEEEED XPC 940 aa; the first 117 aa are
    (SEQ ID NO:240) lacking in the Legerski and
    54 GKRKRG (SEQ ID NO:241) Peterson, (1992) XPC
    69 GPAKKKVAKVTVK sequence (see above); the
    (SEQ ID NO:242) following 823 aa are
    103 PSDLKKAHHLKRG identical.
    (SEQ ID NO:243)
    82 EIDRRKKRPLENDGPVKK Rep-3 Swi4 (S. pom) 1137 aa; mismatch repair
    KVKKVQQKE (SEQ ID (mouse) protein; Rep-3 is in the
    NO:244) Duc-1 immediate 5′ flanking region
    375 KENVRDKKKG (HeLa) of DHFR gene (89 bp) but
    (SEQ ID NO:245) transcribed from the opposite
    571 FGRRKLKKWVT strand; a bidirectional
    (SEQ ID NO:246) promoter is used for both
    710 PLIKKRKDEIQG transcripts.
    (SEQ ID NO:247)
    1091 KELEGLINTKRKRLKYF
    AKLW (SEQ ID NO:248)
    422 EKHEGKHQKLL (weak) hMSH2 MSH2 (S. cer) human mismatch repair
    (SEQ ID NO:249) protein; homologous to S.
    cerevisiae MSH2; associated
    with the hereditary
    nonpolyposis colon cancer
    gene on chromosome 2p16.
    397 PDIRRLTKKLNKRG MSH2
    (SEQ ID NO:250) (S cer)
    547 DAKELRKHKKYIE
    (SEQ ID NO:251)
    869 VKMAKRKANE
    (SEQ ID NO:252)
    95 GELAKRSERRAEAE Human Rad2 Rad2 (S. pom) 400 aa; required for fidelity
    (SEQ ID NO:253) of chromosome separation at
    354 KRKEPEPKGSTKKKAK mitosis; limited similarity to
    TG (SEQ ID NO:254) RAD2 (ssDNA nuclease),
    394 GKFKRGK (SEQ ID rad 13, and XPG (ERCC5).
    NO:255)
    None mouse 339 aa; recombination-repair
    RAD51 protein; 83% homology to S
    cerevisiae RAD51 and 55%
    homology to E. coil RecA.
    None HHR23B/ RAD23 Subunit of XPC (125 kDa)
    p58
    None HHR23A RAD23 Subunit of XPC (125 kDa)
    32 PSQAEKKSRARAQ RPA (34 kDa RPA (70, 34, and 14 kDa
    (SEQ ID NO:256) subunit) subunits) might stabilize the
    helicase-melted DNA around
    the lesion; antibodies against
    RPA 32 kDa subunit inhibit
    DNA replication.
    GAKKRKIDDA ATPase Q1 RecQ (E. coli) 649 aa; altered in XPC cells;
    (SEQ ID NO:257) undetermined role in repair
    PKKPRGKM (SEQ ID NO:258) HMG-1 Calf thymus HMG 1
    EHKKKHP (SEQ ID NO:259) (259 aa); involved in the
    ETKKKFKDP (SEQ ID NO:260) recognition of cisplatin
    EKSKKKK(E/D)41 (SEQ ID lesions
    NO:261)
    E3G2KKKKKFAK (SEQ ID
    NO:262)
    512 RDEKKRKQLKKAKAK SSRP1 ABF (S. cer) 709 aa, 81 kDa, structure-
    MAKDRKSRKKP (SEQ ID specific recognition protein
    NO:263) 1; involved in recognition of
    619 GESSKRDKSKKKKKVKV cisplatin-induced lesions;
    KMEKK (SEQ ID NO:264) also involved in Ig gene
    674 GENKSKKKRRRSEDSEE recombination; one HMG-
    EE (SEQ ID NO:265) box, similarity to SRY,
    MTFII, LEF-1, TCF-1a, and
    ABF2.
    1 MPKRGKKG (SEQ ID Ref-1 Redox factor 1 from HeLa
    NO:266) (HAP1) cells; 37 kDa, 318 aa;
    apurinic/apyrimidinic (AP)
    endonuclease for DNA repair
    but also of redox activity
    stimulating Jun/Fos DNA
    binding.
    1 MPKRGKKG HAP1 ExoIII 323 aa; apurinic/apyrimidinic
    (SEQ ID NO:267) (bovine) (E. coli) (AP)-endonuclease
    ExoA (S.
    pneumoniae)
    DROSOPHILA
    1 MGPPKKSRKDRSGGDKF Haywire ERCC3 (XPB) helicase with 66% identity to
    GKKRRGQDE human ERCC3; flies
    (SEQ ID NO:268) SSL2 (S. cer) expressing marginal levels of
    EMSYSRKRQRFLVNQG Haywire display motor
    (weak) (SEQ ID NO:269) defects and reduced life span
    YYEHRKKNIGSVHPLFK
    KFRG (bipartite) (SEQ ID
    NO:270)
    77 ARGKKKQPK (SEQ ID Rrp1 HAP1 Recombination repair protein
    NO:271) 1); 679 aa; the 252 aa C-
    98 KPKGRAKKA (SEQ ID terminal domain is
    NO:272) homologous to AP-
    157 QAKGRKKKELP (SEQ ID endonucleases, whereas the
    NO:273) 1-426 aa domain is highly
    179 EPPKQRARKE (SEQ ID charged, carries all of the
    NO:274) putative NLSs.
    241 PPKAASKRAKKGK (SEQ
    ID NO:275)
    282 PKKRAKKTT (SEQ ID
    NO:276)
    317 EPAPGKKQKKSAD (SEQ
    ID NO:277)
    336 EEEAKPSTETKPAKGR
    KKAP (SEQ ID NO:278)
    372 KPARGRKKA (SEQ ID
    NO:279)
    394 GSKTTKKAKKAE
    (SEQ ID NO:280)
    S. CEREVISIAE
    200 IEKLRRKLYISGG RAD1 ERCC4 1100 aa; 30% sequence
    (SEQ ID NO:281) (XPF) identity to Rad16; RAD1
    515 NKKRGVRQVLLN (SEQ Rad16 interacts strongly with
    ID NO:282) RAD10
    565 KEQVTTKRRRTRG
    (conserved in Rad16) (SEQ ID
    NO:283)
    1024 NLRKKIKSFNKLQ
    (SEQ ID NO:284)
    89 RQRKERRQGKRE RAD2 XPGC 1031 aa, 117.8 kDa; ssDNA
    (SEQ ID NO:285) Rad13 endonuclease; rad mutants
    907 ENKFEKDLRKKLVNNE are defective in incision
    (SEQ ID NO:286)
    984 RDVNKRKKKGKQKRI
    (SEQ ID NO:287)
    1017 KRISTATGKLKKRXM
    (SEQ ID NO:288)
    672 GKDDYGVMVLADRRF RAD3 ERCC2 or XPD; 778 aa, 89,779 Da; 30%
    SRKRSQLP (contains the bulky (S. cer) Rad15 or Rhp3 sequence identity to rad16;
    F) (SEQ ID NO:289) ATP-dependent DNA
    helicase; single-stranded
    DNA-dependent ATPase.
    26 PLSRRRRVRRKNQPLPD RAD4 XPC 754 aa; mutations in RAD4
    AKKKFKTG (SEQ ID NO:290) that that inactivate the
    134 NEERKRRKYFHMLYL excision repair function of
    (SEQ ID NO:291) RAD4 result in truncated
    160 EWINSKRLSRKLSNL proteins missing the C-
    (weak) (SEQ ID NO:292) terminal one-third of RAD4.
    254 EMSANNKRKFKTLKRSD
    weak (SEQ ID NO:293)
    382 WMNSKVRKRRITKDDF
    GEK (SEQ ID NO:294)
    403 RKVITALHHRKRTKID
    DYED (SEQ ID NO:295)
    504 KTGSRCKKVIKRTVGRP
    (SEQ ID NO:296)
    150 FHPKRRRIYGFR (SEQ ID RAD5 1169 aa; helicase involved in
    NO:297) postreplication-repair (RAD6
    215 DSRGRKKASM (SEQ ID epistasis group); binds DNA
    NO:298) with the seven helicase
    297 DGESLMKRRRTEGGNK motifs and with zinc fingers;
    REK (SEQ ID NO:299) increases the instability of
    1152 DEDERRKRRIEE poly (GT) repeats in the yeast
    (SEQ ID NO:300) genome.
    1 MSTPARRRLMRDFKRM RAD6 RAD6 mediates the
    KEDAPP (SEQ ID NO:301) ubiquitination of H2A and
    H2B histones
    15 GVAKLRKEKSGAD RAD10 ERCC1 210 aa; forms an
    (SEQ ID NO:302) endonuclease with RAD1;
    76 DDYNRKRPFRSTRPGK the basic and tyrosine-rich
    (SEQ ID NO:303) central domain was
    suggested to bind DNA by
    ionic interactions and
    tyrosine intercalation.
    172 EGKAHRREKKYE RAD14 XPAC 247 aa, 29.3 kDa; two zinc
    (SEQ ID NO:304) fingers; involved in lesion
    200 NRLREKKHGKAHIHH recognition; 27% sequence
    (SEQ ID NO:305) identity and 54% sequence
    similarity (if conserved
    residues are grouped
    together) to human XPA;
    deletion of RAD14 gene
    generates high UV
    sensitivity.
    345 ERRKQLKKQGPKRP Ixr1 591 aa; two consecutive
    (SEQ ID NO:306) (S. cer) HMG boxes; involved in
    479 ETYKKRIKEWESCYPDE recognition of 1,2-intrastrand
    (SEQ ID NO:307) d(GpG) and d(ApG) cisplatin
    crosslinks.
    None RAD23 HHR23
    483 LTCKKLKTHNRIILSG RAD26 ERCC6 1075 aa; disruption of the
    weak (SEQ ID NO:308) (yeast CS-B (hum) RAD26 gene gives viable
    934 NALRKSRKKITKQYEIGT ERCC6) yeast cells unable to
    PX9GEIRKRDP preferentially repair the
    (SEQ ID NO:309) actively transcribed strands;
    surprisingly, in contrast to
    human CS-B cells, disruption
    of the RAD26 in yeast does
    not cause sensitivity to UV,
    Cisplatin, or X-rays.
    634 KPTSKPKRVRTATKKKIP MRE11 Rad32 (S. pom) meiotic recombination
    (SEQ ID NO:310) protein; functions in the
    408 FYKKRSPVTRSKKSG same pathway with RAD51
    (SEQ ID NO:311)
    none; RAD51 RecA (E. coli) 402 aa; essential for repair of
    361 GFKKGKGCQR DSBs and recombination;
    (SEQ ID NO:312) associates strongly with
    RAD52; self associates;
    neither RAD51 nor RAD52
    possess a typical simple
    NLS.
    none; RAD51 (K. 364 aa
    328 GFKKGKGCQR lactis)
    (SEQ ID NO:313)
    none; RAD52 Rad22 504 aa; rad52 mutants are
    155 ERAKKSAVTDALKRSLR defective in ionizing
    GFGXgDKDFLAKIDKVKFDP radiation, mitotic
    PD (tripartite) recombination, mating-type
    (SEQ ID NO:314) switching, and repair of
    DSDs.
    1 MARRRLPDRPP RAD54 898 aa; recombination-repair
    (SEQ ID NO:315) protein; ATP-binding motif;
    65 GGRSLRKRSA helicase domains; in the
    (SEQ ID NO:316) same subfamily of helicases
    99 QLTKRRKD with MOT1 and SNF2.
    (SEQ ID NO:317)
    269 DETVFVKSKRVKASSS RAD55 Similarity to RecA, and
    (extremely weak if at all NLS) lower similarity to RAD51,
    (SEQ ID NO:318) RAD57, and DMC1
    317 GEDRKREGRNLKR
    (SEQ ID NO:319)
    371 PISRQSKKRKFDYRVP RAD57 460 aa; nucleotide-binding
    (SEQ ID NO:320) domain; limited similarity to
    RAD51
    62 GLKKPRKKTKSSRH SSL2 ERCC3 (XPB) 843 aa; putative helicase that
    (SEQ ID NO:321) seems to function in repair
    688 GRILRAKRRNDEG but also in the removal of
    (SEQ ID NO:322) secondary structures in the 5′
    784 GRGSNGHKRFKS (weak) untranslated region of mRNA
    (SEQ ID NO:323) to allow ribosome binding
    and scanning.
    50 TRRHLCKIKGLSE (weak) DMC1 RecA 334 aa; yeast homolog of
    (SEQ ID NO:324) RecA, meiosis-specific;
    277 DGRKPIGGHX12RKGRG dmc 1 mutants are defective
    DER (bipartite) (SEQ ID in reciprocal recombmation
    NO:325) and accumulate DSBs
    11 ETEKRCKQKEQRY PMS 1 904 aa, 103 kDa; mismatch-
    (SEQ ID NO:326) repair protein; MutL
    (Salmonella) and HexB
    (Streptococcus) homolog
    None HRR25 Hhp1, Hhp1 (S. pom) Mutations in HRR25 Ser/Thr
    1 MDLRVGRKFRIGRKIG CR1 (mamm protein kinase cause defects
    (SEQ ID NO:327) in DNA repair and
    139 GRRGX8GLSKKYRDFNT retardation in cell cycling
    HRHIP (Bipartite weak NLS)
    (SEQ ID NO:328)
    96 HELTKRSSRRVETEK YKL510 383 aa; structure-specific
    (SEQ ID NO:329) endonuclease; two domains
    of about 100 aa with
    sequence similarity to N- and
    C-terminal regions of RAD2.
    200 MLAMARRKKKMSAK MOT1 Modifier of transcription 1;
    (SEQ ID NO:330) 1867 aa; DNA helicase of S.
    617 EHYKVKHTEK (weak cerevisiae required for
    NLS) (SEQ ID NO:331) viability; increases gene
    670 LHPEKKRSISE (weak expression of several., but
    NLS) (SEQ ID NO:332) not all, pheromone-
    responsive genes rn the
    absence of STEl2; the 1257
    to 1825 aa domain (568 aa
    residues) has homology to
    SNF2 and RAD54
    S. POMBE
    60 SSIDEx5SIKRKRRI (SEQ ID Swi4 Duc-1 113 kDa; KCII sites are
    NO:333) Rep-3 upstream of NLS like in
    SV4O large T; the
    homologous prokaryotic
    MutS and HexA lack NLS
    96 GELAKRVARHQKARE Rad2 380 aa
    (weak NLS) (SEQ ID NO:334)
    362 GSAKRKRDS
    (SEQ ID NO:335)
    372 KGGESKKKR
    (SEQ ID NO:336)
    None Rad9 — 427 aa; no homology to other
    DNA repair proteins; rad9
    fission yeast mutants are
    sensitive to both UV and
    ionizing radiation; may be
    involved in recombination-
    repair.
    None Rhp3 or ERCC2 772 aa; DNA helicase; 65%
    681 DKRYGRSDKRTKLPK rad15 RAD3 identity to RAD3 and 55%
    (SEQ ID NO:337) identity to ERCC2; essential
    for viability
    464 PPSKRRRVRGG Rad16 RAD 1 Function in repair of UV
    (SEQ ID NO:338) damage for both cyclobutane
    dimer and (6-4) photoproduct
    lesions; Rad 16 interacts with
    SwilO.
    431 DFKQAILRKRKNESPE Rad21 628 aa, 67.8 kDa, acidic
    EVEP (SEQ ID NO:339) protein; a single base
    substitution in mutant rad2 1-
    45, changing an Ile into a
    Thr, is responsible for the
    low efficiency in repair of
    DSBs after g-radiation
    although capable of arresting
    atG2.
    490 DKKAKKG (SEQ ID Rad22 RAD52 496 aa; functions in
    NO:340) recombination-repair and
    mating-type switching.
    394 DVVQFYLKKKYTRSKRN Rad32 MRE11 (S. cer) 648 aa; meiotic
    DG (weak because of Y) (SEQ recombination protein; rad32
    ID NO:341) mutants are sensitive tog-
    575 PSPALLKKTNKRRELP and UV radiation; functions
    (SEQ ID NO:342) in the same pathway with
    Rhp51 (RAD51).
    Rad51 recombination-repair
    GLAKKYRDHKTHLHIP (weak Hhp1 CKI (mamm) Ser/Thr protein kinase;
    NLS because of Y and H) (SEQ HRR25 (S. cer) mutation in this gene causes
    ID NO:343) repair defects
    None Hhp2 CKI (mamm) Ser/Thr protein kinase;
    GLAKKYRD KTHVHIP (H in HRR25 (S. cer) mutation in this gene causes
    Hhp1 is replaced by F in Hhp2) repair defects
    (SEQ ID NO:344)
  • [0186]
    TABLE 9
    NLS in Transcription factors
    NLS and Flanks Protein factor and features
    highly basic
    HR4QRTRK7R Human GCF (GC-factor)
    (SEQ ID NO:345)
    LRRKSRP
    (SEQ ID NO:346)
    SRRTKRRQ
    (SEQ ID NO:347)
    GRKRKKRT Oct-6 protein transcription
    (SEQ ID NO:348) factor from mouse cells
    GRRRKKRT Mouse Oct-2 protein transcription
    (SEQ ID NO:349) factors (Oct-2.1 for Oct-2.6 isoforms)
    ARKRKRT Oct-3 from mouse P19
    (SEQ ID NO:350) embryonal carcinoma cells
    NRRQKGKRS
    (SEQ ID NO:351)
    ECRRKKKE Human ATF-1. In basic
    (SEQ ID NO:352) region/leucine zipper.
    ERKKRRRE Human ATF-3 (in basic region
    (SEQ ID NO:353) that binds DNA)
    AKCRNKKKEKT
    (SEQ ID NO:354)
    SKKKIRL Mouse Pu. 1 (Friend
    (SEQ ID NO:355) erythroleukemia cells). Related
    QKGNRKKM to ets oncogene
    (SEQ ID NO:356)
    VKKVKKKL
    (SEQ ID NO:357)
    VKRKKI Human PRDII-BF1 that binds
    (SEQ ID NO:358) to IFN-β gene promoter.
    CRNRYRKLE (The largest DNA-binding
    (SEQ ID NO:359) protein known, of 298 kD).
    IRKRRKMK
    (SEQ ID NO:360)
    PKKKRLRL
    (SEQ ID NO:361)
    GKKKKRKREKL Murine LEF-1 (397 aa).
    (within the Lymphoid-specific with an
    HMG-box) HMG1-like box. NLS is identical
    (SEQ ID NO:362) to that of human TCF-1α.
    GKKKKRKREKL Human TCF-1α (399 aa)
    (within the HMG-box) (T cell-specific transcription factor that
    HMG-box) activates the T cell receptor
    (SEQ ID NO:363) Cα). Contains an HMG box.
    NLS core is identical to
    that of murine LEF-1.
    GKKKRRSREKH Human TCF-1
    (within the (uniquely T cell-specific).
    (SEQ ID NO:364) HMG box containing.
    PKKCRARF
    (SEQ ID NO:365)
    FKQRRIKL Xenopus laevis Oct-1(within
    (SEQ ID NO:366) POU-domain)
    NRRRKKRT
    (SEQ ID NO:367)
    NRRQKEKRI
    (SEQ ID NO:368)
    DKRSRKRKRSK Drosophila Suvar (3) 7 gene product
    (SEQ ID NO:369) involved in position-effect
    RLRIDRKRN variegation (932 aas). Five widely
    (SEQ ID NO:370) spaced zinc-fingers could help
    AKRSRRS condensation of the chromatin fiber.
    (SEQ ID NO:371)
    IRKRRKMKSVGD2E2 Human MBP-1 (class I MHC enhancer
    (SEQ ID NO:372) binding protein 1) mw 200 kD.
    (not suggested Induced by phorbol esters and
    as NLS by the mitogens in Jurkat T cells.
    authors; between
    the 1st and 2nd
    zinc finger)
    PPKKKRLRLAE
    (suggested as NLS by the
    authors; just before 2nd zinc
    finger)
    (SEQ ID NO:373)
    CRNRYRKLE
    (within 1st zinc finger)
    (SEQ ID NO:374)
    PRRKRRV rat TTF-1 (thyroid nuclear factor
    (SEQ ID NO:375) that binds to the promoter of
    HRYKMKRQ thyroid-specific genes). An
    (SEQ ID NO:376) homeodomain protein.
    DGKRKRKN Human thyroid hormone receptor α
    (SEQ ID NO:377) (c-erbA-1 gene). Belongs to the
    DDSKRVAKRKL family of cytoplasmic proteins that
    (SEQ ID NO:378) are receptors of hydrophobic
    NRERRRKEE ligands such as steroids, vitD,
    (SEQ ID NO:379) retinoic acid, thyroid hormones.
    WKQRRKF The ligand binding may expose the NLS
    for nuclear import of the
    (SEQ ID NO:380) receptor-ligand complex.
    NRRKRKRS Drosophila gcl (germ cell-less) gene
    (SEQ ID NO:381) product (569 aa, 65 kD), located
    PKKKKL in nuclei, required for germ
    (SEQ ID NO:382) line formation.
    ARRKRRRL C. elegans Sdc-3 protein
    (SEQ ID NO:383) (sex-determining protein)
    LKFKKVRD (2,150 aas). A zinc finger protein.
    (SEQ ID NO:384)
    FKKFRKF
    (SEQ ID NO:385)
    GKQKRRF
    (SEQ ID NO:386)
    ERLKRDKEKREKE
    (SEQ ID NO:387)
    TRGRPKKVKE
    (SEQ ID NO:388)
    SKKRGRRRKKT
    (SEQ ID NO:389)
    TRRQKRAKV
    (SEQ ID NO:390)
    SRKSKKRLRA
    (SEQ ID NO:391)
    LKKIRRKIKNKI Drosophila BBF-2 (related to
    (SEQ ID NO:392) CREB/ATF)
    ESRRKKKE
    (SEQ ID NO:393)
    Group 0000
    DRNKKKKE Xenopus RAR (retinoic acid receptor)
    (SEQ ID NO:394)
    ARRRRP
    (SEQ ID NO:395)
    GRRRRA Human ATF-2 (the 2nd and
    (SEQ ID NO:396) 3rd NLS are in basic region
    DEKRRKV that binds DNA)
    (SEQ ID NO:397)
    CRQKRKV
    (SEQ ID NO:398)
    ERKRRD Myn (murine homolog of Max). Forms
    (SEQ ID NO:399) a specific DNA-binding
    SRKKLRME complex with c-Myc oncoprotein
    (SEQ ID NO:400) through a helix-loop-helix/
    leucine zipper.
    EEKRKRTYE human NFκB p65 (550 aa).
    (SEQ ID NO:401) Not binding DNA; complexed
    with p50 that binds DNA. NFκB p50
    also contains a NLS (Table 3b).
    GRRRRA Human HB16, a cAMP response
    (SEQ ID NO:402) element-binding protein
    DEKRRKF
    (SEQ ID NO:403)
    SRCRQKRKV
    (SEQ ID NO:404)
    SKKKKTKV Human TFIIE-β (general
    (SEQ ID NO:405) transcription initiation
    NRPDKKKI protein factor; forms
    (SEQ ID NO:406) tetramer α2β2 with TFIIE-α)
    QRRKKP
    (SEQ ID NO:407)
    QKKRRFKT
    (SEQ ID NO:408)
    SRKRKM Human kup transcriptional activator
    (SEQ ID NO:409) (433 aas). Two distantly spaced
    zinc fingers. Expressed in
    hematopoietic cells and testis.
    ERKRLRNRLA Mouse Jun-B homologue to
    (SEQ ID NO:410) avian sarcoma virus 17 oncogene
    v-jun product. One region is similar
    ATKCRKRKL to yeast GCN4 and to Fos.
    (SEQ ID NO:411)
    (19 aa stretch)
    DKRx6ERKRRD (N-terminus) Max (specifically associates with
    (SEQ ID NO:412) c-Myc, N-Myc, L-Myc). The Max-Myc
    QSRKKLRME complex binds to DNA; neither
    (C-terminus) Max nor Myc alone exhibit
    (SEQ ID NO:413) appreciable DNA binding.
    DKEKKIKLEEDE Chicken VBP (vitellogenin gene-
    (within an binding protein). Leucine zipper.
    acidic region) Related to rat DBP.
    (SEQ ID NO:414)
    IKKAKKV
    (SEQ ID NO:415)
    TRRKKN
    (SEQ ID NO:416)
    TRDDKRRA Xenopus borealis B1 factor. Closely
    (SEQ ID NO:417) related to the mammalian USF.
    EVERRRRDK Binds to CACGTG in TFIIIA promoter
    (SEQ ID NO:418) to developmentally regulate
    its expression.
    TRDEKRRA Human USF (upstream stimulatory
    (SEQ ID NO:419) factor) activating the major late
    EVERRRRDK adenovirus promoter
    (SEQ ID NO:420)
    YRRYPRRRG YB-1, a protein that binds to the MHC
    (SEQ ID NO:421) class II Y box. YB-1 is a negative
    QRRPYRRRRF regulator.
    (SEQ ID NO:422)
    YRPRFRRG
    (SEQ ID NO:423)
    QRRYRRN
    (SEQ ID NO:424)
    YRRRRP
    (SEQ ID NO:425)
    AKERQKKD Human TFEB Binds to IgH enhancer.
    (SEQ ID NO:426)
    ERRRRF
    (SEQ ID NO:427)
    LKERQKKD Human TFE3 (536 aa). Binds to μE3
    (SEQ ID NO:428) enhancer of IgH genes.
    IERRRRFN
    (SEQ ID NO:429)
    YFRRRRLEKD
    (SEQ ID NO:430)
    KTVALKRRLKASSRL Human Dr1 (176 aa, 19 kD).
    (SEQ ID NO:431) Interacts with TBP (TATA-binding
    protein) thus inhibiting association
    of TFIIA and/or TFIIB with TBP.
    TBP-Dr1 association is affected by
    Dr1 phosphorylation to repress
    activated and basal transcription.
    1 LRRRGRQTY Drosophila ultrabithorax
    (SEQ ID NO:432) protein (from the conserved 61
    27 LTRRRRIEM amino acid homeodomain segment
    (SEQ ID NO:433) only). Conserved in the antenappedia
    51 QNRRMKLKKEI homeodomam protein.
    (SEQ ID NO:434)
    SNRRRPDHR C. elegans sex-determining Tra-1
    (SEQ ID NO:435) protein. Zinc finger. Peaks in the
    VYRGRRRVRRE second larval stage.
    (SEQ ID NO:436)
    P7AP2RRRRSADNKD2
    (SEQ ID NO:437)
    PKKPRHQF
    (SEQ ID NO:438)
    EKRKKERN Yeast NPS1 transcription protein
    (SEQ ID NO:439) factor (1359 aa) involved in cell
    LLRRLKKEVE growth control at G2 phase.
    (SEQ ID NO:440) Has a catalytic domain of
    protein kinases.
    EPLGRIRQKKRVY2D2
    (SEQ ID NO:441)
    (EDAIKKRREARERRRLRQ)
    (SEQ ID NO:442)
    DKETTASRSKRRSSRKKRT
    (SEQ ID NO:443)
    ESKKKKPKL
    (SEQ ID NO:444)
    KKTAAKKTKTKS
    (SEQ ID NO:445)
    QRKRQKL Human 243 transcriptional
    (SEQ ID NO:446) activator (968 aas), induced
    KAKKQK by mitogens
    (SEQ ID NO:447) in T cells. N-terminal half is
    LRRKRQK homologous to oncoprotein Rel and
    (SEQ ID NO:448) Drosophila Dorsal protein
    involved in development. The C-
    terminal half contains repeats
    found in proteins involved in
    cell-cycle control of yeast and
    tissue differentiation in Drosophila.
    RDIRRRGKNKV Mouse NF-E2 (45 kD), an erythroid
    (SEQ ID NO:449) transcription factor from mouse
    erythroleukemia (MEL) cells. Involved
    in globin gene regulation.
    QNCRKRKLE Binds to AP-1-1ike sites.
    (SEQ ID NO:450) Homology to Jun B, GCN4, Fos,
    ATF1 and CREB in basic region/leucine
    zipper (see FIG. 2).
    Group 000x00
    DKIRRKN Human glucocorticoid receptor
    (SEQ ID NO:451)
    ARKTKKKI
    (SEQ ID NO:452)
    473 DKIRRKNCP Mouse and human GR
    (SEQ ID NO:453) (glucocorticoid recptor)
    EARKTKKKIKGIQ
    (SEQ ID NO:454)
    Group 000x0
    YRVRRERN C/EBP (CCAAT/enhancer
    (SEQ ID NO:455) binding protein).
    VRKSRDKA Functions in liver-specific
    (SEQ ID NO:456) gene expression.
    DRLRKRVE
    (SEQ ID NO:457)
    DKIRRKN Human mineralocorticoid receptor
    (SEQ ID NO:458)
    ARKSKKL
    (SEQ ID NO:459)
    DKIRRKN Human PR (progesterone receptor)
    (SEQ ID NO:460)
    GRKFKKF
    (SEQ ID NO:461)
    EEVQRKRQKLMP Human and mouse NFκB 105 kD
    (SEQ ID NO:462) precursor of p50 (968 aas) (first R is at
    361 position).
    EEVQRKRQKL Human NF-κB p50 (DNA-binding
    (SEQ ID NO:463) subunit). Identical to protein
    KBF1, homologous to rel oncogene
    product. NF-κB p65 also
    contains a NLS (Table 3a).
    GKTRTRKQ Human TEF-1 (SV40 transcriptional
    (SEQ ID NO:464) enhancer factor 1). 426 aa.
    ARRKSRD
    (SEQ ID NO:465)
    QRKERKSKS Rat, mouse, human IRF-1 (interferon
    (SEQ ID NO:466) regulatory factor-1). Induced in
    TKSKTKRKL lymphoma T cells by the pituitary
    (SEQ ID NO:467) peptide hormone prolactin.
    Regulates the growth-inhibitory
    interferon genes.
    GKCRKKN Ehrlich ascites S-II transcription factor.
    (SEQ ID NO:468) A general factor that acts at
    the elongation step.
    ERSKKRSRE Tobacco TAF-1 transcriptional activator
    (SEQ ID NO:469)
    ERELKREKRKQ
    (SEQ ID NO:470)
    ARRSRLRKQ
    (SEQ ID NO:471)
    YKLDHMRRRIETDE Drosophila TFIIEα (433 aa), a general
    (SEQ ID NO:472) transcription factor for RNA
    polymerase II. Composed of
    subunits α and β.
    DKNRRKS Human ER (estrogen receptor); 595 aa.
    (SEQ ID NO:473)
    IRKDRRG
    (SEQ ID NO:474)
    IKRSKKN
    (SEQ ID NO:475)
    EQRRHRIE Yeast ADA2 (434 aa), a potential
    (SEQ ID NO:476) transcriptional adaptor required
    TTRAEKKRLL for the function of certain
    (SEQ ID NO:477) acidic activation domains.
    IDKKRSKEAKE
    (SEQ ID NO:478)
    EAALRRKIRTISK Yeast GCN5 gene product (439 aa),
    (SEQ ID NO:479) required for the function of GCN4
    transcriptional activator and for
    the activity of the HAP2-3-4 complex.
    Group 00x00
    NKKMRRNRF Mouse LFB3
    (SEQ ID NO:480)
    NRRKx4RQK
    (SEQ ID NO:481)
    TKKGRRNRF Mouse LFB1
    (SEQ ID NO:482)
    NRRKx4RHK
    (SEQ ID NO:483)
    NKKMRRNRFK rat vHNF1-A
    (SEQ ID NO:484)
    NKKMRRNR murine HNF-1β
    (SEQ ID NO:485)
    TKKGRRNRF mouse HNF-1
    (SEQ ID NO:486)
    NKKMRRNRF human vHNF1
    (SEQ ID NO:487)
    TKKGRRNRF rat liver HNF1
    (SEQ ID NO:488)
    LRRQKRFK rat HNF-3β
    (SEQ ID NO:489)
    QQH3SH4Q
    (SEQ ID NO:490)
    LRRQKRFK rat HNF-3γ
    (SEQ ID NO:491)
    LRRQKRFK rat HNF-3α
    (SEQ ID NO:492)
    LKEKERKA rat DBP a protein factor that
    (SEQ ID NO:493) binds to the D site of the albumin
    MKKARKV gene promoter
    (SEQ ID NO:494)
    PRRERRY rat AT-BP1. Highly acidic domain. Two
    (SEQ ID NO:495) zinc fingers. Binds to the
    B-domain of α1-antitrypsin gene
    promoter and to the NF-κB site in the
    MHC gene enhancer.
    DRRVRKGKV A 19 kD Drosophila melanogaster
    (SEQ ID NO:496) nonhistone associated with
    heterochromatin.
    SKHGRRARRLDP murine EBF (early B-cell factor)
    (SEQ ID NO:497) of 591 aa. Regulates the pre-B and
    B lymphocyte-specific mb-1 gene.
    Expressed in pre-B and B-cell
    lines but not in plasmocytomas,
    T-cell and nonlymphoid cell lines.
    GRRTRRE human Sp1
    (SEQ ID NO:498)
    DEQKRAEKKAKE yeast SNF2, a transcriptional regulator
    (SEQ ID NO:499) of many genes.
    IRRIHKVIRP
    (SEQ ID NO:500)
    LLRRLKKDVE
    (SEQ ID NO:501)
    Group 0x00x0
    AKAKAKKA mouse AGP/EBP (87% similarity to
    (SEQ ID NO:502) C/EBP), ubiquitously expressed
    YKMRRERN
    (SEQ ID NO:503)
    VRKSRDKA
    (SEQ ID NO:504)
    AKAKAKKA rat LAP, a 32-kD liver-enriched
    (SEQ ID NO:505) transcriptional activator, also present
    YKMRRERN in lung, with 71% sequence similarity
    (SEQ ID NO:506) to C/EBP. Leucine zipper.
    VRKSRDKA Accumulates to maximal levels
    (SEQ ID NO:507) around birth.
    YRQRRER Ig/EBP-1 (immunoglobulin gene
    (SEQ ID NO:508) enhancer-binding protein). Forms
    VKKSRLKSKQK heterodimers with C/EBP.
    (SEQ ID NO:509)
    EDPEKEKRIKELE mouse c-Myb
    (SEQ ID NO:510)
    MRRKV
    (SEQ ID NO:511)
    DYYKVKRPKTD Drosophila eyes absent protein (760 aa),
    (SEQ ID NO:512) a nuclear protein that functions in
    GRARGRRHQ early development to prevent
    (SEQ ID NO:513) programmed cell death and to allow the
    FRYRKIKDIY event that generate the eye to proceed.
    (SEQ ID NO:514) Mutations cause programmed cell death
    of eye progenitor cells.
    Group 0x0x00
    AKAKAKKA rat IL-6DBP interacting with
    (SEQ ID NO:515) interleukin-6 responsive elements.
    Has a leucine zipper domain.
    DKRQRNRC mouse H-2RIIBP (MHC class I genes
    (SEQ ID NO:516) H-2 region II binding protein).
    FkrtirkD Member of the nuclear hormone
    receptor superfamily.
    FkrtirkD chicken RXR, related to RAR (retinoic
    DKRQRNRC acid receptor), a nuclear
    (SEQ ID NO:517) protein factor from the thyroid/steroid
    hormone receptor family
    VKSKAKKT human NF-IL6 (345 aa). Specifically
    (SEQ ID NO:518) binds to IL1-responsive
    YKIRRERN element in the IL-6 gene.
    (SEQ ID NO:519) Leucine zipper. Homology to C/EBP.
    VRKSRDKA
    (SEQ ID NO:520)
    QKKNRNKC mouse PPAR (peroxisome proliferator
    (SEQ ID NO:521) activated receptor)
    Group 000xx00
    EQIRKLVKKHG yeast RAP1
    (SEQ ID NO:522) It binds regulatory sites at
    FRRSMKRKA yeast mating type silencers.
    (SEQ ID NO:523) human vitamin D receptor (427 aa)
    Group 00xx00
    LKRHQRRH mouse WT1 (the murine homolog
    (SEQ ID NO:524) of human Wilms' tumor
    predisposition gene WT1)
    LKRHQRRH human WT33 (Wilms' tumor
    (SEQ ID NO:525) predisposition)
    Group 000xx0
    LKESKRKYDE yeast SWI3 99 kD, highly
    (SEQ ID NO:526) acidic protein.
    Global transcription
    activator.
    EVLKVQKRRIYD human RBAP-1 (retinoblastoma-
    (SEQ ID NO:527) associated protein 1) factor (412 aa).
    A protein that binds to the pocket
    (functional domain) of the
    retinoblastoma (RB) protein involved
    in suppression of cell growth
    (tumor suppressor). The transcription
    factor E2F, implicated in cell
    growth, binds to the same pocket of RB.
  • [0187]
    TABLE 10
    NLS in other nuclear proteins
    Putative NLS Protein
    YKSKKKA (SEQ ID NO:528) Yeast L3
    TKKLPRKT (SEQ ID NO:529)
    TRKKGGRRGRRL (SEQ ID NO:530) Yeast 59 ribosomal protein
    C-terminus
    ARATRRKRCKG (SEQ ID NO:531) Yeast L16 ribosomal protein
    GKGKYRNRRW (SEQ ID NO:532) yeast L2 ribosomal protein (homologous to
    Xenopus L1). Encoded by intronless genes.
    GKGKMRNRRRIQRRG (SEQ ID NO:533) Xenopus laevis L1 ribosomal protein (homologous
    NKKVKRRELKKN (SEQ ID NO:534) to yeast L2) Encoded by intronless genes.
    AKTARRKA (SEQ ID NO:535)
    IKAKEKKP (SEQ ID NO:536)
    GKPKAKKP (SEQ ID NO:537)
    AKAKKRQ (SEQ ID NO:538)
    ERKRKS (SEQ ID NO:539) human S6 ribosomal protein (homologous to yeast
    GKRPRTKA (SEQ ID NO:540) S10)
    HKRRRI (SEQ ID NO:541)
    LKKQRTKKNKE (SEQ ID NO:542)
    PKMRRRTYR (SEQ ID NO:543) Rat L17 ribosomal protein (184 aas)
    KKKISQKKLKK (SEQ ID NO:544)
    YMRRRTYRA (SEQ ID NO:545) Podocoryne carnea (hydrozoan, Coelenteratum)
    EVKKVSKKKL (SEQ ID NO:546) L17 ribosomal protein (184 aas) highly
    homologous to rat L17.
    ERNRKDKDAKFR (SEQ ID NO:547) human, rat ribosomal S13 protein
    ERKRKS (SEQ ID NO:548) yeast S10 ribosomal protein (homologous to human
    QRLQRKRH (SEQ ID NO:549) S6)
    IRKRRA (SEQ ID NO:550)
    GRRRKKHRSRSRSRERRSRSRDRGRG12GRER 35 kD subunit of U2 small nuclear
    DRRRSRDRER (SEQ ID NO:551) ribonucleoprotein auxiliary factor (U2AF), an
    essential mammalian splicing factor. U2AF35
    interacts with the 65 kD subunit (U2AF65). Both
    proteins are concentrated in a small number of
    subnuclear organelles, the coiled bodies.
    EFEDPRD (SEQ ID NO:552) human UsnRNP-associated 70 k protein (437 aas)
    ETREERME (SEQ ID NO:553) that is phosphorylated at Arg/Ser-rich domains;
    EAGDAPPDP (SEQ ID NO:554) involved in splicing
    EERMERKRREK (SEQ ID NO:555)
    HRDRDRDRERERRESRERDKERERRRSRSRD
    RRRRSRSRDKEERRRSRERSKDKDRDRKRRS
    SRSRERARRERERKEE (SEQ ID NO:556)
    RDRDRERRRSHRSERERRRDRDRDRDRDREH
    KRGER (SEQ ID NO:557)
    QKRNNKKSKKKRCAE (SEQ ID NO:558) yeast TRM1 enzyme for the N2, N2-
    EKLRKLKI (near C-terminus) (SEQ ID NO:559) dimethylguanosine modification of both
    mitochondrial and cytoplasmic tRNAs. TRM1 is
    both nuclear and mitochondrial. The first motif is
    within a region (70-213 aa segment) known to
    cause nuclear localization of β-galactosidase.
    NKRKRV (SEQ ID NO:560) Yeast nucleoporin NUP1 (1076 aa, 113 kD); an
    SLKINRSNRKRE (SEQ ID NO:561) integral component of the pore complex. Involved
    EPKRKRRLP (SEQ ID NO:562) in both binding and translocation steps of nuclear
    ARMRHSKR (C-terminus) (SEQ ID NO:563) import.
    KAEKEx3KVD2E2 (SEQ ID NO:564) Chicken, Xenopus No 38 nucleolar (38 kD);
    Kx3Kx5Kx3R (SEQ ID NO:565) involved in intranuclear packaging of preribosomal
    particles. Shuttles between nucleus and cytoplasm.
    KTEREAEKALEEKx7R (SEQ ID NO:566) Chicken, hamster nucleolin (92 kD). Binds
    Kx5Kx7Kx4RX3EDTTEETLR (SEQ ID NO:567) preribosomal RNA. Shuttles between nucleus and
    RG2RG2RG3RG2FG2RG3RGFG2RG3FRG2RG4 cytoplasm.
    DHKPQGKKIKFE (SEQ ID NO:568)
    (C-terminus)
    WYKHFKKTKD (SEQ ID NO:569) human SATB1 (763 aa) which binds selectively to
    AT-rich MARs with mixed
    A, T, C on one strand excluding G. Binds to minor
    groove with little contact with bases.
    QKKKQMKAD (SEQ ID NO:570) yeast CBF5p, a centromere-binding protein
    (KKEKKE)5 (SEQ ID NO:571) (55kDa, 483aa). The
    KKEKKRKSED (SEQ ID NO:572) KKE repeat at its C-terminus
    EEKKSKKSKK (SEQ ID NO:573) occurs in microtubule-binding domains; yeast cells
    containing only three copies of the KKE repeat of
    CBF5p delay at G2/M; depletion of CBE5p arrests
    cells at G1/S.
    TKKKSFKL (SEQ ID NO:574) yeast CCE1, a cruciform cutting endonuclease
    KSERERMLRESLKEERRRF (SEQ ID NO:575) rat nucleoporin 155 or Nup155 (1390 aas, 155
    kDa), a protein of the nuclear pore complex;
    contains 46 consensus sites for various kinases;
    associated with both the nucleoplasmic and the
    cytoplasmic region of pores.
    PKKGSKKA (SEQ ID NO:576) human H2B variant differentially expressed during
    DGKKRKRSRKES (SEQ ID NO:577) the cell cycle
    GAKRHRKVLRD (SEQ ID NO:578) Calf thymus histone H4
    14-24 (102 aa)
    PAIRRLARRG (SEQ ID NO:579)
    32-41
    EHARRKT (SEQ ID NO:580)
    74-80
    ARRIRGERA 127-135 (SEQ ID NO:581) Calf thymus H3
    (135 aa)
    GSHHKAKGK 121-129 (SEQ ID NO:582) Calf thymus H2A
    (129 aa)
    RGKSGKARTKAKSRSSR 3-19 (SEQ ID Sea urchin Psammechinus miliaris H2A (123 aa)
    NO:583)
    PKKGSKKA 10-17 (SEQ ID NO:584) Calf thymus H2B
    QKKDGKKRKRSRKES 22-36 (SEQ ID NO:585) (125 aa)
    GGKKRHRKRKGSY (SEQ ID NO:586) Sea urchin Psammechinus miliaris H2B (122 aa)
    22-34
    PRTDKKRRRKRKES 19-32 (SEQ ID NO:587) Starfish H2B
    (121 aa)
    PAKAPKKKA 12-20 (SEQ ID NO:588) Trout testis H1
    EAKKPAKKA 104-112 (SEQ ID NO:589) (194 aa)
    AKKPKKV 128-134 (SEQ ID NO:590)
    AKKSPKKAKKP 142-152 (SEQ ID NO:591)
    PKKVKKP 183-189 (SEQ ID NO:592)
    PRRKAKRA 30-37 (SEQ ID NO:593) Sea urchin Parechinus angulosus sperm H1 (248
    PKKAKKT 119-125 (SEQ ID NO:594) aa)
    AKAKKAKA 129-136 (SEQ ID NO:595)
    AKKARKAKA 139-147 (SEQ ID NO:596)
    AKKAKKPKKKA 171-181 (SEQ ID NO:597)
    AKKAKKPAKK 182-191 (SEQ ID NO:598)
    SPKKAKKP 192-199 (SEQ ID NO:599)
    AKKSPKKKKAKRS 200-212 (SEQ ID NO:600)
    PKKAKKA 213-219 (SEQ ID NO:601)
    AKKAKKS 227-233 (SEQ ID NO:602)
    PRKAGKRRSPKKARK 234-248 (SEQ ID
    NO:603)
    ARRRKTA 1-7 (SEQ ID NO:604) Annelid sperm H1a
    IRKFIRKA 55-61 (SEQ ID NO:605) (119 aa)
    PKKKKA 83-88 (SEQ ID NO:606)
    AKKPKAKKVKKP 89-100 (SEQ ID NO:607)
    AKKKTNRARKPKTKKNR 104-120 (SEQ ID
    NO:608)
    PKRKVSS 1-7 (SEQ ID NO:609) Calf thymus HMG14
    EEPKRRSARLS 14-24 (SEQ ID NO:610) (100 aa)
    PKRKAEGDAK 1-10 (SEQ ID NO:611) Calf thymus HMG17
    PKGKKGKA 52-59 (SEQ ID NO:612) (89aa; 9,247 D)
    PKKPRGKM (SEQ ID NO:613) Calf thymus HMG 1
    EHKKKHP (SEQ ID NO:614) (259 aa)
    ETKKKFKDP (SEQ ID NO:615)
    EKSKKKK(E/D)41 (SEQ ID NO:616)
    E3G2KKKKKFAK (SEQ ID NO:617)
    EHKKKHP (SEQ ID NO:618) Calf thymus HMG 2
    PKGDKKGKKKDP (SEQ ID NO:619) (256 aa)
    E4G3KKKKKFAK (SEQ ID NO:620)
    PKRKSATKGDEPARR 1-15 (SEQ ID NO:621) Trout testis H6 (60 aa)
    KPKKAAAPKKA 30-34 (SEQ ID NO:622)
    • REFERENCES
  • U.S. Patent Documents [0188]
  • U.S. Pat. No. 4,394,448 July, 1983 Szoka, Jr. et al. [0189]
  • U.S. Pat. No. 4,598,051 July, 1986 Papahadjopoulos et al. [0190]
  • U.S. Pat. No. 5,013,556 May, 1991 Woodle et al. [0191]
  • Journal Articles [0192]
  • Allen, T. M. and Chonn, A. (1987) “Large unilamellar liposomes with low uptake into the reticuloendothelial system” [0193] FEBS Lett. 223:42-46.
  • Allen, T. M. et al. (1991) “Liposomes containing synthetic lipid derivatives of polyethylene glycol show prolonged circulation half-lives in vivo” [0194] Biochim. Biophys. Acta 1066:29-36.
  • Anderson, W. F. (1992) “Human gene therapy” [0195] Science 256:808-813.
  • Aoki, K. et al. (1995) “Liposome-mediated in vivo gene transfer of antisense K-ras construct inhibits pancreatic tumor dissemination in the murine peritoneal cavity” [0196] Cancer Res. 55:3810-3816.
  • Arcasoy, S. M. et al. (1997) “Polycations increase the efficiency of adenovirus-mediated gene transfer to epithelial and endothelial cells in vitro” [0197] Gene Ther. 4:32-38.
  • Beauchamp, C. O. et al. (1983) “A new procedure for the synthesis of polyethylene glycol-protein adducts; effects on function, receptor recognition, and clearance of superoxide dismutase, lactoferrin, and alpha 2-macroglobulin” [0198] Anal. Biochem. 131:25-33.
  • Bongartz, J. -P. et al. (1994) “Improved biological activity of antisense oligonucleotides conjugated to a fusogenic peptide” [0199] Nucl. Acids Res. 22:4681-4688.
  • Boulikas, T. (1993) “Nuclear localization signals (NLS)” [0200] Crit. Rev. Eukar. Gene Expression 3:193-227.
  • Boulikas, T. (1994) “Putative nuclear localization signals (NLS) in protein transcription factors” [0201] J. Cell. Biochem. 55:32-58.
  • Boulikas, T. (1996a) “Cancer gene therapy and immunotherapy” [0202] Intl. J. Oncol. 9:941-954.
  • Boulikas, T. (1996b) “Gene therapy to human diseases: ex vivo and in vivo studies” [0203] Intl. J. Oncol. 9:1239-1251.
  • Boulikas, T. (1996c) “Liposome DNA delivery and uptake by cells” [0204] Oncol. Rep. 3:989-995.
  • Boulikas, T. (1996d) “Nuclear import of protein kinases and cyclins” [0205] J. Cell. Biochem. 60:61-82.
  • Boulikas, T. (1997a) “Gene therapy of prostate cancer: p53, suicidal genes, and other targets” [0206] Anticancer Res. 17:1471-1506.
  • Boulikas, T. (1997b) “Nuclear import of DNA repair proteins” [0207] Anticancer Res. 17:843-864.
  • Boulikas, T. (1997c) “Nuclear localization signal peptides for the import of plasmid DNA in gene therapy” [0208] Int. J. Oncol. 10:301-309.
  • Boulikas, T. (1998a) “Status of gene therapy in 1997: Molecular mechanisms, disease targets, and clinical applications” [0209] Gene Ther. Mol. Biol. 1:1-172.
  • Boulikas, T. (1998b) “Nucleocytoplasmic trafficking: implications for the nuclear import of plasmid DNA during gene therapy” [0210] Gene Ther. Mol. Biol. 1:713-740.
  • Boulikas, T. and Martin, F. (1997) “Histones, protamine, and polylysine but not poly(E:K) enhance transfection efficiency” [0211] Int. J. Oncol. 10:317-322.
  • Capaccioli, S. et al. (1993) “Cationic lipids improve antisense oligonucleotide uptake and prevent degradation in cultured cells and in human serum” [0212] Biochem. Biophys. Res. Comm. 197:818-825.
  • Creuzenet, C. et al. (1997) “Interaction of alpha s2- and beta-casein signal peptides with DMPC and DMPG liposomes” [0213] Peptides 18:463-472.
  • Culver, K. W. (1996) in: Gene Therapy: A primer for physicians, Second Edition. Mary Ann Liebert, Inc. Publications, NY, pp. 1-198. [0214]
  • Curtain, C. et al. (1999) “The interactions of the N-terminal fusogenic peptide of HIV-1 gp41 with neutral phospholipids” [0215] Eur. Biophys. J 28:427-436.
  • de la Maza, A. et al. (1998) “Solubilization of phosphatidylcholine liposomes by the amphoteric surfactant dodecyl betaine” [0216] Chem. Phys. Lipids 94:71-79.
  • Decout, A. et al. (1999) “Contribution of the hydrophobicity gradient to the secondary structure and activity of fusogenic peptides” [0217] Mol. Membr. Biol. 16:237-246.
  • Duguid, J. G. et al. (1998) “A physicochemical approach for predicting the effectiveness of peptide-based gene delivery systems for use in plasmid-based gene therapy” [0218] Biophys. J. 74:2802-2814.
  • Filion, M. C. and Phillips, N. C. (1997) “Toxicity and immunomodulatory activity of liposomal vectors formulated with cationic lipids toward immune effector cells” [0219] Biochim. Biophys. Acta 1329:345-356.
  • Fresta, M. et al. (1998) “Liposomal delivery of a 30-mer antisense oligodeoxynucleotide to inhibit proopiomelanocortin expression” [0220] J. Pharm. Sci. 87:616-625.
  • Gabizon, A. and Papahadjopoulos, D. (1988) “Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors” [0221] Proc. Natl. Acad. Sci. USA 85:6949-6953.
  • Gabizon, A. et al. (1989) “Pharmacokinetics and tissue localization of doxorubicin encapsulated in stable liposomes with long circulation times” [0222] J. Natl. Cancer Inst. 81:1484-1488.
  • Ghosh, J. K. and Shai, Y. (1999) “Direct Evidence that the N-Terminal Heptad Repeat of Sendai Virus Fusion Protein Participates in Membrane Fusion” [0223] J. Mol. Biol. 292:531-546.
  • Green, M. and Loewenstein, P. M. (1988) “Autonomous functional domains of chemically synthesized human immunodeficiency virus tat transactivator protein” [0224] Cell 55:1179-1188.
  • Gupta, D. and Kothekar, V. (1997) “500 picosecond molecular dynamics simulation of amphiphilic polypeptide Ac(LKKL)[0225] 4 NHEt with 1,2 di-mysristoyl-sn-glycero-3-phosphorylcholine (DMPC) molecules” Indian J. Biochem. Biophys. 34:501-511.
  • Hofland, H. E. J. et al. (1996) “Formation of stable cationic lipid/DNA complexes for gene transfer” [0226] Proc. Natl. Acad. Sci. USA 93:7305-7309.
  • Jaaskelainen, I. et al. (1994) “Oligonucleotide-cationic liposome interactions. A physicochemical study” [0227] Biochim. Biophys. Acta 1195:115-123.
  • Judice, J. K. et al. (1997) “Inhibition of HIV type 1 infectivity by constrained alpha-helical peptides: implications for the viral fusion mechanism” [0228] Proc. Natl. Acad. Sci. USA 94:13426-13430.
  • Kono, K. et al. (1993) “Fusion activity of an amphiphilic polypeptide having acidic amino acid residues: generation of fusion activity by alpha-helix formation and charge neutralization” [0229] Biochim. Biophys. Acta 1164:81-90.
  • Lambert, G. et al. (1998) “The C-terminal helix of human apolipoprotein AII promotes the fusion of unilamellar liposomes and displaces apolipoprotein AI from high-density lipoproteins” [0230] Eur. J. Biochem. 253:328-338.
  • Lambert, O. et al. (1998) “A new “gel-like” phase in dodecyl maltoside-lipid mixtures: implications in solubilization and reconstitution studies” [0231] Biophys. J. 74:918-930.
  • Lappalainen, K. et al. (1997) “Intracellular distribution of oligonucleotides delivered by cationic liposomes: light and electron microscopic study” [0232] Histochem. Cytochem. 45:265-274.
  • Lasic, D. (1997) in: Liposomes in Gene Delivery, CRC Press, pp. 1-295. [0233]
  • Lee, S. et al. (1992) “Effect of amphipathic peptides with different alpha-helical contents on liposome-fusion” [0234] Biochim. Biophys. Acta 1103:157-162.
  • Lelkes, P. I. and Lazarovici, P. (1988) “Pardaxin induces aggregation but not fusion of phosphatidylserine vesicles” [0235] FEBS Lett. 230:131-136.
  • Leonard, A. N. and Cohen, D. E. (1998) “Submicellar bile salts stimulate phosphatidylcholine transfer activity of sterol carrier protein 2[0236] ” J. Lipid Res. 39:1981-1988.
  • Lewis, J. G. et al. (1996) “A serum-resistant cytofectin for cellular delivery of antisense oligodeoxynucleotides and plasmid DNA” [0237] Proc. Natl. Acad. Sci. USA 93:3176-3181.
  • Li, S. and Huang, L. (1997) “In vivo gene transfer via intravenous administration of cationic lipid-protamine-DNA (LPD) complexes” [0238] Gene Ther. 4:891-900.
  • Lins, L. et al. (1999) “Molecular determinants of the interaction between the C-terminal domain of Alzheimer's beta-amyloid peptide and apolipoprotein E alpha-helices” [0239] J. Neurochem. 73:758-769.
  • Litzinger, D. C. et al. (1996) “Fate of cationic liposomes and their complex with oligonucleotide in vivo” [0240] Biochim. Biophys. Acta 1281:139-149.
  • Lopez, O. et al. (1998) “Direct formation of mixed micelles in the solubilization of phospholipid liposomes by Triton X-100[0241] ” FEBS Lett. 426:314-318.
  • Lusa, S. et al. (1998) “Direct observation of lipoprotein cholesterol ester degradation in lysosomes” [0242] Biochem. J 332:451-457.
  • Macosko, J. C. et al. (1997) “The membrane topology of the fusion peptide region of influenza hemagglutinin determined by spin-labeling EPR” [0243] J. Mol. Biol. 267:1139-1148.
  • Macreadie, I. G. et al. (1997) “Cytotoxicity resulting from addition of HIV-1 Nef N-terminal peptides to yeast and bacterial cells” [0244] Biochem. Biophys. Res. Commun. 232:707-711.
  • Martin, F. and Boulikas, T. (1998) “The challenge of liposomes in gene therapy” [0245] Gene Ther. Mol. Biol 1: 173-214.
  • Martin, I. et al. (1999) “Membrane fusion induced by a short fusogenic peptide is assessed by its insertion and orientation into target bilayers” [0246] Biochemistry 38:9337-9347.
  • Martin, I. and Ruysschaert, J. M. (1997) “Comparison of lipid vesicle fusion induced by the putative fusion peptide of fertilin (a protein active in sperm-egg fusion) and the NH2-terminal domain of the HIV2 gp41[0247] ” FEBS Lett. 405:351-355.
  • Massari, S. and Colonna, R. (1986) “Gramicidin induced aggregation and size increase of phosphatidylcholine vesicles” [0248] Chem. Phys. Lipids 39:203-220.
  • Melino, S. et al. (1999) “Zn(2+) ions selectively induce antimicrobial salivary peptide histatin-5 to fuse negatively charged vesicles. Identification and characterization of a zinc-binding motif present in the functional domain” [0249] Biochemistry 38:9626-9633.
  • Midoux, P. and Monsigny, M. (1999) “Efficient gene transfer by histidylated polylysine/pDNA complexes” [0250] Bioconjug. Chem. 10:406-411.
  • Murata, M. et al. (1991) “Modification of the N-terminus of membrane fusion-active peptides blocks the fusion activity” [0251] Biochem. Biophys. Res. Commun. 179:1050-1055.
  • Niidome, T. et al. (1997) “Membrane interaction of synthetic peptides related to the putative fusogenic region of PH-30 alpha, a protein in sperm-egg fusion” [0252] J. Peptide Res. 49:563-569.
  • Pak, C. C. et al. (1999) “Elastase activated liposomal delivery to nucleated cells” [0253] Biochim. Biophys. Acta 1419:111-126.
  • Papahadjopoulos, D. et al. (1991) “Sterically stabilized liposomes: Improvements in pharmacokinetics and antitumor therapeutic efficacy” [0254] Proc. Natl. Acad. Sci. USA 88:11460-11464.
  • Parente, R. A. et al. (1988) “pH-dependent fusion of phosphatidylcholine small vesicles. Induction by a synthetic amphipathic peptide” [0255] J. Biol. Chem. 263:4724-4730.
  • Partidos, C. D. et al. (1996) “Priming of measles virus-specific CTL responses after immunization with a CTL epitope linked to a fusogenic peptide” [0256] Virology 215:107-110.
  • Pecheur, E. I. et al. (1997) “Membrane anchorage brings about fusogenic properties in a short synthetic peptide” [0257] Biochemistry 36:3773-3781.
  • Peelman, F. et al. (1999) “Characterization of functional residues in the interfacial recognition domain of lecithin cholesterol acyltransferase (LCAT)” [0258] Protein Eng. 12:71-78.
  • Pereira, F. B. et al. (1997) “Permeabilization and fusion of uncharged lipid vesicles induced by the HIV-1 fusion peptide adopting an extended conformation: dose and sequence effects” [0259] Biophys. J. 73:1977-1986.
  • Pillot, T. et al. (1999) “The nonfibrillar amyloid beta-peptide induces apoptotic neuronal cell death: involvement of its C-terminal fusogenic domain” [0260] J. Neurochem. 73:1626-1634.
  • Pillot, T. et al. (1997) “Specific modulation of the fusogenic properties of the Alzheimer beta- amyloid peptide by apolipoprotein E iso forms” [0261] Eur. J. Biochem. 243:650-659.
  • Pillot, T. et al. (1997) “The 118-135 peptide of the human prion protein forms amyloid fibrils and induces liposome fusion” [0262] J. Mol. Biol. 274:381-393.
  • Plank, C. et al. (1996) “Activation of the complement system by synthetic DNA complexes: a potential barrier for intravenous gene delivery” [0263] Hum. Gene Ther. 7:1437-1446.
  • Rodriguez-Crespo, I. et al. (1994) “Prediction of a putative fusion peptide in the S protein of hepatitis B virus” [0264] J. Gen. Virol. 75:637-639.
  • Rodriguez-Crespo, I. et al. (1999) “Fusogenic activity of hepadenavirus peptides corresponding to sequences downstream of the putative cleavage site” [0265] Virology 261:133-142.
  • Ross, G. et al. (1996) “Gene therapy in the United States: a five-year status report” [0266] Hum. Gene Ther. 7:1781-1790.
  • Schroeder, F. et al. (1990) “Intermembrane cholesterol transfer: role of sterol carrier proteins and phosphatidylserine” [0267] Lipids 25:669-674.
  • Schroth-Diez, B. et al. (1998) “Fusion activity of transmembrane and cytoplasmic domain chimeras of the influenza virus glycoprotein hemagglutinin” [0268] J. Virol. 72:133-141.
  • Schutze, W. and Muller-Goymann, C. C. (1998) “Phase transformation of a liposomal dispersion into a micellar solution induced by drug-loading” [0269] Pharm. Res. 15:538-543.
  • Song, Y. K. et al. (1997) “Characterization of cationic liposome-mediated gene transfer in vivo by intravenous administration” [0270] Hum. Gene Ther. 8:1585-1594.
  • Sorgi, F. L. et al. (1997) “Protamine sulfate enhances lipid-mediated gene transfer” [0271] Gene Ther. 4:961-968.
  • Suenaga, M. et al. (1989) “Basic amphipathic helical peptides induce destabilization and fusion of acidic and neutral liposomes” [0272] Biochim. Biophys. Acta 981:143-150.
  • Takle, G. B. et al. (1997) “Delivery of oligoribonucleotides to human hepatoma cells using cationic lipid particles conjugated to ferric protoporphyrin IX (heme)” [0273] Antisense Nucleic Acid Drug Dev. 7:177-185.
  • Templeton, N. S. et al. (1997) “Improved DNA: liposome complexes for increased systemic delivery and gene expression” [0274] Nature Biotechnol. 15:647-652.
  • Thierry, A.R. and Dritschilo, A. (1992) “Intracellular availability of unmodified, phosphorothioated and liposomally encapsulated oligodeoxynucleotides for antisense activity” [0275] Nucl. Acids Res. 20:5691-5698.
  • Tirosh, 0. et al. (1998) “Hydration of polyethylene glycol-grafted liposomes” [0276] Biophys. J. 74:1371-1379.
  • Torchilin, V. P. (1998) “Polymer-coated long-circulating microparticulate pharmaceuticals” [0277] J. Microencapsul. 15:1-19.
  • Torchilin, V. P. et al. (1992) “Targeted accumulation of polyethylene glycol-coated immunoliposomes in infarcted rabbit myocardium” [0278] FASEB J 6:2716-2719.
  • Toumois, H. et al. (1990) “Gramicidin A induced fusion of large unilamellar dioleoylphosphatidylcholine vesicles and its relation to the induction of type II nonbilayer structures” [0279] Biochemistry 29:8297-8307.
  • Ulrich, A. S. et al. (1999) “Ultrastructural characterization of peptide-induced membrane fusion and peptide self-assembly in the lipid bilayer” [0280] Biophys. J. 77:829-841.
  • Voneche, V. et al. (1992) “The 19-27 amino acid segment of gp51 adopts an amphiphilic structure and plays a key role in the fusion events induced by bovine leukemia virus” [0281] J. Biol. Chem. 267:15193-15197.
  • Wattiaux, R. et al. (1997) “Cationic lipids destabilize lysosomal membrane in vitro” [0282] FEBS Lett. 417:199-202.
  • Weissig, V. et al. (1998) “Accumulation of protein-loaded long-circulating micelles and liposomes in subcutaneous Lewis lung carcinoma in mice” [0283] Pharm. Res. 15:1552-1556.
  • Zelphati, O. and Szoka, Jr., F. C. (1997) “Intracellular distribution and mechanism of delivery of oligonucleotides mediated by cationic lipids” [0284] Pharm. Res. 13:1367-1372.
  • Zuidam, N. J. and Barenholz, Y. (1997) “Electrostatic parameters of cationic liposomes commonly used for gene delivery as determined by 4-heptadecyl-7-hydroxycoumarin” [0285] Biochim. Biophys. Acta 1329:211-222.

Claims (42)

What is claimed is:
1. A method for producing micelles with entrapped therapeutic agents, comprising:
a) combining an effective amount of a negatively charged therapeutic agent with an effective amount of a cationic lipid in a ratio where about 30% to about 90% the negatively charged atoms are neutralized by positive charges on lipid molecules to form an electrostatic micelle complex in about 20% to about 80% ethanol; and
b) combining the micelle complex of step a) with an effective amount of a fusogenic-karyophilic peptide conjugates in a ratio range of about 0.0 to about 0.3, thereby producing micelles with entrapped therapeutic agents.
2. The method of claim 1, wherein the negatively charged therapeutic agent is a therapeutic agent selected from the group consisting of a polynucleotide and a negatively charged drug.
3. The method of claim 2, wherein the polynucleotide is a DNA polynucleotide or an RNA polynucleotide.
4. The method of claim 2, wherein the polynucleotide is a DNA polynucleotide.
5. The method of claim 4, wherein the DNA polynucleotide comprises plasmid DNA.
6. The method of claim 1, further comprising combining an effective amount of an anionic lipid in step a).
7. The method of claim 6, wherein the anionic lipid is dipalmitoyl phosphatidyl glycerol (DDPG) or a derivative thereof.
8. The method of claim 4, further comprising combining an effective amount of a DNA condensing agent selected from the group consisting of spermine, spermidine, polylysine, polyarginine, polyhistidine, polyornithine and magnesium or a divalent metal ion.
9. The method of claim 5, wherein the plasmid DNA comprises a sequence encoding p53, HSV-tk, p21, Bax, Bad, IL-2, IL-12, GM-CSF, angiostatin, endostatin and oncostatin.
10. The method of claim 1, wherein the cationic lipids are selected from the group consisting of 3β-(N—(N′,N′-dimethylaminoethane)carbamoyl)cholesterol, dimethyldioctadecyl ammonium bromide (DDAB), N-[1-(2,3-dimyristyloxy)propyl]-N,N-dimethyl-N-(2-hydroxyethyl) ammonium bromide (DMRIE), 1 ,2-dimyristoyl-3-trimethylammonium propane (DMTAP), dioctadecylamidoglycylspermine (DOGS), N-(1-(2,3-dioleoyloxy)propyl)-N,N,N-trimethylammonium chloride (DOTMA), 1,2- dipalmitoyl-3-trimethylammonium propane (DPTAP), 1 ,2-disteroyl-3-trimethylammonium propane (DSTAP).
11. The method of claim 10, wherein the cationic lipids are combined with the fusogenic lipid DOPE in a molar ratio from about 1:1 to about 2:1.
12. The method of claim 11, wherein the cationic lipids are combined with the fusogenic lipid DOPE in a molar ratio of 1:1.
13. The method of claim 1, wherein the fusogenic-karyophilic peptide is an NLS peptide.
14. The method of claim 13, wherein the NLS peptide is a peptide selected from the group consisting of Seq. ID Nos. 20-622.
15. The method of claim 1, wherein the fusogenic-karyophilic peptide conjugate is a sole fusogenic peptide.
16. The method of claim 1, wherein the NLS peptide component of the fusogenic-karyophilic peptide conjugate is an NLS peptide selected from the group consisting of Seq. ID Nos. 20-622.
17. The method of claim 1, wherein the fusogenic/NLS peptide conjugates comprise amino acid sequences selected from the group consisting of (KAWLKAF)3 (SEQ ID NO:1), GLFKAAAKLLKSLWKLLLKA (SEQ ID NO:2), LLLKAFAKLLKSLWKLLLKA (SEQ ID NO:3) as well as all derivatives of the prototype (Hydrophobic3Karyophilic1Hydrophobic2Karyophilicl)2-3 where Hydrophobic is any of the A, I, L, V, P, G, W, F and Karyophilic is any of the K, R, or H, containing a positively-charged residue every 3rd or 4th amino acid, that form alpha helices and direct a net positive charge to the same direction of the helix.
18. The method of claim 1, wherein the fusogenic/NLS peptide conjugate comprise an amino acid sequence selected from the group consisting of GLFKAIAGFIKNGWKGMIDGGGYC (SEQ ID NO:4) from influenza virus hemagglutinin HA-2 and YGRKKRRQRRR (SEQ ID NO:5) from TAT of HIV.
19. The method of claim 1, wherein the fusogenic/NLS peptide conjugate comprise an amino acid sequence selected from the group consisting of MSGTFGGILAGLIGLL(K/R/H)1-6 (SEQ ID NO:6), derived from the N-terminal region of the S protein of duck hepatitis B virus but with the addition of one to six positively-charged lysine, arginine or histidine residues, and combinations of these, GAAIGLAWIPYFGPAA (SEQ ID NO:7) derived from the fusogenic peptide of the Ebola virus transmembrane protein; residues 53-70 (C-terminal helix) of apolipoprotein (apo) All peptide, the 23-residue fusogenic N-terminal peptide of HIV-1 transmembrane glycoprotein gp41, the 29-42-residue fragment from Alzheimer's beta-amyloid peptide, the fusion peptide and N-terminal heptad repeat of Sendai virus, the 56-68 helical segment of lecithin cholesterol acyltransferase.
20. The method of any of claims 13 to 19, wherein the NLS peptide component in fusogenic/NLS peptide conjugates are synthetic peptides containing the above said NLS but further modified by additional K, R, H residues at the central part of the peptide or with P or G at the N- or C-terminus.
21. The method of claim 13, wherein the fusogenic peptide/NLS peptide conjugates are linked to each other with a short amino acid stretch representing an endogenous protease cleavage site.
22. The method of claim 1, wherein the structure of the preferred prototype fusogenic/NLS peptide conjugate used in this invention is: PKKRRGPSP(L/A/I)12-20 (SEQ ID NO:8) where (L/A/I)12-20 is a stretch of 12-20 hydrophobic amino acids containing A, L, I, Y, W, F and other hydrophobic amino acids.
23. The method of claim 1, wherein the fusogenic/NLS peptide conjugates are added to the mixture of DNA/cationic lipid and are incorporated into micelles.
24. The method of claim 1, further comprising combining an effective amount of an encapsulating lipid solution to step b).
25. The method of claim 24, wherein the encapsulating lipid is a lipid comprising cholesterol (40%), dioleoylphosphatidylethanolamine (DOPE) (20%), palmitoyloleoylphosphatidylcholine (POPC) (12%), hydrogenated soy phosphatidylcholine (HSPC) (10%), distearoylphosphatidylethanolamine (DSPE) (10%), sphingomyelin (SM) (5%), and derivatized vesicle-forming lipid M-PEG-DSPE (3%).
26. The method of claim 24, wherein the encapsulating lipid is a liposome.
27. The method of claim 26, wherein the liposomes comprises vesicle-forming lipids and between about 1 to about 7 mole percent of distearoylphosphatidyl ethanolamine (DSPE) derivatized with an effective amount of polyethyleneglycol.
28. The method of claim 27, wherein the liposomes have a selected average size of about 80 to about 160 nm.
29. The method of claim 27, wherein the polyethyleneglycol has a molecular weight from about 1,000 to about 5,000 daltons.
30. A micelle with an entrapped therapeutic agent produced by the method of claim 1.
31. A liposome encapsulated therapeutic agent produced by the method of claim 24.
32. The method of claim 31, wherein the therapeutic agent further comprises regulation by a liver, spleen or bone marrow regulatory DNA sequence.
33. The method of claim 32, wherein the regulatory DNA sequence is nuclear matrix DNA isolated from liver, spleen or bone marrow cells.
34. A method for delivering a therapeutic agent in vivo, comprising administration of an effective amount of the micelle of claim 30 to a subject.
35. The method of claim 34, wherein the therapeutic agent further comprises regulation by a tumor-specific regulatory DNA sequence.
36. The method of claim 35, wherein the tumor-specific regulatory sequence is nuclear matrix DNA isolated from specific tumor cells.
37. A method for delivering a therapeutic agent in vivo, comprising administration of an effective amount of the liposome encapsulated agent of claim 31 to the subject.
38. The method of claim 34 or 37, wherein the administration is intravenous administration or by injection.
39. A micelle with an entrapped DNA polynucleotide produced by the method of claim 9.
40. A method for reducing tumor size in a subject comprising administration of an effective amount of the micelle of claim 39 to the subject.
41. The method of claim 40, further comprising administration of an effective amount of a second therapeutic agent, wherein the agent is selected from the group consisting of ganciclovir, 5-fluorocytosine, an antisense oligonucleotides a ribozyme, and a triplex-forming oligonucleotide directed against genes that control the cell cycle or signaling pathways.
42. The method of claim 41, further comprising administration of an effective amount of a second therapeutic agent, wherein the second therapeutic agent is selected from the group consisting of adriamycin, angiostatin, azathioprine, bleomycin, busulfane, camptothecin, carboplatin, carmustine, chlorambucile, chlormethamine, chloroquinoxaline sulfonamide, cisplatin, cyclophosphamide, cycloplatam, cytarabine, dacarbazine, dactinomycin, daunorubicin, didox, doxorubicin, endostatin, enloplatin, estramustine, etoposide, extramustinephosphat, flucytosine, fluorodeoxyuridine, fluorouracil, gallium nitrate, hydroxyurea, idoxuridine, interferons, interleukins, leuprolide, lobaplatin, lomustine, mannomustine, mechlorethamine, mechlorethaminoxide, melphalan, mercaptopurine, methotrexate, mithramycin, mitobronitole, mitomycin, mycophenolic acid, nocodazole, oncostatin, oxaliplatin, paclitaxel, pentamustine, platinum-triamine complex, plicamycin, prednisolone, prednisone, procarbazine, protein kinase C inhibitors, puromycine, semustine, signal transduction inhibitors, spiroplatin, streptozotocine, stromelysin inhibitors, taxol, tegafur, telomerase inhibitors, teniposide, thalidomide, thiamiprine, thioguanine, thiotepa, tiamiprine, tretamine, triaziquone, trifosfamide, tyrosine kinase inhibitors, uramustine, vidarabine, vinblastine, vinca alcaloids, vincristine, vindesine, vorozole, zeniplatin, zeniplatin, and zinostatin.
US09/876,904 2000-06-09 2001-06-08 Encapsulation of plasmid DNA (lipogenes™) and therapeutic agents with nuclear localization signal/fusogenic peptide conjugates into targeted liposome complexes Abandoned US20030072794A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US09/876,904 US20030072794A1 (en) 2000-06-09 2001-06-08 Encapsulation of plasmid DNA (lipogenes™) and therapeutic agents with nuclear localization signal/fusogenic peptide conjugates into targeted liposome complexes
US12/830,118 US20120183596A1 (en) 2000-06-09 2010-07-02 Encapsulation of Plasmid DNA (Lipogenes) and Therapeutic Agents with Nuclear Localization Signal/Fusogenic Peptide Conjugates into Targeted Liposome Complexes
US13/900,433 US9278067B2 (en) 2000-06-09 2013-05-22 Encapsulation of plasmid DNA (lipogenes™) and therapeutic agents with nuclear localization signal/fusogenic peptide conjugates into targeted liposome complexes

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21092500P 2000-06-09 2000-06-09
US09/876,904 US20030072794A1 (en) 2000-06-09 2001-06-08 Encapsulation of plasmid DNA (lipogenes™) and therapeutic agents with nuclear localization signal/fusogenic peptide conjugates into targeted liposome complexes

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/830,118 Continuation US20120183596A1 (en) 2000-06-09 2010-07-02 Encapsulation of Plasmid DNA (Lipogenes) and Therapeutic Agents with Nuclear Localization Signal/Fusogenic Peptide Conjugates into Targeted Liposome Complexes

Publications (1)

Publication Number Publication Date
US20030072794A1 true US20030072794A1 (en) 2003-04-17

Family

ID=26905654

Family Applications (3)

Application Number Title Priority Date Filing Date
US09/876,904 Abandoned US20030072794A1 (en) 2000-06-09 2001-06-08 Encapsulation of plasmid DNA (lipogenes™) and therapeutic agents with nuclear localization signal/fusogenic peptide conjugates into targeted liposome complexes
US12/830,118 Abandoned US20120183596A1 (en) 2000-06-09 2010-07-02 Encapsulation of Plasmid DNA (Lipogenes) and Therapeutic Agents with Nuclear Localization Signal/Fusogenic Peptide Conjugates into Targeted Liposome Complexes
US13/900,433 Expired - Fee Related US9278067B2 (en) 2000-06-09 2013-05-22 Encapsulation of plasmid DNA (lipogenes™) and therapeutic agents with nuclear localization signal/fusogenic peptide conjugates into targeted liposome complexes

Family Applications After (2)

Application Number Title Priority Date Filing Date
US12/830,118 Abandoned US20120183596A1 (en) 2000-06-09 2010-07-02 Encapsulation of Plasmid DNA (Lipogenes) and Therapeutic Agents with Nuclear Localization Signal/Fusogenic Peptide Conjugates into Targeted Liposome Complexes
US13/900,433 Expired - Fee Related US9278067B2 (en) 2000-06-09 2013-05-22 Encapsulation of plasmid DNA (lipogenes™) and therapeutic agents with nuclear localization signal/fusogenic peptide conjugates into targeted liposome complexes

Country Status (1)

Country Link
US (3) US20030072794A1 (en)

Cited By (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030162293A1 (en) * 2002-01-04 2003-08-28 Yong Liang Chu Cell transfection compositions comprising genetic material, an amphipathic compound and an enzyme inhibitor and method of use
US20030180348A1 (en) * 2002-03-22 2003-09-25 Levinson R. Saul Transcellular drug delivery system
US20050026859A1 (en) * 2002-11-12 2005-02-03 John Hilfinger Methods and compositions of gene delivery agents for systemic and local therapy
US20050070721A1 (en) * 2002-05-19 2005-03-31 University Of Utah Research Foundation PH-sensitive polymeric micelles for drug delivery
US20050232984A1 (en) * 2002-08-23 2005-10-20 Heinrich Haas Non-vesicular cationic lipid formulations
US20060024374A1 (en) * 2002-10-31 2006-02-02 Gasco Maria R Pharmaceutical compositions suitable for the treatment of ophthalmic diseases
US20060198882A1 (en) * 2003-03-21 2006-09-07 Yechezkel Barenholz Stable liposomes or micelles comprising a sphinolipid and a peg-lipopolymer
US20060222696A1 (en) * 2005-03-10 2006-10-05 Kazushi Okada Novel liposome compositions
US20060257317A1 (en) * 2005-05-04 2006-11-16 Duke University Combination therapy in the treatment of cancer
US20060286161A1 (en) * 2003-05-09 2006-12-21 Steffen Panzner Injectable liposomal depots for delivering active ingredients
US20070059353A1 (en) * 2003-10-01 2007-03-15 Japan Science And Technology Agency Polyarginine-modified liposome having nuclear entry ability
US20070116691A1 (en) * 2005-10-18 2007-05-24 National Jewish Medical And Research Center Conditionally immortalized long-term stem cells and methods of making and using such cells
US20080026077A1 (en) * 2002-11-12 2008-01-31 John Hilfinger Methods and compositions of gene delivery agents for systemic and local therapy
EP1932516A1 (en) * 2006-12-11 2008-06-18 Universiteit Utrecht Holding B.V. Anti-inflammatory compounds containing compositions for treatment of cancer
US20080152661A1 (en) * 2006-08-18 2008-06-26 Rozema David B Polyconjugates for In Vivo Delivery of Polynucleotides
US20080281074A1 (en) * 1999-06-07 2008-11-13 Rozema David B Compounds and Methods for Reversible Modification of Biologically Active Molecules
US20080281041A1 (en) * 1999-06-07 2008-11-13 Rozema David B Reversibly Masked Polymers
US20080287630A1 (en) * 2006-08-18 2008-11-20 Wakefield Darren H Endosomolytic Poly(Acrylate) Polymers
US20080287628A1 (en) * 2002-03-11 2008-11-20 Rozema David B Endosomolytic Poly(Vinyl Ether) Polymers
US20090048410A1 (en) * 2002-03-11 2009-02-19 Wakefield Darren H Membrane Active Heteropolymers
WO2009082817A1 (en) 2007-12-27 2009-07-09 Protiva Biotherapeutics, Inc. Silencing of polo-like kinase expression using interfering rna
WO2009129319A2 (en) 2008-04-15 2009-10-22 Protiva Biotherapeutics, Inc. Silencing of csn5 gene expression using interfering rna
US20090274753A1 (en) * 2002-05-19 2009-11-05 University Of Utah Research Foundation Ph-sensitive polymeric micelles for drug delivery
US20090291094A1 (en) * 2008-05-16 2009-11-26 Taiga Biotechnologies, Inc. Antibodies and processes for preparing the same
US20100009926A1 (en) * 2002-05-19 2010-01-14 University Of Utah Research Foundation Ph-sensitive polymeric micelles for drug delivery
US20100047217A1 (en) * 2008-07-21 2010-02-25 Taiga Biotechnologies, Inc. Differentiated anucleated cells and method for preparing the same
US20100055129A1 (en) * 2008-08-28 2010-03-04 Taiga Biotechnologies, Inc. Modulators of myc, methods of using the same, and methods of indentifiying agents that modulate myc
US20100120893A1 (en) * 2008-10-20 2010-05-13 Dinah Wen-Yee Sah Compositions and Methods for Inhibiting Expression of Transthyretin
WO2010060068A1 (en) * 2008-11-24 2010-05-27 Polytechnic Institute Of Nyu Liposome drug carriers with ph-sensitivity
US20100279351A1 (en) * 2007-03-13 2010-11-04 National Jewish Medical And Research Center Method for Generation of Antibodies
WO2011011442A1 (en) * 2009-07-20 2011-01-27 Bio-Rad Laboratories, Inc. Delivery of nucleic acids across membranes
WO2011056883A1 (en) * 2009-11-03 2011-05-12 Alnylam Pharmaceuticals, Inc. Lipid formulated compositions and methods for inhibiting expression of transthyretin (ttr)
US20110207799A1 (en) * 2010-02-24 2011-08-25 Roche Madison Inc. Compositions for Targeted Delivery of siRNA
EP2395012A2 (en) 2005-11-02 2011-12-14 Protiva Biotherapeutics Inc. Modified siRNA molecules and uses thereof
WO2011160062A2 (en) 2010-06-17 2011-12-22 The Usa As Represented By The Secretary, National Institutes Of Health Compositions and methods for treating inflammatory conditions
US20120121670A1 (en) * 2009-04-22 2012-05-17 Lopez Victoria Lozano Polyarginine nanocapsules
WO2012106490A1 (en) 2011-02-03 2012-08-09 The Government Of The U.S.A., As Represented By The Secretary, Department Of Health & Human Services Multivalent vaccines for rabies virus and filoviruses
US20120201872A1 (en) * 2009-08-03 2012-08-09 The University Of North Carolina At Chapel Hill Liposomes comprising a calcium phosphate-containing precipitate
WO2012129077A3 (en) * 2011-03-18 2012-11-15 Duke University Peptides for suppressing inflammation
WO2013075132A1 (en) 2011-11-17 2013-05-23 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Therapeutic rna switches compositions and methods of use
WO2014015027A1 (en) 2012-07-18 2014-01-23 Onyx Therapeutics, Inc. Liposomal compositions of epoxyketone-based proteasome inhibitors
EP2711000A1 (en) * 2012-09-19 2014-03-26 Georgetown University Targeted Liposomes
US20140086996A1 (en) * 2009-07-09 2014-03-27 Kyushu University, National University Corporation Water-soluble drug carrier and process for producing the same
WO2014046983A1 (en) 2012-09-21 2014-03-27 Intensity Therapeutic Method of treating cancer
US20140193483A1 (en) * 2013-01-07 2014-07-10 Biomedical Research Models, Inc. Therapeutic vaccines for treating herpes simplex virus type-2 infections
US8822668B2 (en) 2008-04-15 2014-09-02 Protiva Biotherapeutics, Inc. Lipid formulations for nucleic acid delivery
WO2014153114A1 (en) * 2013-03-14 2014-09-25 Fred Hutchinson Cancer Research Center Compositions and methods to modify cells for therapeutic objectives
US9006417B2 (en) 2010-06-30 2015-04-14 Protiva Biotherapeutics, Inc. Non-liposomal systems for nucleic acid delivery
US9035039B2 (en) 2011-12-22 2015-05-19 Protiva Biotherapeutics, Inc. Compositions and methods for silencing SMAD4
US9228186B2 (en) 2002-11-14 2016-01-05 Thermo Fisher Scientific Inc. Methods and compositions for selecting siRNA of improved functionality
US9303063B2 (en) 2011-03-18 2016-04-05 Duke University Peptide compounds for suppressing inflammation
WO2016054421A1 (en) 2014-10-02 2016-04-07 Protiva Biotherapeutics, Inc Compositions and methods for silencing hepatitis b virus gene expression
US9365825B2 (en) 2013-03-11 2016-06-14 Taiga Biotechnologies, Inc. Expansion of adult stem cells in vitro
US9387152B2 (en) 2010-06-28 2016-07-12 The General Hospital Corporation Blood substitutes and uses thereof
US9399775B2 (en) 2011-11-18 2016-07-26 Alnylam Pharmaceuticals, Inc. RNAi agents, compositions and methods of use thereof for treating transthyretin (TTR) associated diseases
US9492386B2 (en) 2002-06-28 2016-11-15 Protiva Biotherapeutics, Inc. Liposomal apparatus and manufacturing methods
WO2016197132A1 (en) 2015-06-04 2016-12-08 Protiva Biotherapeutics Inc. Treating hepatitis b virus infection using crispr
WO2017019891A2 (en) 2015-07-29 2017-02-02 Protiva Biotherapeutics, Inc. Compositions and methods for silencing hepatitis b virus gene expression
US9738899B2 (en) 2002-02-20 2017-08-22 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
WO2017147540A1 (en) 2016-02-25 2017-08-31 Applied Biological Laboratories, Inc. Compositions and methods for protecting against airborne pathogens and irritants
US9771588B2 (en) 2002-02-20 2017-09-26 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
WO2017176596A1 (en) 2016-04-04 2017-10-12 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Multivalent vaccines for rabies virus and coronaviruses
US9789135B2 (en) 2012-07-20 2017-10-17 Taiga Biotechnologies, Inc. Enhanced reconstitution and autoreconstitution of the hematopoietic compartment
US9878042B2 (en) 2009-07-01 2018-01-30 Protiva Biotherapeutics, Inc. Lipid formulations for delivery of therapeutic agents to solid tumors
WO2018087720A1 (en) 2016-11-14 2018-05-17 Novartis Ag Compositions, methods, and therapeutic uses related to fusogenic protein minion
US10060921B2 (en) 2014-08-29 2018-08-28 Alnylam Pharmaceuticals, Inc. Methods of treating transthyretin (TTR) mediated amyloidosis
CN108884131A (en) * 2016-04-15 2018-11-23 凯尔格恩有限公司 Peptides with anti-obesity and anti-diabetic effects and uses thereof
WO2019032613A1 (en) * 2017-08-08 2019-02-14 Ionis Pharmaceuticals, Inc. Compositions and methods for modulation of protein aggregation
US10208307B2 (en) 2015-07-31 2019-02-19 Alnylam Pharmaceuticals, Inc. Transthyretin (TTR) iRNA compositions and methods of use thereof for treating or preventing TTR-associated diseases
WO2019046426A1 (en) 2017-08-30 2019-03-07 Applied Biological Laboratories, Inc. Compositions and methods for protecting against airborne pathogens and irritants
US10272115B2 (en) 2013-03-11 2019-04-30 Taiga Biotechnologies, Inc. Production and use of red blood cells
US10864259B2 (en) 2017-08-03 2020-12-15 Taiga Biotechnologies, Inc. Methods and compositions for the treatment of melanoma
US10961289B2 (en) * 2015-10-02 2021-03-30 The University Of Copenhagen Small molecules blocking histone reader domains
US20210147487A1 (en) * 2018-04-04 2021-05-20 The University Of North Carolina At Chapel Hill Methods and compositions for engineered assembly activating proteins (eaaps)
US11116796B2 (en) 2016-12-02 2021-09-14 Taiga Biotechnologies, Inc. Nanoparticle formulations
CN114632062A (en) * 2022-03-21 2022-06-17 南京大学 Neutral liposome for delivering nucleic acid medicament and preparation method and application thereof
JP2022530853A (en) * 2019-04-18 2022-07-04 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Selective targeting of ubiquitin and ubiquitin-like E1 activating enzymes with structurally stabilized peptides
CN115137839A (en) * 2021-03-30 2022-10-04 南京纳么美科技有限公司 Ferritin cage nano-carrier of targeting-co-loading hydrophilic/hydrophobic drugs and application thereof
CN115348873A (en) * 2020-03-26 2022-11-15 北京脑科学与类脑研究中心 Amino acid-mediated gene delivery and uses thereof
US11566061B2 (en) 2017-01-05 2023-01-31 Fred Hutchinson Cancer Center Systems and methods to improve vaccine efficacy
US11591544B2 (en) 2020-11-25 2023-02-28 Akagera Medicines, Inc. Ionizable cationic lipids
US11806360B2 (en) 2017-09-19 2023-11-07 Alnylam Pharmaceuticals, Inc. Compositions and methods for treating transthyretin (TTR) mediated amyloidosis
US11872195B2 (en) 2016-04-14 2024-01-16 Fred Hutchinson Cancer Center Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers
US11951167B2 (en) 2012-09-19 2024-04-09 Georgetown University Targeted liposomes
US11959081B2 (en) 2021-08-03 2024-04-16 Alnylam Pharmaceuticals, Inc. Transthyretin (TTR) iRNA compositions and methods of use thereof
US12064479B2 (en) 2022-05-25 2024-08-20 Akagera Medicines, Inc. Lipid nanoparticles for delivery of nucleic acids and methods of use thereof
US12250943B2 (en) 2019-04-08 2025-03-18 Htyr Acquisition Llc Compositions and methods for the cryopreservation of immune cells
US12370217B2 (en) 2019-05-14 2025-07-29 Htyr Acquisition Llc Compositions and methods for treating T cell exhaustion

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104873982A (en) 2007-08-17 2015-09-02 普渡研究基金会 PSMA binding ligand-linker conjugates and methods of use thereof
US9951324B2 (en) 2010-02-25 2018-04-24 Purdue Research Foundation PSMA binding ligand-linker conjugates and methods for using
US20130142863A1 (en) 2010-06-17 2013-06-06 Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. Phosphatidylcholine lipid liposomes as boundry lubricants in aqueous media
SG10201610869TA (en) 2012-06-26 2017-02-27 Del Mar Pharmaceuticals Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalacti
KR102575825B1 (en) 2012-11-15 2023-09-06 엔도사이트, 인코포레이티드 Conjugates for treating diseases caused by psma expressing cells
DE102013005154B4 (en) 2013-03-26 2015-01-22 Forschungszentrum Jülich GmbH Method for incorporation of lysosomal transmembrane proteins into cellular membranes
JP2016519684A (en) 2013-04-08 2016-07-07 デニス エム ブラウン Methods and compositions for improving the efficacy of suboptimally administered medication and / or reducing side effects
CN105636924B (en) 2013-10-18 2018-08-07 德国癌症研究中心 Labeled inhibitors of prostate-specific membrane antigen (PSMA), their use as imaging agents and agents for the treatment of prostate cancer
WO2015073678A1 (en) 2013-11-14 2015-05-21 Endocyte, Inc. Compounds for positron emission tomography
WO2015176737A1 (en) * 2014-05-19 2015-11-26 Biontech Ag Particles comprising protamine and rna in combination with endosome destabilizing agents
US10188759B2 (en) 2015-01-07 2019-01-29 Endocyte, Inc. Conjugates for imaging
WO2017062502A1 (en) * 2015-10-05 2017-04-13 The Regents Of The University Of Colorgo, A Body Corporate Lipoplexes formulated for catalytic delivery
KR20190075968A (en) * 2016-10-19 2019-07-01 어바이브, 인크. New PEGylated liposomal preparations of apelin for the treatment of cardiovascular-related disorders
US10463746B2 (en) 2017-11-09 2019-11-05 International Business Machines Corporation Macromolecular chemotherapeutics
JP2021522193A (en) 2018-04-17 2021-08-30 エンドサイト・インコーポレイテッドＥｎｄｏｃｙｔｅ， Ｉｎｃ． How to treat cancer
CA3210451A1 (en) 2021-03-22 2022-09-29 Illumina Cambridge Limited Methods for improving nucleic acid cluster clonality
CN113741449B (en) * 2021-08-30 2023-07-14 南京信息工程大学 A multi-agent control method for sea-air collaborative observation tasks
CN114014915B (en) * 2021-10-13 2023-03-31 东北农业大学 Broad-spectrum antibacterial alpha helical peptide and preparation method and application thereof
KR20240086940A (en) * 2022-12-09 2024-06-19 (주)케어젠 Peptide for cartilage regeneration and uses thereof

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4394448A (en) * 1978-02-24 1983-07-19 Szoka Jr Francis C Method of inserting DNA into living cells
US4598051A (en) * 1980-03-12 1986-07-01 The Regents Of The University Of California Liposome conjugates and diagnostic methods therewith
US5013556A (en) * 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5635467A (en) * 1994-06-30 1997-06-03 Amway Corporation Powdered composition exhibiting increased liquid surfactant loading for free flowing powder detergents
US5736392A (en) * 1995-06-07 1998-04-07 Life Technologies, Inc. Peptide-enhanced cationic lipid transfections
US6093701A (en) * 1997-12-12 2000-07-25 Mirus, Inc. Method for covalent attachment of compounds to genes
US6210717B1 (en) * 1997-12-12 2001-04-03 Samyang Corporation Biodegradable mixed polymeric micelles for gene delivery
US6511676B1 (en) * 1999-11-05 2003-01-28 Teni Boulikas Therapy for human cancers using cisplatin and other drugs or genes encapsulated into liposomes
US20030100113A1 (en) * 1998-12-23 2003-05-29 Universite Louis Pasteur De Strasbourg Non-viral transfection vector

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4394448A (en) * 1978-02-24 1983-07-19 Szoka Jr Francis C Method of inserting DNA into living cells
US4598051A (en) * 1980-03-12 1986-07-01 The Regents Of The University Of California Liposome conjugates and diagnostic methods therewith
US5013556A (en) * 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5635467A (en) * 1994-06-30 1997-06-03 Amway Corporation Powdered composition exhibiting increased liquid surfactant loading for free flowing powder detergents
US5736392A (en) * 1995-06-07 1998-04-07 Life Technologies, Inc. Peptide-enhanced cationic lipid transfections
US6093701A (en) * 1997-12-12 2000-07-25 Mirus, Inc. Method for covalent attachment of compounds to genes
US6210717B1 (en) * 1997-12-12 2001-04-03 Samyang Corporation Biodegradable mixed polymeric micelles for gene delivery
US20030100113A1 (en) * 1998-12-23 2003-05-29 Universite Louis Pasteur De Strasbourg Non-viral transfection vector
US6511676B1 (en) * 1999-11-05 2003-01-28 Teni Boulikas Therapy for human cancers using cisplatin and other drugs or genes encapsulated into liposomes
US20030185879A1 (en) * 1999-11-05 2003-10-02 Teni Boulikas Therapy for human cancers using cisplatin and other drugs or genes encapsulated into liposomes

Cited By (187)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080281074A1 (en) * 1999-06-07 2008-11-13 Rozema David B Compounds and Methods for Reversible Modification of Biologically Active Molecules
US10022456B2 (en) 1999-06-07 2018-07-17 Arrowhead Pharmaceuticals, Inc. Reversibly masked polymers
US8541548B2 (en) 1999-06-07 2013-09-24 Arrowhead Madison Inc. Compounds and methods for reversible modification of biologically active molecules
US20080281041A1 (en) * 1999-06-07 2008-11-13 Rozema David B Reversibly Masked Polymers
US20030162293A1 (en) * 2002-01-04 2003-08-28 Yong Liang Chu Cell transfection compositions comprising genetic material, an amphipathic compound and an enzyme inhibitor and method of use
US20050100527A1 (en) * 2002-01-04 2005-05-12 Chu Yong L. Compounds for delivering substances into cells
US10000754B2 (en) 2002-02-20 2018-06-19 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US9957517B2 (en) 2002-02-20 2018-05-01 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US9738899B2 (en) 2002-02-20 2017-08-22 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US9771588B2 (en) 2002-02-20 2017-09-26 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US10351852B2 (en) 2002-02-20 2019-07-16 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US10889815B2 (en) 2002-02-20 2021-01-12 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US10662428B2 (en) 2002-02-20 2020-05-26 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US8138383B2 (en) 2002-03-11 2012-03-20 Arrowhead Madison Inc. Membrane active heteropolymers
US8008355B2 (en) 2002-03-11 2011-08-30 Roche Madison Inc. Endosomolytic poly(vinyl ether) polymers
US20090048410A1 (en) * 2002-03-11 2009-02-19 Wakefield Darren H Membrane Active Heteropolymers
US20080287628A1 (en) * 2002-03-11 2008-11-20 Rozema David B Endosomolytic Poly(Vinyl Ether) Polymers
US20030180348A1 (en) * 2002-03-22 2003-09-25 Levinson R. Saul Transcellular drug delivery system
US20050070721A1 (en) * 2002-05-19 2005-03-31 University Of Utah Research Foundation PH-sensitive polymeric micelles for drug delivery
US7951846B2 (en) 2002-05-19 2011-05-31 You Han Bae pH-sensitive polymeric micelles for drug delivery
US20100009926A1 (en) * 2002-05-19 2010-01-14 University Of Utah Research Foundation Ph-sensitive polymeric micelles for drug delivery
US8263664B2 (en) 2002-05-19 2012-09-11 University Of Utah Research Foundation pH-sensitive polymeric micelles for drug delivery
US20090274753A1 (en) * 2002-05-19 2009-11-05 University Of Utah Research Foundation Ph-sensitive polymeric micelles for drug delivery
US7229973B2 (en) * 2002-05-19 2007-06-12 You Han Bae pH-sensitive polymeric micelles for drug delivery
US11298320B2 (en) 2002-06-28 2022-04-12 Arbutus Biopharma Corporation Liposomal apparatus and manufacturing methods
US9492386B2 (en) 2002-06-28 2016-11-15 Protiva Biotherapeutics, Inc. Liposomal apparatus and manufacturing methods
US9504651B2 (en) 2002-06-28 2016-11-29 Protiva Biotherapeutics, Inc. Lipid compositions for nucleic acid delivery
US11318098B2 (en) 2002-06-28 2022-05-03 Arbutus Biopharma Corporation Liposomal apparatus and manufacturing methods
US20050232984A1 (en) * 2002-08-23 2005-10-20 Heinrich Haas Non-vesicular cationic lipid formulations
US20060024374A1 (en) * 2002-10-31 2006-02-02 Gasco Maria R Pharmaceutical compositions suitable for the treatment of ophthalmic diseases
US20080026077A1 (en) * 2002-11-12 2008-01-31 John Hilfinger Methods and compositions of gene delivery agents for systemic and local therapy
US20050026859A1 (en) * 2002-11-12 2005-02-03 John Hilfinger Methods and compositions of gene delivery agents for systemic and local therapy
US9777270B2 (en) 2002-11-14 2017-10-03 Thermo Fisher Scientific Inc. Methods and compositions for selecting siRNA of improved functionality
US10233449B2 (en) 2002-11-14 2019-03-19 Thermo Fisher Scientific Inc. Methods and compositions for selecting siRNA of improved functionality
US9228186B2 (en) 2002-11-14 2016-01-05 Thermo Fisher Scientific Inc. Methods and compositions for selecting siRNA of improved functionality
US11198870B2 (en) 2002-11-14 2021-12-14 Thermo Fisher Scientific Inc. Methods and compositions for selecting siRNA of improved functionality
US20060198882A1 (en) * 2003-03-21 2006-09-07 Yechezkel Barenholz Stable liposomes or micelles comprising a sphinolipid and a peg-lipopolymer
US20060286161A1 (en) * 2003-05-09 2006-12-21 Steffen Panzner Injectable liposomal depots for delivering active ingredients
US20070059353A1 (en) * 2003-10-01 2007-03-15 Japan Science And Technology Agency Polyarginine-modified liposome having nuclear entry ability
US8592210B2 (en) * 2003-10-01 2013-11-26 Japan Science And Technology Agency Polyarginine-modified liposome having nuclear entry ability
US8758810B2 (en) 2005-03-10 2014-06-24 Mebiopharm Co., Ltd. Liposome compositions
US20060222696A1 (en) * 2005-03-10 2006-10-05 Kazushi Okada Novel liposome compositions
US20110081404A1 (en) * 2005-03-10 2011-04-07 Mebiopharm Co., Ltd. Novel liposome compositions
US7829113B2 (en) 2005-03-10 2010-11-09 Mebiopharm Co., Ltd. Liposome compositions
US20060257317A1 (en) * 2005-05-04 2006-11-16 Duke University Combination therapy in the treatment of cancer
US20100047167A1 (en) * 2005-05-04 2010-02-25 Duke University Combination therapy in the treatment of cancer
US9796961B2 (en) 2005-10-18 2017-10-24 The Regents Of The University Of Colorado Conditionally immortalized long-term stem cells and methods of making and using such cells
US20070116691A1 (en) * 2005-10-18 2007-05-24 National Jewish Medical And Research Center Conditionally immortalized long-term stem cells and methods of making and using such cells
US10760055B2 (en) 2005-10-18 2020-09-01 National Jewish Health Conditionally immortalized long-term stem cells and methods of making and using such cells
US8883507B2 (en) 2005-10-18 2014-11-11 The Regents Of The University Of Colorado Conditionally immortalized long-term hematopoietic stem cells and methods of making and using such cells
US9150831B2 (en) 2005-10-18 2015-10-06 The Regents Of The University Of Colorado Conditionally immortalized long-term stem cells and methods of making and using such cells
EP2395012A2 (en) 2005-11-02 2011-12-14 Protiva Biotherapeutics Inc. Modified siRNA molecules and uses thereof
US20090023890A1 (en) * 2006-08-18 2009-01-22 Monahan Sean D Membrane Active Heteropolymers
US20080287630A1 (en) * 2006-08-18 2008-11-20 Wakefield Darren H Endosomolytic Poly(Acrylate) Polymers
US7985406B2 (en) 2006-08-18 2011-07-26 Roche Madison Inc. Membrane active heteropolymers
US20080152661A1 (en) * 2006-08-18 2008-06-26 Rozema David B Polyconjugates for In Vivo Delivery of Polynucleotides
US8017109B2 (en) 2006-08-18 2011-09-13 Roche Madison Inc. Endosomolytic poly(acrylate) polymers
US20080269450A1 (en) * 2006-08-18 2008-10-30 Wakefield Darren H Endosomolytic Poly-Beta-Aminoester Polymers
US8137695B2 (en) 2006-08-18 2012-03-20 Arrowhead Madison Inc. Polyconjugates for in vivo delivery of polynucleotides
US20080281044A1 (en) * 2006-08-18 2008-11-13 Monahan Sean D Endosomolytic Modified Poly(Alcohol) and Poly(Amine) Polymers
WO2008072952A3 (en) * 2006-12-11 2008-09-12 Univ Utrecht Holding Bv Anti-inflammatory compounds containing compositions for treatment of cancer
EP1932516A1 (en) * 2006-12-11 2008-06-18 Universiteit Utrecht Holding B.V. Anti-inflammatory compounds containing compositions for treatment of cancer
US20100143453A1 (en) * 2006-12-11 2010-06-10 Raymond Michel Schiffelers Anti-inflammatory compounds containing compositions for treatment of cancer
US8551968B2 (en) 2007-03-13 2013-10-08 National Jewish Health Methods for generation of antibodies
US20100279351A1 (en) * 2007-03-13 2010-11-04 National Jewish Medical And Research Center Method for Generation of Antibodies
WO2009082817A1 (en) 2007-12-27 2009-07-09 Protiva Biotherapeutics, Inc. Silencing of polo-like kinase expression using interfering rna
US11141378B2 (en) 2008-04-15 2021-10-12 Arbutus Biopharma Corporation Lipid formulations for nucleic acid delivery
US9364435B2 (en) 2008-04-15 2016-06-14 Protiva Biotherapeutics, Inc. Lipid formulations for nucleic acid delivery
WO2009129319A2 (en) 2008-04-15 2009-10-22 Protiva Biotherapeutics, Inc. Silencing of csn5 gene expression using interfering rna
EP2770057A1 (en) 2008-04-15 2014-08-27 Protiva Biotherapeutics Inc. Silencing of CSN5 gene expression using interfering RNA
US8822668B2 (en) 2008-04-15 2014-09-02 Protiva Biotherapeutics, Inc. Lipid formulations for nucleic acid delivery
US10442853B2 (en) 2008-05-16 2019-10-15 Taiga Biotechnologies, Inc. Antibodies and processes for preparing the same
US11667695B2 (en) 2008-05-16 2023-06-06 Taiga Biotechnologies, Inc. Antibodies and processes for preparing the same
US9428571B2 (en) 2008-05-16 2016-08-30 Taiga Biotechnologies, Inc. Antibodies and processes for preparing the same
US20090291094A1 (en) * 2008-05-16 2009-11-26 Taiga Biotechnologies, Inc. Antibodies and processes for preparing the same
US8986702B2 (en) 2008-05-16 2015-03-24 Taiga Biotechnologies, Inc. Antibodies and processes for preparing the same
AU2009246876B2 (en) * 2008-05-16 2015-04-02 Htyr Acquisition Llc Antibodies and processes for preparing the same
US20100047217A1 (en) * 2008-07-21 2010-02-25 Taiga Biotechnologies, Inc. Differentiated anucleated cells and method for preparing the same
US9169462B2 (en) 2008-07-21 2015-10-27 Taiga Biotechnologies, Inc. Methods for preparing mature erythrocytes from conditionally immortalized hematopoietic stem cells
US20100055129A1 (en) * 2008-08-28 2010-03-04 Taiga Biotechnologies, Inc. Modulators of myc, methods of using the same, and methods of indentifiying agents that modulate myc
US11369678B2 (en) 2008-08-28 2022-06-28 Taiga Biotechnologies, Inc. Compositions and methods for modulating immune cells
US9775897B2 (en) 2008-08-28 2017-10-03 Taiga Biotechnologies, Inc. Modulators of MYC and methods of using the same
US10556006B2 (en) 2008-08-28 2020-02-11 Taiga Biotechnologies, Inc. Compositions and methods for modulating an immune response
US8828723B2 (en) 2008-08-28 2014-09-09 Taiga Biotechnologies, Inc. Modulators of MYC, methods of using the same, and methods of identifying agents that modulate MYC
US8784825B2 (en) 2008-08-28 2014-07-22 Taiga Biotechnologies, Inc. Modulators of MYC, methods of using the same, and methods of identifying agents that modulate MYC
US20100120893A1 (en) * 2008-10-20 2010-05-13 Dinah Wen-Yee Sah Compositions and Methods for Inhibiting Expression of Transthyretin
US10240152B2 (en) 2008-10-20 2019-03-26 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of transthyretin
US12227744B2 (en) 2008-10-20 2025-02-18 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of transthyretin
US9234196B2 (en) 2008-10-20 2016-01-12 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of transthyretin
US8168775B2 (en) 2008-10-20 2012-05-01 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of transthyretin
US8741866B2 (en) 2008-10-20 2014-06-03 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of transthyretin
WO2010060068A1 (en) * 2008-11-24 2010-05-27 Polytechnic Institute Of Nyu Liposome drug carriers with ph-sensitivity
US20120121670A1 (en) * 2009-04-22 2012-05-17 Lopez Victoria Lozano Polyarginine nanocapsules
US9878042B2 (en) 2009-07-01 2018-01-30 Protiva Biotherapeutics, Inc. Lipid formulations for delivery of therapeutic agents to solid tumors
US11786598B2 (en) 2009-07-01 2023-10-17 Arbutus Biopharma Corporation Lipid formulations for delivery of therapeutic agents
US12016929B2 (en) 2009-07-01 2024-06-25 Arbutus Biopharma Corporation Lipid formulations for delivery of therapeutic agents
US11446383B2 (en) 2009-07-01 2022-09-20 Arbutus Biopharma Corporation Lipid formulations for delivery of therapeutic agents
US20140086996A1 (en) * 2009-07-09 2014-03-27 Kyushu University, National University Corporation Water-soluble drug carrier and process for producing the same
US20110177599A1 (en) * 2009-07-20 2011-07-21 Bio-Rad Laboratories, Inc. Delivery of nucleic acids across membranes
WO2011011442A1 (en) * 2009-07-20 2011-01-27 Bio-Rad Laboratories, Inc. Delivery of nucleic acids across membranes
US10624852B2 (en) 2009-08-03 2020-04-21 The University Of North Carolina At Chapel Hill Liposomes comprising a calcium phosphate-containing precipitate
US9937128B2 (en) * 2009-08-03 2018-04-10 The University Of North Carolina At Chapel Hill Liposomes comprising a calcium phosphate-containing precipitate
US20120201872A1 (en) * 2009-08-03 2012-08-09 The University Of North Carolina At Chapel Hill Liposomes comprising a calcium phosphate-containing precipitate
WO2011056883A1 (en) * 2009-11-03 2011-05-12 Alnylam Pharmaceuticals, Inc. Lipid formulated compositions and methods for inhibiting expression of transthyretin (ttr)
US9101643B2 (en) 2009-11-03 2015-08-11 Alnylam Pharmaceuticals, Inc. Lipid formulated compositions and methods for inhibiting expression of transthyretin (TTR)
US10316316B2 (en) 2010-02-24 2019-06-11 Arrowhead Pharmaceuticals, Inc. Compositions for targeted delivery of siRNA
US8313772B2 (en) 2010-02-24 2012-11-20 Arrowhead Madison Inc. Compositions for targeted delivery of siRNA
US20110207799A1 (en) * 2010-02-24 2011-08-25 Roche Madison Inc. Compositions for Targeted Delivery of siRNA
US9345775B2 (en) 2010-02-24 2016-05-24 Arrowhead Madison Inc. Compositions for targeted delivery of siRNA
WO2011160062A2 (en) 2010-06-17 2011-12-22 The Usa As Represented By The Secretary, National Institutes Of Health Compositions and methods for treating inflammatory conditions
US9387152B2 (en) 2010-06-28 2016-07-12 The General Hospital Corporation Blood substitutes and uses thereof
US9518272B2 (en) 2010-06-30 2016-12-13 Protiva Biotherapeutics, Inc. Non-liposomal systems for nucleic acid delivery
US9404127B2 (en) 2010-06-30 2016-08-02 Protiva Biotherapeutics, Inc. Non-liposomal systems for nucleic acid delivery
US9006417B2 (en) 2010-06-30 2015-04-14 Protiva Biotherapeutics, Inc. Non-liposomal systems for nucleic acid delivery
US12129467B2 (en) 2010-06-30 2024-10-29 Arbutus Biopharma Corporation Non-liposomal systems for nucleic acid delivery
US11718852B2 (en) 2010-06-30 2023-08-08 Arbutus Biopharma Corporation Non-liposomal systems for nucleic acid delivery
US10849975B2 (en) 2011-02-03 2020-12-01 Thomas Jefferson University Multivalent vaccines for rabies virus and filoviruses
WO2012106490A1 (en) 2011-02-03 2012-08-09 The Government Of The U.S.A., As Represented By The Secretary, Department Of Health & Human Services Multivalent vaccines for rabies virus and filoviruses
US10280210B2 (en) 2011-03-18 2019-05-07 Duke University Peptide compounds for suppressing inflammation
US9687521B2 (en) 2011-03-18 2017-06-27 Duke University Peptides for suppressing inflammation
AU2012231268B2 (en) * 2011-03-18 2017-02-02 Duke University Peptides for suppressing inflammation
WO2012129077A3 (en) * 2011-03-18 2012-11-15 Duke University Peptides for suppressing inflammation
US12071469B2 (en) 2011-03-18 2024-08-27 Duke University Peptide compounds for suppressing inflammation
US9303063B2 (en) 2011-03-18 2016-04-05 Duke University Peptide compounds for suppressing inflammation
CN103429610A (en) * 2011-03-18 2013-12-04 杜克大学 Peptides for Inhibiting Inflammation
US9018169B2 (en) 2011-03-18 2015-04-28 Duke University Peptides for suppressing inflammation
US11136371B2 (en) 2011-03-18 2021-10-05 Duke University Peptide compounds for suppressing inflammation
WO2013075132A1 (en) 2011-11-17 2013-05-23 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Therapeutic rna switches compositions and methods of use
US10570391B2 (en) 2011-11-18 2020-02-25 Alnylam Pharmaceuticals, Inc. RNAi agents, compositions and methods of use thereof for treating transthyretin (TTR) associated diseases
US9399775B2 (en) 2011-11-18 2016-07-26 Alnylam Pharmaceuticals, Inc. RNAi agents, compositions and methods of use thereof for treating transthyretin (TTR) associated diseases
US9035039B2 (en) 2011-12-22 2015-05-19 Protiva Biotherapeutics, Inc. Compositions and methods for silencing SMAD4
US10022326B2 (en) 2012-07-18 2018-07-17 Onyx Therapeutics, Inc. Liposomal compositions of epoxyketone-based proteasome inhibitors
WO2014015027A1 (en) 2012-07-18 2014-01-23 Onyx Therapeutics, Inc. Liposomal compositions of epoxyketone-based proteasome inhibitors
US9789135B2 (en) 2012-07-20 2017-10-17 Taiga Biotechnologies, Inc. Enhanced reconstitution and autoreconstitution of the hematopoietic compartment
US10206952B2 (en) 2012-07-20 2019-02-19 Taiga Biotechnologies, Inc. Enhanced reconstitution and autoreconstitution of the hematopoietic compartment
US10953048B2 (en) 2012-07-20 2021-03-23 Taiga Biotechnologies, Inc. Enhanced reconstitution and autoreconstitution of the hematopoietic compartment
TWI614034B (en) * 2012-09-19 2018-02-11 美國喬治城大學 Targeted liposomes
US11951167B2 (en) 2012-09-19 2024-04-09 Georgetown University Targeted liposomes
EP2711000A1 (en) * 2012-09-19 2014-03-26 Georgetown University Targeted Liposomes
WO2014046983A1 (en) 2012-09-21 2014-03-27 Intensity Therapeutic Method of treating cancer
US9566325B2 (en) * 2013-01-07 2017-02-14 Biomedical Research Models, Inc. Therapeutic vaccines for treating herpes simplex virus type-2 infections
US20140193483A1 (en) * 2013-01-07 2014-07-10 Biomedical Research Models, Inc. Therapeutic vaccines for treating herpes simplex virus type-2 infections
US10272115B2 (en) 2013-03-11 2019-04-30 Taiga Biotechnologies, Inc. Production and use of red blood cells
US10786534B2 (en) 2013-03-11 2020-09-29 Taiga Biotechnologies, Inc. Production and use of red blood cells
US10087420B2 (en) 2013-03-11 2018-10-02 Taiga Biotechnologies, Inc. Expansion of adult stem cells in vitro
US9365825B2 (en) 2013-03-11 2016-06-14 Taiga Biotechnologies, Inc. Expansion of adult stem cells in vitro
WO2014153114A1 (en) * 2013-03-14 2014-09-25 Fred Hutchinson Cancer Research Center Compositions and methods to modify cells for therapeutic objectives
US10392446B2 (en) 2013-03-14 2019-08-27 Fred Hutchinson Cancer Research Center Compositions and methods to modify cells for therapeutic objectives
US10060921B2 (en) 2014-08-29 2018-08-28 Alnylam Pharmaceuticals, Inc. Methods of treating transthyretin (TTR) mediated amyloidosis
US11079379B2 (en) 2014-08-29 2021-08-03 Alnylam Pharmaceuticals, Inc. Methods of treating transthyretin (TTR) mediated amyloidosis
WO2016054421A1 (en) 2014-10-02 2016-04-07 Protiva Biotherapeutics, Inc Compositions and methods for silencing hepatitis b virus gene expression
WO2016197132A1 (en) 2015-06-04 2016-12-08 Protiva Biotherapeutics Inc. Treating hepatitis b virus infection using crispr
WO2017019891A2 (en) 2015-07-29 2017-02-02 Protiva Biotherapeutics, Inc. Compositions and methods for silencing hepatitis b virus gene expression
US12049628B2 (en) 2015-07-31 2024-07-30 Alnylam Pharmaceuticals, Inc. Transthyretin (TTR) iRNA compositions and methods of use thereof for treating or preventing TTR-associated diseases
US11286486B2 (en) 2015-07-31 2022-03-29 Alnylam Pharmaceuticals, Inc. Transthyretin (TTR) iRNA compositions and methods of use thereof for treating or preventing TTR-associated diseases
US10208307B2 (en) 2015-07-31 2019-02-19 Alnylam Pharmaceuticals, Inc. Transthyretin (TTR) iRNA compositions and methods of use thereof for treating or preventing TTR-associated diseases
US10683501B2 (en) 2015-07-31 2020-06-16 Alnylam Pharmaceuticals, Inc. Transthyretin (TTR) iRNA compositions and methods of use thereof for treating or preventing TTR-associated diseases
US10961289B2 (en) * 2015-10-02 2021-03-30 The University Of Copenhagen Small molecules blocking histone reader domains
WO2017147540A1 (en) 2016-02-25 2017-08-31 Applied Biological Laboratories, Inc. Compositions and methods for protecting against airborne pathogens and irritants
WO2017176596A1 (en) 2016-04-04 2017-10-12 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Multivalent vaccines for rabies virus and coronaviruses
EP4104854A2 (en) 2016-04-04 2022-12-21 The United States of America as represented by the Secretary of the Department of Health and Human Services Multivalent vaccines for rabies virus and coronaviruses
US11872195B2 (en) 2016-04-14 2024-01-16 Fred Hutchinson Cancer Center Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers
CN108884131A (en) * 2016-04-15 2018-11-23 凯尔格恩有限公司 Peptides with anti-obesity and anti-diabetic effects and uses thereof
CN116333043A (en) * 2016-04-15 2023-06-27 凯尔格恩有限公司 Peptides with anti-obesity and anti-diabetic effects and uses thereof
WO2018087720A1 (en) 2016-11-14 2018-05-17 Novartis Ag Compositions, methods, and therapeutic uses related to fusogenic protein minion
US12344658B2 (en) 2016-12-02 2025-07-01 HTYR Acquistion LLC Nanoparticle formulations
US11116796B2 (en) 2016-12-02 2021-09-14 Taiga Biotechnologies, Inc. Nanoparticle formulations
US11566061B2 (en) 2017-01-05 2023-01-31 Fred Hutchinson Cancer Center Systems and methods to improve vaccine efficacy
US10864259B2 (en) 2017-08-03 2020-12-15 Taiga Biotechnologies, Inc. Methods and compositions for the treatment of melanoma
US11492617B2 (en) 2017-08-08 2022-11-08 Ionis Pharmaceuticals, Inc Compositions and methods for modulation of protein aggregation
WO2019032613A1 (en) * 2017-08-08 2019-02-14 Ionis Pharmaceuticals, Inc. Compositions and methods for modulation of protein aggregation
WO2019046426A1 (en) 2017-08-30 2019-03-07 Applied Biological Laboratories, Inc. Compositions and methods for protecting against airborne pathogens and irritants
US11806360B2 (en) 2017-09-19 2023-11-07 Alnylam Pharmaceuticals, Inc. Compositions and methods for treating transthyretin (TTR) mediated amyloidosis
US20210147487A1 (en) * 2018-04-04 2021-05-20 The University Of North Carolina At Chapel Hill Methods and compositions for engineered assembly activating proteins (eaaps)
US12250943B2 (en) 2019-04-08 2025-03-18 Htyr Acquisition Llc Compositions and methods for the cryopreservation of immune cells
JP2022530853A (en) * 2019-04-18 2022-07-04 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Selective targeting of ubiquitin and ubiquitin-like E1 activating enzymes with structurally stabilized peptides
US12358960B2 (en) 2019-04-18 2025-07-15 Dana-Farber Cancer Institute, Inc. Selective targeting of ubiquitin- and ubiquitin-like E1-activating enzymes by structurally-stabilized peptides
JP7727551B2 (en) 2019-04-18 2025-08-21 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Selective targeting of ubiquitin and ubiquitin-like E1-activating enzymes with structurally stabilized peptides
US12370217B2 (en) 2019-05-14 2025-07-29 Htyr Acquisition Llc Compositions and methods for treating T cell exhaustion
CN115348873A (en) * 2020-03-26 2022-11-15 北京脑科学与类脑研究中心 Amino acid-mediated gene delivery and uses thereof
US12077725B2 (en) 2020-11-25 2024-09-03 Akagera Medicines, Inc. Ionizable cationic lipids
US12331264B2 (en) 2020-11-25 2025-06-17 Akagera Medicines, Inc. Lipid nanoparticles for delivery of nucleic acids and methods of use thereof
US11591544B2 (en) 2020-11-25 2023-02-28 Akagera Medicines, Inc. Ionizable cationic lipids
CN115137839A (en) * 2021-03-30 2022-10-04 南京纳么美科技有限公司 Ferritin cage nano-carrier of targeting-co-loading hydrophilic/hydrophobic drugs and application thereof
US11959081B2 (en) 2021-08-03 2024-04-16 Alnylam Pharmaceuticals, Inc. Transthyretin (TTR) iRNA compositions and methods of use thereof
CN114632062A (en) * 2022-03-21 2022-06-17 南京大学 Neutral liposome for delivering nucleic acid medicament and preparation method and application thereof
US12064479B2 (en) 2022-05-25 2024-08-20 Akagera Medicines, Inc. Lipid nanoparticles for delivery of nucleic acids and methods of use thereof

Also Published As

Publication number Publication date
US20140134232A1 (en) 2014-05-15
US9278067B2 (en) 2016-03-08
US20120183596A1 (en) 2012-07-19

Similar Documents

Publication Publication Date Title
US9278067B2 (en) Encapsulation of plasmid DNA (lipogenes™) and therapeutic agents with nuclear localization signal/fusogenic peptide conjugates into targeted liposome complexes
AU2001275423B2 (en) Encapsulation of polynucleotides and drugs into targeted liposomes
AU2001275423A1 (en) Encapsulation of polynucleotides and drugs into targeted liposomes
Magar et al. Liposome-based delivery of biological drugs
US7393478B2 (en) Therapy for human cancers using cisplatin and other drugs or genes encapsulated into liposomes
Weissig et al. Cationic bolasomes with delocalized charge centers as mitochondria-specific DNA delivery systems
AU2003205049B2 (en) Efficient nucleic acid encapsulation into medium sized liposomes
PL199201B1 (en) Cationic virosomes as a genetic material carrying system
Uddin Cationic lipids used in non-viral gene delivery systems
Akkewar et al. Liposomes in the targeted gene therapy of cancer: A critical review
Kaneda et al. Development of HVJ envelope vector and its application to gene therapy
WO2003057190A1 (en) Efficient nucleic acid encapsulation into medium sized liposomes
JP4450656B2 (en) Carrier for gene transfer comprising liposome
Sharma et al. Liposomes: vesicular system an overview
CN117460537A (en) Nucleic acid delivery
HK1108834A (en) A method for preparing the micelles and the use of said micelles
JP2007166946A (en) Composition for suppressing expression of target gene
MXPA01006862A (en) Therapy for human cancers using cisplatin and other drugs or genes encapsulated into liposomes

Legal Events

Date Code Title Description
AS Assignment

Owner name: REGULON, INC., CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BOULIKAS, TENI;REEL/FRAME:016936/0040

Effective date: 20051222

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION